The	O
incidence	O
of	O
TEAEs	O
was	O
similar	O
across	O
the	O
different	O
doses	O
of	O
GP	O
MDI	O
,	O
ranging	O
from	O
22.0	O
%	O
of	O
patients	O
with	O
GP	O
MDI	O
0.6	O
μg	O
to	O
29.7	O
%	O
with	O
GP	O
MDI	O
2.4	O
μg	O
,	O
and	O
compared	O
with	O
24.2	O
%	O
and	O
25.8	O
%	O
in	O
placebo	O
MDI	O
and	O
open-label	B-Blinding_Open_Label
tiotropium	O
groups	O
,	O
respectively	O
(	O
Table	O
3	O
)	O
.	O

Results	O
A	O
total	O
of	O
614	B-Sample_Size_Actual_at_Enrollment
participants	O
were	O
randomized	O
to	O
treatment	O
.	O

Randomisation	O
occurred	O
through	O
the	B-Randomization_Personnel
Nottingham	I-Randomization_Personnel
Clinical	I-Randomization_Personnel
Trials	I-Randomization_Personnel
Unit	I-Randomization_Personnel
using	O
a	B-Randomization_Sequence_Generation_Method
web	I-Randomization_Sequence_Generation_Method
based	I-Randomization_Sequence_Generation_Method
database	I-Randomization_Sequence_Generation_Method
and	I-Randomization_Sequence_Generation_Method
randomisation	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
.	O

Images	O
were	O
read	O
by	O
an	O
experienced	O
musculoskeletal	B-Blinding_Object_Others
radiologist	I-Blinding_Object_Others
,	O
blind	O
to	O
treatment	O
and	O
chronologic	O
sequence	O
of	O
images	O
.	O

Results	O
Patient	O
disposition	O
,	O
demographics	O
,	O
and	O
baseline	O
characteristics	O
Out	O
of	O
796	O
patients	O
who	O
were	O
screened	O
,	O
356	B-Sample_Size_Actual_at_Enrollment
(	O
45	O
%	O
)	O
met	O
the	O
entry	O
criteria	O
and	O
were	O
randomly	O
assigned	O
to	O
treatment	O
groups	O
(	O
Figure1	O
)	O
.	O

Considering	O
a	O
10	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
dropout	O
rate	O
,	O
randomisation	O
of	O
approximately	O
180	B-Sample_Size_Target
subjects	O
(	O
90	O
per	O
group	O
)	O
was	O
required	O
.	O

We	O
excluded	O
patients	O
who	O
had	O
received	O
trimethoprim-sulfamethoxazole	O
or	O
vancomycin	O
for	O
more	O
than	O
48	O
hours	O
;	O
patients	O
with	O
MRSA	O
resistant	O
to	O
trimethoprim-sulfamethoxazole	O
or	I-Design_Parallel_Group
vancomycin	I-Design_Parallel_Group
;	O
those	O
with	O
highly	O
suspected	O
or	O
confirmed	O
left	O
sided	O
endocarditis	O
or	O
meningitis	O
;	O
patients	O
with	O
chronic	O
renal	O
failure	O
(	O
creatinine	O
clearance	O
<	O
15	O
mL/min	O
)	O
and	O
chronic	O
haemodialysis	O
(	O
those	O
with	O
severe	O
acute	O
renal	O
failure	O
,	O
including	O
acute	O
haemodialysis	O
,	O
could	O
be	O
included	O
)	O
;	O
neutropenic	O
patients	O
with	O
acute	O
leukaemia	O
or	O
bone	O
marrow	O
transplantation	O
;	O
and	O
patients	O
with	O
known	O
allergy	O
to	O
either	O
study	O
drug	O
,	O
treatment	O
with	O
methotrexate	O
,	O
pregnancy	O
or	O
lactation	O
,	O
previous	O
enrolment	O
in	O
this	O
study	O
,	O
or	O
concurrent	O
participation	O
in	O
another	O
trial	O
.	O

RESULTS	O
Noninferiority	B-Design_Comparative_Intent_NonInferiority
for	O
the	O
change	O
from	O
baseline	O
in	O
HbA1c	O
16	O
weeks	O
after	O
randomization	O
(	O
primary	O
end	O
point	O
)	O
was	O
confirmed	O
for	O
faster	O
aspart	O
versus	O
IAsp	O
(	O
estimated	O
treatment	O
difference	O
[	O
ETD	O
]	O
−0.04	O
%	O
[	O
95	O
%	O
CI	O
−0.11	O
;	O
0.03	O
]	O
;	O
−0.39	O
mmol/mol	O
[	O
−1.15	O
;	O
0.37	O
]	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Statistical	O
Analysis	O
Approximately	O
120	B-Sample_Size_Target
patients	O
(	O
60	O
per	O
group	O
)	O
were	O
planned	O
to	O
be	O
enrolled	O
to	O
confirm	O
that	O
the	O
responder	O
rate	O
based	O
on	O
the	O
elbow	O
MAS	O
score	O
in	O
the	O
400	O
U	O
group	O
would	O
exceed	O
that	O
in	O
the	O
240	O
U	O
group	O
.	O

Airway	O
reversibility	O
at	O
baseline	O
ranged	O
from	O
0.272	O
L	O
(	O
open-label	B-Blinding_Open_Label
tiotropium	O
)	O
to	O
0.206	O
L	O
(	O
GP	O
MDI	O
9	O
μg	O
[	O
Table	O
1	O
]	O
)	O
.	O

Patients	O
were	O
randomized	O
2:1:2:2	B-Randomization_Ratio
to	O
placebo	B-Design_Parallel_Group
or	I-Design_Parallel_Group
erenumab	I-Design_Parallel_Group
28	I-Design_Parallel_Group
,	I-Design_Parallel_Group
70	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
140	I-Design_Parallel_Group
mg.	O
Randomization	O
was	O
based	O
on	O
a	O
schedule	O
generated	O
by	O
the	O
study	B-Randomization_Personnel
sponsor	I-Randomization_Personnel
and	O
was	O
centrally	O
executed	O
using	O
an	O
interactive	B-Randomization_Sequence_Generation_Method
voice	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
(	O
Fig	O
.	O

Randomization	O
and	O
Treatment	O
Children	O
were	O
enrolled	O
in	O
parallel	B-Design_Parallel_Group
to	O
2	O
cohorts	O
:	O
1–	O
<	O
5	O
years	O
old	O
(	O
minimum	O
of	O
20	O
children	O
)	O
and	O
5–	O
<	O
12	O
years	O
old	O
(	O
minimum	O
of	O
40	O
children	O
)	O
.	O

The	O
sponsor	B-Blinding_Object_Others
(	I-Blinding_Object_Others
Dermira	I-Blinding_Object_Others
,	I-Blinding_Object_Others
Inc	I-Blinding_Object_Others
)	I-Blinding_Object_Others
,	O
investigators	B-Blinding_Object_Investigators
,	O
study	B-Blinding_Object_Care_Providers
site	I-Blinding_Object_Care_Providers
personnel	I-Blinding_Object_Care_Providers
,	O
and	O
patients	B-Blinding_Object_Patients
were	O
blinded	O
to	O
treatment	O
assignments	O
,	O
and	O
blind	O
integrity	O
was	O
maintained	O
throughout	O
the	O
study	O
.	O

Thus	O
,	O
noninferiority	B-Design_Comparative_Intent_NonInferiority
in	O
the	O
rate	O
of	O
fever	O
was	O
demonstrated	O
for	O
the	O
full	O
dose	O
compared	O
with	O
the	O
half	O
dose	O
of	O
IIV4	O
.	O

Results	O
Four	B-Sample_Size_Actual_at_Enrollment
hundred	I-Sample_Size_Actual_at_Enrollment
forty	I-Sample_Size_Actual_at_Enrollment
patients	I-Sample_Size_Actual_at_Enrollment
(	O
male	O
:	O
98	O
[	O
22.3	O
%	O
]	O
;	O
female	O
:	O
342	O
[	O
77.7	O
%	O
]	O
)	O
were	O
randomized	O
.	O

Results	O
A	O
total	O
of	O
1538	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
enrolled	O
(	O
mean	O
estimated	O
glomerular	O
filtration	O
rate	O
35.5	O
mL/min/1.73	O
m2	O
)	O
.	O

Materials	O
and	O
Methods	O
Study	O
Design	O
This	O
is	O
a	O
randomized	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
pilot	O
study	O
comparing	O
WL	O
plus	O
AI	O
vs.	O
WL	O
plus	O
PBO	O
.	O

Participants	O
The	O
trial	O
was	O
conducted	O
at	O
143	B-Settings_Multicenter
sites	I-Settings_Multicenter
(	O
hospitals	O
,	O
private	O
clinics	O
and	O
clinical	O
research	O
centres	O
)	O
in	O
the	O
USA	B-Settings_Location
.	O

Although	O
59	O
patients	O
entered	O
the	O
extension	O
,	O
only	O
58	B-Sample_Size_Actual_at_Outcome_Analysis
received	O
evolocumab	O
and	O
were	O
included	O
in	O
the	O
open-label	O
extension	O
analysis	O
set	O
.	O

Participants	B-Blinding_Object_Patients
,	O
care	B-Blinding_Object_Care_Providers
providers	I-Blinding_Object_Care_Providers
,	O
and	O
investigators	B-Blinding_Object_Investigators
were	O
masked	O
to	O
group	O
assignment	O
.	O

Statistical	O
Analysis	O
The	O
primary	O
objective	O
was	O
assessed	O
by	O
determining	O
if	O
the	O
rate	O
of	O
any	O
fever	O
(	O
temperature	O
≥100.4°F	O
[	O
38.0°C	O
]	O
)	O
within	O
7	O
days	O
after	O
administration	O
of	O
any	O
full	O
dose	O
of	O
IIV4	O
was	O
noninferior	B-Design_Comparative_Intent_NonInferiority
to	O
the	O
rate	O
of	O
fever	O
after	O
administration	O
of	O
any	O
half	O
dose	O
.	O

Thus	O
a	O
study	O
with	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
and	O
95	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
significance	O
needed	O
22	O
079	O
child-months	O
per	O
group	O
(	O
total	O
of	O
2454	B-Sample_Size_Required
children	O
for	O
18	O
months	O
follow-up	O
)	O
.	O

Randomization	O
,	O
Stratification	O
,	O
and	O
Blinding	O
Eligible	O
patients	O
,	O
stratified	B-Randomization_Type_Stratified
by	O
geographic	B-Randomization_Stratified_Criteria
region	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
age	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
18–64	I-Randomization_Stratified_Criteria
years	I-Randomization_Stratified_Criteria
and	I-Randomization_Stratified_Criteria
≥65	I-Randomization_Stratified_Criteria
years	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
and	O
underlying	B-Randomization_Stratified_Criteria
diagnosis	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
trauma	I-Randomization_Stratified_Criteria
or	I-Randomization_Stratified_Criteria
nontrauma	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
were	O
randomized	O
1:1	B-Randomization_Ratio
to	O
tedizolid	B-Design_Parallel_Group
phosphate	I-Design_Parallel_Group
or	I-Design_Parallel_Group
linezolid	I-Design_Parallel_Group
(	O
Supplementary	O
Figure	O
1	O
)	O
via	O
an	B-Randomization_Sequence_Generation_Method
interactive	I-Randomization_Sequence_Generation_Method
voice	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
.	O

To	O
account	O
for	O
possible	O
dropouts	O
,	O
we	O
intended	O
to	O
include	O
134	B-Sample_Size_Target
patients	I-Sample_Size_Target
per	I-Sample_Size_Target
group	I-Sample_Size_Target
.	O

Methods	O
Study	O
Design	O
This	O
double-blind	B-Blinding_Double_Blind
,	O
randomized	O
,	O
multicenter	B-Settings_Multicenter
,	O
phase	B-Design_Phase_3
3	I-Design_Phase_3
study	O
randomized	O
patients	O
to	O
evolocumab	B-Design_Parallel_Group
or	I-Design_Parallel_Group
ezetimibe	O
at	O
30	B-Settings_Multicenter
sites	I-Settings_Multicenter
in	O
Japan	B-Settings_Location
.	O

Participants	B-Blinding_Open_Label
,	I-Blinding_Open_Label
treating	I-Blinding_Open_Label
clinicians	I-Blinding_Open_Label
,	I-Blinding_Open_Label
and	I-Blinding_Open_Label
coordinators	I-Blinding_Open_Label
were	I-Blinding_Open_Label
not	I-Blinding_Open_Label
masked	I-Blinding_Open_Label
.	O

At	O
the	O
same	O
time	O
,	O
an	O
additional	B-Design_Parallel_Group
injection	I-Design_Parallel_Group
of	I-Design_Parallel_Group
onabotulinumtoxinA	I-Design_Parallel_Group
160	I-Design_Parallel_Group
U	I-Design_Parallel_Group
(	I-Design_Parallel_Group
400	I-Design_Parallel_Group
U	I-Design_Parallel_Group
group	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
(	O
240	O
U	O
group	O
)	O
was	O
given	O
,	O
in	O
3	O
elbow	O
flexors	O
(	O
biceps	O
brachii	O
,	O
brachialis	O
,	O
and	O
brachioradialis	O
)	O
.	O

Open-label	B-Blinding_Open_Label
assessments	O
were	O
performed	O
every	O
12	O
weeks	O
to	O
week	O
104	O
(	O
ClinicalTrials.gov	O
number	O
NCT00535782	O
)	O
.	O

MacroGenics	O
provided	O
teplizumab	B-Design_Parallel_Group
and	I-Design_Parallel_Group
matching	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
but	O
was	O
not	O
involved	O
in	O
the	O
conduct	O
of	O
the	O
trial	O
or	O
in	O
data	O
analysis	O
.	O

The	O
mean	O
ARR	O
was	O
lower	O
with	O
40	O
mg	O
ponesimod	B-Design_Parallel_Group
versus	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
,	O
with	O
a	O
maximum	O
reduction	O
of	O
52	O
%	O
(	O
0.25	O
vs	O
0.53	O
;	O
p=0.0363	O
)	O
.	O

Oral	O
ponesimod	O
in	O
relapsing–remitting	O
multiple	O
sclerosis	O
:	O
a	O
randomised	O
phase	B-Design_Phase_2
II	I-Design_Phase_2
trial	O

All	O
ponesimod	B-Allocation_Concealment_Method
doses	I-Allocation_Concealment_Method
and	I-Allocation_Concealment_Method
matching	I-Allocation_Concealment_Method
placebo	I-Allocation_Concealment_Method
were	I-Allocation_Concealment_Method
indistinguishable	I-Allocation_Concealment_Method
and	I-Allocation_Concealment_Method
identically	I-Allocation_Concealment_Method
packaged	I-Allocation_Concealment_Method
.	O

Randomization	O
was	O
performed	O
using	O
an	O
interactive	B-Randomization_Sequence_Generation_Method
voice/web	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
.	O

We	O
assessed	O
the	O
time	O
in	O
minutes	O
that	O
gabapentin	B-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
was	O
administered	O
prior	O
to	O
the	O
different	O
pain	O
assessments	O
.	O

Patients	O
and	O
Methods	O
This	O
multinational	B-Settings_Multicenter
,	O
double-blind	B-Blinding_Double_Blind
,	O
randomized	O
,	O
phase	B-Design_Phase_3
III	I-Design_Phase_3
study	O
(	O
STELLA	O
)	O
compared	O
MB02	B-Design_Parallel_Group
or	I-Design_Parallel_Group
EU-bevacizumab	I-Design_Parallel_Group
(	I-Design_Parallel_Group
15	I-Design_Parallel_Group
mg/kg	I-Design_Parallel_Group
)	I-Design_Parallel_Group
administered	I-Design_Parallel_Group
with	I-Design_Parallel_Group
chemotherapy	I-Design_Parallel_Group
(	O
paclitaxel	O
200	O
mg/m2	O
and	O
carboplatin	O
AUC6	O
)	O
on	O
Day	O
1	O
of	O
every	O
3-week	O
cycle	O
for	O
6	O
cycles	O
(	O
Week	O
18	O
)	O
,	O
followed	O
by	O
MB02/EU-bevacizumab	O
in	O
blinded	O
monotherapy	O
until	O
disease	O
progression	O
,	O
unacceptable	O
toxicity	O
,	O
death	O
,	O
withdrawal	O
of	O
consent	O
or	O
end	O
of	O
study	O
(	O
Week	O
52	O
)	O
.	O

Efficacy	O
and	O
Safety	O
of	O
OnabotulinumtoxinA	O
400	O
Units	O
in	O
Patients	O
with	O
Post-Stroke	O
Upper	O
Limb	O
Spasticity	O
:	O
Final	O
Report	O
of	O
a	O
Randomized	B-Randomization_Type_Simple
,	O
Double-Blind	B-Blinding_Double_Blind
,	O
Placebo-Controlled	O
Trial	O
with	O
an	O
Open-Label	B-Blinding_Open_Label
Extension	O
Phase	O

Methods	O
In	O
this	O
randomized	O
,	O
noninferiority	B-Design_Comparative_Intent_NonInferiority
,	O
double-blind	B-Blinding_Double_Blind
,	O
double-dummy	O
,	O
global	O
phase	B-Design_Phase_3
3	I-Design_Phase_3
trial	O
,	O
patients	O
were	O
randomized	O
1:1	B-Randomization_Ratio
to	O
receive	O
intravenous	B-Design_Parallel_Group
tedizolid	I-Design_Parallel_Group
phosphate	I-Design_Parallel_Group
200	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
once	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
for	I-Design_Parallel_Group
7	I-Design_Parallel_Group
days	I-Design_Parallel_Group
or	I-Design_Parallel_Group
intravenous	I-Design_Parallel_Group
linezolid	I-Design_Parallel_Group
600	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
every	I-Design_Parallel_Group
12	I-Design_Parallel_Group
hours	I-Design_Parallel_Group
for	I-Design_Parallel_Group
10	I-Design_Parallel_Group
days	I-Design_Parallel_Group
.	O

Modified-	O
versus	O
immediate-release	O
tofacitinib	O
in	O
Japanese	O
rheumatoid	O
arthritis	O
patients	O
:	O
a	O
randomized	B-Randomization_Type_Simple
,	O
phase	B-Design_Phase_3
III	I-Design_Phase_3
,	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
study	O

Randomisation	O
and	O
masking	O
Study	O
drug	O
packs	O
were	O
prepared	O
by	O
Bilcare	O
Global	O
Clinical	O
Supplies	O
(	O
Europe	O
;	O
Powys	O
,	O
UK	B-Settings_Location
)	O
.	O

Based	O
on	O
simulations	O
,	O
a	O
sample	O
size	O
of	O
at	O
least	O
600	B-Sample_Size_Required
participants	O
(	O
100	O
in	O
each	O
of	O
the	O
6	O
study	O
treatment	O
groups	O
)	O
was	O
used	O
to	O
allow	O
for	O
adequate	O
precision	O
in	O
estimation	O
of	O
the	O
35	O
mg	O
DNX	O
dose	O
as	O
well	O
as	O
a	O
sufficient	O
proportion	O
with	O
90	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
confidence	O
interval	O
(	O
CI	O
)	O
difference	O
from	O
placebo	O
excluding	O
0	O
,	O
and	O
a	O
sufficient	O
proportion	O
with	O
90	O
%	O
CI	O
of	O
dose	O
estimate	O
excluding	O
0	O
.	O

The	O
Duke	O
Family	O
Planning	O
Clinic	O
is	O
a	O
hospital-affiliated	O
clinic	O
that	O
provides	O
care	O
to	O
both	O
insured	O
and	O
uninsured	O
patients	O
in	O
Durham	B-Settings_Location
,	I-Settings_Location
North	I-Settings_Location
Carolina	I-Settings_Location
.	O

The	O
primary	O
objective	O
was	O
to	O
demonstrate	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
of	O
MR	O
11	O
mg	O
QD	O
to	O
IR	O
5	O
mg	O
BID	O
.	O

PAST-BP	O
was	O
an	O
individually	O
randomised	O
trial	O
in	O
which	O
participants	O
were	O
allocated	O
to	O
either	O
an	B-Design_Parallel_Group
intensive	I-Design_Parallel_Group
blood	I-Design_Parallel_Group
pressure	I-Design_Parallel_Group
target	I-Design_Parallel_Group
(	I-Design_Parallel_Group
<	I-Design_Parallel_Group
130	I-Design_Parallel_Group
mm	I-Design_Parallel_Group
Hg	I-Design_Parallel_Group
or	I-Design_Parallel_Group
a	I-Design_Parallel_Group
10	I-Design_Parallel_Group
mm	I-Design_Parallel_Group
Hg	I-Design_Parallel_Group
reduction	I-Design_Parallel_Group
if	I-Design_Parallel_Group
baseline	I-Design_Parallel_Group
pressure	I-Design_Parallel_Group
was	I-Design_Parallel_Group
<	I-Design_Parallel_Group
140	I-Design_Parallel_Group
mm	I-Design_Parallel_Group
Hg	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
a	I-Design_Parallel_Group
standard	I-Design_Parallel_Group
target	I-Design_Parallel_Group
(	I-Design_Parallel_Group
<	I-Design_Parallel_Group
140	I-Design_Parallel_Group
mm	I-Design_Parallel_Group
Hg	I-Design_Parallel_Group
)	I-Design_Parallel_Group
.	O

Of	O
the	O
nine	O
subjects	O
who	O
were	O
randomised	O
,	O
three	B-Sample_Size_Actual_at_Outcome_Analysis
subjects	O
(	O
33.3	O
%	O
)	O
completed	O
the	O
study	O
.	O

Phase	B-Design_Phase_2
II	I-Design_Phase_2
,	O
randomised	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
multicentre	B-Settings_Multicenter
study	O
evaluating	O
the	O
safety	O
and	O
efficacy	O
of	O
filgotinib	O
and	O
lanraplenib	O
in	O
patients	O
with	O
lupus	O
membranous	O
nephropathy	O

Patients	O
were	O
randomly	O
assigned	O
using	O
an	B-Randomization_Sequence_Generation_Method
interactive	I-Randomization_Sequence_Generation_Method
voice	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
to	O
blinded	O
(	O
patient	B-Blinding_Object_Patients
and	O
treating	B-Blinding_Object_Care_Providers
clinical	I-Blinding_Object_Care_Providers
team	I-Blinding_Object_Care_Providers
)	O
intravenous	O
treatment	O
with	O
TCZ	B-Design_Parallel_Group
8	I-Design_Parallel_Group
mg/kg	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
in	O
a	O
1:1	B-Randomization_Ratio
ratio	O
,	O
both	O
in	O
combination	O
with	O
oral	O
MTX	O
,	O
every	O
4	O
weeks	O
for	O
6	O
months	O
between	O
November	O
2007	O
and	O
June	O
2008	O
.	O

A	O
sample	O
size	O
of	O
162	B-Sample_Size_Required
subjects	O
(	O
81	O
per	O
treatment	O
group	O
)	O
provided	O
≥90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
show	O
PK	O
equivalence	O
of	O
CT‐P17	O
AI	O
and	O
CT‐P17	O
PFS	O
,	O
given	O
the	O
primary	O
endpoint	O
equivalence	O
margin	O
,	O
expected	O
geometric	O
mean	O
ratio	O
of	O
1.0	O
,	O
and	O
coefficient	O
of	O
variation	O
of	O
45	O
%	O
(	O
assumed	O
based	O
on	O
historical	O
PK	O
data	O
in	O
healthy	O
individuals	O
)	O
.	O

Results	O
:	O
In	O
total	O
,	O
173	B-Sample_Size_Actual_at_Enrollment
children	I-Sample_Size_Actual_at_Enrollment
were	O
randomized	O
and	O
dosed	O
,	O
115	O
to	O
the	O
baloxavir	O
group	O
and	O
58	O
to	O
the	O
oseltamivir	O
group	O
.	O

Eligible	O
patients	O
were	O
randomized	O
at	O
2:2:1:1	B-Randomization_Ratio
into	O
four	O
groups	O
:	O
420	O
mg	O
evolocumab	O
every	O
4	O
weeks	O
(	O
Q4W	O
)	O
+	O
oral	O
placebo	O
daily	O
,	O
140	O
mg	O
evolocumab	O
every	O
2	O
weeks	O
(	O
Q2W	O
)	O
+	O
oral	O
placebo	O
daily	O
,	O
subcutaneous	O
(	O
SC	O
)	O
placebo	O
Q4W	O
+	O
10	O
mg	O
ezetimibe	O
daily	O
,	O
and	O
SC	O
placebo	O
Q2W	O
+	O
10	O
mg	O
ezetimibe	O
daily	O
.	O

GO-DACT	O
:	O
a	O
phase	B-Design_Phase_3
3b	I-Design_Phase_3
randomised	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
trial	O
of	O
GOlimumab	O
plus	O
methotrexate	O
(	O
MTX	O
)	O
versus	O
placebo	O
plus	O
MTX	O
in	O
improving	O
DACTylitis	O
in	O
MTX-naive	O
patients	O
with	O
psoriatic	O
arthritis	O

Methods	O
Patients	O
(	O
N	O
=	O
189	B-Sample_Size_Actual_at_Enrollment
)	O
with	O
atherosclerotic	O
disease	O
and	O
either	O
type	O
2	O
diabetes	O
mellitus	O
or	O
impaired	O
glucose	O
tolerance	O
were	O
randomized	O
to	O
receive	O
placebo	B-Design_Parallel_Group
(	I-Design_Parallel_Group
n	I-Design_Parallel_Group
=	I-Design_Parallel_Group
94	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
canakinumab	I-Design_Parallel_Group
150	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
monthly	I-Design_Parallel_Group
(	I-Design_Parallel_Group
n	I-Design_Parallel_Group
=	I-Design_Parallel_Group
95	I-Design_Parallel_Group
)	I-Design_Parallel_Group
for	O
12	O
months	O
.	O

Thus	O
,	O
57	B-Sample_Size_Actual_at_Outcome_Analysis
patients	O
(	O
97	O
%	O
)	O
completed	O
the	O
extension	O
.	O

One	O
patient	O
in	O
the	O
gabapentin	O
group	O
did	O
not	O
complete	O
the	O
procedure	O
,	O
for	O
a	O
total	O
of	O
95	B-Sample_Size_Actual_at_Outcome_Analysis
patients	O
who	O
received	O
their	O
allocated	O
intervention	O
.	O

Patients	O
were	O
recruited	O
from	O
106	B-Settings_Multicenter
general	I-Settings_Multicenter
practices	I-Settings_Multicenter
(	O
of	O
which	O
99	O
contributed	O
at	O
least	O
one	O
patient	O
)	O
in	O
England	B-Settings_Location
during	O
2009-11	O
.	O

The	O
study	O
sample	O
size	O
was	O
determined	O
based	O
on	O
the	O
following	O
assumptions	O
for	O
treatment	O
comparisons	O
:	O
one-sided	B-Sample_Size_Calculation_Alpha_Value
type	I-Sample_Size_Calculation_Alpha_Value
I	I-Sample_Size_Calculation_Alpha_Value
error	I-Sample_Size_Calculation_Alpha_Value
of	I-Sample_Size_Calculation_Alpha_Value
0.025	I-Sample_Size_Calculation_Alpha_Value
;	O
patient	O
assignment	O
to	O
treatment	O
in	O
a	O
1:1	B-Randomization_Ratio
ratio	O
;	O
the	O
true	O
difference	O
in	O
treatment	O
means	O
between	O
the	O
tofacitinib	O
formulations	O
of	O
zero	O
;	O
and	O
an	O
s.d	O
.	O

Methods	O
This	O
was	O
a	O
3	O
week	O
,	O
randomised	O
,	O
stratified	B-Randomization_Type_Stratified
,	O
examiner-blind	B-Blinding_Single_Blind
,	O
two-treatment	O
,	O
parallel-group	B-Design_Parallel_Group
clinical	O
trial	O
performed	O
at	O
a	B-Settings_Single_Center
clinical	I-Settings_Single_Center
study	I-Settings_Single_Center
centre	I-Settings_Single_Center
in	O
Las	B-Settings_Location
Vegas	I-Settings_Location
,	I-Settings_Location
USA	I-Settings_Location
.	O

To	O
ensure	O
120	O
datasets	O
with	O
12-month	O
follow-up	O
data	O
,	O
it	O
was	O
planned	O
to	O
randomize	O
190	B-Sample_Size_Target
patients	O
.	O

An	O
independent	B-Blinding_Object_Others
medical	I-Blinding_Object_Others
monitor	I-Blinding_Object_Others
(	O
who	O
was	O
unaware	O
of	O
the	O
treatment-group	O
assignments	O
)	O
reviewed	O
all	O
accruing	O
safety	O
data	O
.	O

Randomisation	O
was	O
stratified	B-Randomization_Type_Stratified
by	O
prior	B-Randomization_Stratified_Criteria
treatment	I-Randomization_Stratified_Criteria
with	I-Randomization_Stratified_Criteria
cyclophosphamide	I-Randomization_Stratified_Criteria
.	O

Randomisation	O
was	O
undertaken	O
by	O
the	O
Biostatistics	B-Randomization_Personnel
Department	I-Randomization_Personnel
of	I-Randomization_Personnel
the	I-Randomization_Personnel
study	I-Randomization_Personnel
sponsor	I-Randomization_Personnel
using	O
validated	B-Randomization_Sequence_Generation_Method
internal	I-Randomization_Sequence_Generation_Method
software	I-Randomization_Sequence_Generation_Method
.	O

Including	O
a	O
5	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
dropout	O
rate	O
,	O
we	O
estimated	O
that	O
100	B-Sample_Size_Required
patients	O
,	O
at	O
α=0.05	O
,	O
would	O
have	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
the	O
difference	O
between	O
groups	O
.	O

With	O
a	O
sample	O
size	O
of	O
80	B-Sample_Size_Required
patients	O
,	O
we	O
had	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
this	O
40	O
%	O
difference	O
in	O
AUC	O
cTnI	O
with	O
a	O
significance	O
level	O
of	O
5	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
,	O
using	O
a	O
t	O
test	O
with	O
unequal	O
variances	O
and	O
allowing	O
for	O
four	B-Sample_Size_Calculation_Dropout_Rate_Value
dropouts	I-Sample_Size_Calculation_Dropout_Rate_Value
in	I-Sample_Size_Calculation_Dropout_Rate_Value
each	I-Sample_Size_Calculation_Dropout_Rate_Value
arm	I-Sample_Size_Calculation_Dropout_Rate_Value
.	O

A	O
sample	O
size	O
of	O
120	B-Sample_Size_Required
patients	O
(	O
60	O
per	O
arm	O
)	O
,	O
calculated	O
based	O
on	O
previous	O
results	O
in	O
patients	O
with	O
RA	O
,	O
was	O
expected	O
to	O
provide	O
sufficient	O
power	O
to	O
detect	O
a	O
difference	O
at	O
week	O
12	O
in	O
PWV	O
(	O
−1.14	O
m/s	O
)	O
and	O
small	O
LDL	O
(	O
−5.51	O
mg/dL	O
(	O
30	O
%	O
reduction	O
)	O
)	O
in	O
patients	O
treated	O
with	O
TCZ	B-Design_Parallel_Group
compared	I-Design_Parallel_Group
with	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
.	O

Based	O
on	O
these	O
assumptions	O
,	O
a	O
total	O
of	O
⩾200	O
patients	O
(	O
100	O
per	O
treatment	O
arm	O
)	O
were	O
required	O
to	O
demonstrate	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
with	O
a	O
power	O
of	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
.	O

Methods	O
A	O
randomized	O
,	O
open-label	B-Blinding_Open_Label
trial	O
was	O
conducted	O
at	O
19	B-Settings_Multicenter
hospitals/clinics	I-Settings_Multicenter
in	O
Argentina	B-Settings_Location
,	I-Settings_Location
Brazil	I-Settings_Location
,	I-Settings_Location
South	I-Settings_Location
Africa	I-Settings_Location
,	I-Settings_Location
Tanzania	I-Settings_Location
,	I-Settings_Location
Thailand	I-Settings_Location
,	I-Settings_Location
and	I-Settings_Location
the	I-Settings_Location
US	I-Settings_Location
.	O

Non-inferiority	B-Design_Comparative_Intent_NonInferiority
was	O
defined	O
by	O
a	O
difference	O
of	O
less	O
than	O
15	O
%	O
for	O
treatment	O
failure	O
.	O

The	O
block	O
size	O
was	O
six	B-Randomization_Block_Size
.	O

Study	O
Design	O
This	O
was	O
a	O
randomized	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
multicenter	B-Settings_Multicenter
,	O
placebo	O
,	O
and	O
active	O
comparator-controlled	O
trial	O
designed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
once-daily	O
aprocitentan	O
5	O
,	O
10	O
,	O
25	O
,	O
and	O
50	O
mg	O
in	O
patients	O
with	O
grade	O
1	O
to	O
2	O
essential	O
hypertension	O
.	O

METHODS	O
This	O
was	O
a	O
prospective	O
,	O
randomized	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
trial	O
approved	O
by	O
the	O
Duke	O
Health	O
Institutional	O
Review	O
Board	O
(	O
Pro00063872	O
)	O
.	O

A	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
,	O
randomized	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
trial	O
of	O
AMG	O
301	O
,	O
a	O
pituitary	O
adenylate	O
cyclase-activating	O
polypeptide	O
PAC1	O
receptor	O
monoclonal	O
antibody	O
for	O
migraine	O
prevention	O

Methods	O
Study	O
Design	O
and	O
Participants	O
We	O
conducted	O
a	O
prospective	O
,	O
randomized	O
,	O
blinded	B-Blinding_Double_Blind
clinical	O
trial	O
at	O
CDC-sponsored	B-Settings_Multicenter
Clinical	I-Settings_Multicenter
Immunization	I-Settings_Multicenter
Safety	I-Settings_Multicenter
Assessment	I-Settings_Multicenter
(	I-Settings_Multicenter
CISA	I-Settings_Multicenter
)	I-Settings_Multicenter
Project	I-Settings_Multicenter
centers	I-Settings_Multicenter
during	O
the	O
2017	O
to	O
2018	O
(	O
Duke	O
University	O
Medical	O
Center	O
and	O
Boston	O
Medical	O
Center	O
)	O
and	O
2018	O
to	O
2019	O
(	O
Duke	O
,	O
Boston	O
,	O
and	O
Cincinnati	O
Children	O
’	O
s	O
Hospital	O
Medical	O
Center	O
)	O
influenza	O
seasons	O
.	O

Patients	O
were	O
randomised	O
(	O
1:1	B-Randomization_Ratio
)	O
to	O
receive	O
elafin	B-Design_Parallel_Group
or	I-Design_Parallel_Group
matched	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
by	O
Edinburgh	B-Settings_Location
Clinical	I-Settings_Location
Trials	I-Settings_Location
Unit	I-Settings_Location
to	O
ensure	O
allocation	O
concealment	O
.	O

However	O
,	O
trimethoprim-sulfamethoxazole	O
did	O
not	O
meet	O
the	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
criterion—absolute	O
difference	O
10.4	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
−1.2	O
%	O
to	O
21.5	O
%	O
)	O
.	O

The	O
participant	B-Blinding_Object_Patients
,	O
study	B-Blinding_Object_Others
site	I-Blinding_Object_Others
personnel	I-Blinding_Object_Others
(	O
including	O
investigators	B-Blinding_Object_Investigators
)	O
and	O
sponsor	B-Blinding_Object_Others
’	I-Blinding_Object_Others
s	I-Blinding_Object_Others
clinical	I-Blinding_Object_Others
team	I-Blinding_Object_Others
members	I-Blinding_Object_Others
involved	O
in	O
the	O
study	O
were	O
blinded	O
to	O
the	O
vaccine	O
dose	O
administered	O
,	O
with	O
the	O
exception	O
of	O
unblinded	O
qualified	O
study	O
staff	O
who	O
administered	O
the	O
vaccine	O
.	O

Interventions	O
Patients	O
were	O
randomized	O
2:1	B-Randomization_Ratio
to	O
either	O
IIM	B-Design_Parallel_Group
(	I-Design_Parallel_Group
Monofer®/Monoferric®	I-Design_Parallel_Group
,	I-Design_Parallel_Group
Pharmacosmos	I-Design_Parallel_Group
A/S	I-Design_Parallel_Group
,	I-Design_Parallel_Group
Holbaek	I-Design_Parallel_Group
,	I-Design_Parallel_Group
Denmark	I-Design_Parallel_Group
)	I-Design_Parallel_Group
administered	I-Design_Parallel_Group
at	I-Design_Parallel_Group
baseline	I-Design_Parallel_Group
as	I-Design_Parallel_Group
a	I-Design_Parallel_Group
single	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
of	I-Design_Parallel_Group
1000	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
infused	I-Design_Parallel_Group
over	I-Design_Parallel_Group
20	I-Design_Parallel_Group
min	I-Design_Parallel_Group
or	I-Design_Parallel_Group
IS	I-Design_Parallel_Group
(	I-Design_Parallel_Group
Venofer®	I-Design_Parallel_Group
,	I-Design_Parallel_Group
American	I-Design_Parallel_Group
Regent	I-Design_Parallel_Group
,	I-Design_Parallel_Group
Shirley	I-Design_Parallel_Group
,	I-Design_Parallel_Group
NY	I-Design_Parallel_Group
,	I-Design_Parallel_Group
USA	I-Design_Parallel_Group
)	I-Design_Parallel_Group
administered	I-Design_Parallel_Group
as	I-Design_Parallel_Group
200	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
IV	I-Design_Parallel_Group
injections	I-Design_Parallel_Group
repeated	O
according	O
to	O
standard	O
practice	O
or	O
physician	O
choice	O
up	O
to	O
a	O
maximum	O
of	O
five	O
times	O
within	O
the	O
first	O
2	O
weeks	O
starting	O
at	O
baseline	O
.	O

Results	O
Patient	O
disposition	O
and	O
baseline	O
characteristics	O
Overall	O
,	O
140	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomly	O
assigned	O
to	O
treatment	O
groups	O
,	O
and	O
110	B-Sample_Size_Actual_at_Outcome_Analysis
(	O
79	O
%	O
)	O
patients	O
completed	O
four	O
treatment	O
periods	O
with	O
120	O
included	O
in	O
the	O
mITT	O
population	O
(	O
Fig	O
.	O

Randomization	O
was	O
performed	O
through	O
an	O
interactive	B-Randomization_Sequence_Generation_Method
voice	I-Randomization_Sequence_Generation_Method
and	I-Randomization_Sequence_Generation_Method
web	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
(	I-Randomization_Sequence_Generation_Method
IxRS	I-Randomization_Sequence_Generation_Method
)	I-Randomization_Sequence_Generation_Method
and	O
stratified	B-Randomization_Type_Stratified
for	O
baseline	B-Randomization_Stratified_Criteria
BCVA	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
ETDRS	I-Randomization_Stratified_Criteria
letter	I-Randomization_Stratified_Criteria
score	I-Randomization_Stratified_Criteria
≥55	I-Randomization_Stratified_Criteria
vs	I-Randomization_Stratified_Criteria
≤54	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
.	O

Results	O
Disposition	O
and	O
demographics	O
Of	O
124	O
screened	O
participants	O
,	O
89	B-Sample_Size_Actual_at_Enrollment
were	O
randomized	O
(	O
placebo	O
,	O
n	O
=	O
44	O
;	O
SHP465	O
MAS	O
,	O
n	O
=	O
45	O
;	O
Fig	O
.	O

We	O
used	O
a	B-Randomization_Sequence_Generation_Method
computer-generated	I-Randomization_Sequence_Generation_Method
randomisation	I-Randomization_Sequence_Generation_Method
sequence	I-Randomization_Sequence_Generation_Method
with	O
a	O
block	B-Randomization_Type_Block
size	O
of	O
eight	B-Randomization_Block_Size
.	O

Sample	O
size	O
and	O
statistical	O
analysis	O
The	O
primary	O
objective	O
was	O
to	O
demonstrate	O
equivalence	B-Design_Comparative_Intent_Equivalence
of	O
ACR20	O
at	O
week	O
30	O
.	O

Antiretroviralnaïve	O
pregnant	O
women	O
(	O
20–36	O
weeks	O
gestation	O
)	O
living	O
with	O
HIV	O
were	O
assigned	O
to	O
antiretroviral	B-Design_Parallel_Group
regimens	I-Design_Parallel_Group
containing	I-Design_Parallel_Group
either	I-Design_Parallel_Group
RAL	I-Design_Parallel_Group
(	I-Design_Parallel_Group
400mg	I-Design_Parallel_Group
twice	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
EFV	I-Design_Parallel_Group
(	I-Design_Parallel_Group
600	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
each	I-Design_Parallel_Group
night	I-Design_Parallel_Group
)	I-Design_Parallel_Group
,	O
plus	O
lamivudine	O
150	O
mg/zidovudine	O
300	O
mg	O
twice	O
daily	O
(	O
or	O
approved	O
alternative	O
backbone	O
regimen	O
)	O
,	O
using	O
a	B-Randomization_Sequence_Generation_Method
web-based	I-Randomization_Sequence_Generation_Method
,	I-Randomization_Sequence_Generation_Method
permuted-block	B-Randomization_Type_Block
randomization	I-Randomization_Sequence_Generation_Method
stratified	B-Randomization_Type_Stratified
by	O
gestational	B-Randomization_Stratified_Criteria
age	I-Randomization_Stratified_Criteria
and	O
backbone	B-Randomization_Stratified_Criteria
regimen	I-Randomization_Stratified_Criteria
.	O

Patients	O
were	O
enrolled	O
from	O
one	B-Settings_Multicenter
center	I-Settings_Multicenter
in	I-Settings_Multicenter
Hong	I-Settings_Multicenter
Kong	I-Settings_Multicenter
and	I-Settings_Multicenter
five	I-Settings_Multicenter
centers	I-Settings_Multicenter
in	I-Settings_Multicenter
the	I-Settings_Multicenter
Republic	I-Settings_Multicenter
of	I-Settings_Multicenter
Korea	I-Settings_Multicenter
.	O

A	O
Phase	B-Design_Phase_2
II	I-Design_Phase_2
Trial	O
of	O
Safety	O
,	O
Tolerability	O
and	O
Immunogenicity	O
of	O
V114	O
,	O
a	O
15-Valent	O
Pneumococcal	O
Conjugate	O
Vaccine	O
,	O
Compared	O
With	O
13-Valent	O
Pneumococcal	O
Conjugate	O
Vaccine	O
in	O
Healthy	O
Infants	O

In	O
the	O
analysis	O
of	O
the	O
primary	O
outcome	O
performed	O
on	O
all	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
the	O
interventional	O
treatment	O
(	O
eg	O
,	O
103	B-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
in	I-Sample_Size_Actual_at_Outcome_Analysis
the	I-Sample_Size_Actual_at_Outcome_Analysis
rhEPO	I-Sample_Size_Actual_at_Outcome_Analysis
arm	I-Sample_Size_Actual_at_Outcome_Analysis
and	I-Sample_Size_Actual_at_Outcome_Analysis
97	I-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
in	I-Sample_Size_Actual_at_Outcome_Analysis
the	I-Sample_Size_Actual_at_Outcome_Analysis
placebo	I-Sample_Size_Actual_at_Outcome_Analysis
arm	I-Sample_Size_Actual_at_Outcome_Analysis
)	O
,	O
the	O
rate	O
of	O
events	O
(	O
death	O
,	O
tracheotomy	O
,	O
>	O
23	O
h	O
NIV	O
)	O
at	O
12-month	O
follow-up	O
did	O
not	O
differ	O
between	O
the	O
treatment	O
groups	O
,	O
even	O
after	O
stratification	O
by	O
disease	O
severity	O
and	O
onset	O
(	O
table	O
2	O
)	O
.	O

Blinded	O
assessors	B-Blinding_Object_Outcome_Assessors
from	O
all	O
centres	O
underwent	O
training	O
with	O
an	O
expert	O
assessor	O
,	O
and	O
certification	O
was	O
provided	O
by	O
AtCor	O
.	O

Results	O
:	O
Overall	O
,	O
1044	O
of	O
1051	B-Sample_Size_Actual_at_Enrollment
randomized	O
infants	O
received	O
≥1	O
dose	O
of	O
vaccine	O
(	O
V114	O
Lot	O
1	O
[	O
n	O
=	O
350	O
]	O
,	O
V114	O
Lot	O
2	O
[	O
n	O
=	O
347	O
]	O
or	O
PCV13	O
[	O
n	O
=	O
347	O
]	O
)	O
.	O

Effect	O
on	O
the	O
incidence	O
of	O
pneumonia	O
of	O
vitamin	O
D	O
supplementation	O
by	O
quarterly	O
bolus	O
dose	O
to	O
infants	O
in	O
Kabul	B-Settings_Location
:	O
a	O
randomised	O
controlled	O
superiority	B-Design_Comparative_Intent_Superiority
trial	O

Design	O
,	O
Setting	O
,	O
and	O
Participants	O
This	O
randomized	O
blinded	O
clinical	O
trial	O
was	O
a	O
multicenter	B-Settings_Multicenter
US	B-Settings_Location
study	O
conducted	O
during	O
the	O
2017	O
to	O
2018	O
and	O
2018	O
to	O
2019	O
influenza	O
seasons	O
.	O

Taking	O
into	O
account	O
an	O
expected	O
15	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
dropout	O
rate	O
,	O
60	B-Sample_Size_Target
participants	O
were	O
targeted	O
for	O
randomization	O
.	O

The	O
primary	O
hypotheses	O
were	O
that	O
:	O
1	O
)	O
intravitreal	O
triamcinolone	O
acetonide	O
will	O
have	O
superior	B-Design_Comparative_Intent_Superiority
efficacy	O
to	O
periocular	O
triamcinolone	O
acetonide	O
in	O
the	O
treatment	O
of	O
uveitic	O
macular	O
edema	O
;	O
2	O
)	O
the	O
intravitreal	O
dexamethasone	O
implant	O
will	O
have	O
superior	B-Design_Comparative_Intent_Superiority
efficacy	O
to	O
periocular	O
triamcinolone	O
acetonide	O
in	O
the	O
treatment	O
of	O
uveitic	O
macular	O
edema	O
;	O
and	O
that	O
3	O
)	O
the	O
intravitreal	O
dexamethasone	O
implant	O
will	O
be	O
non-inferior	O
to	O
intravitreal	O
triamcinolone	O
acetonide	O
in	O
the	O
treatment	O
of	O
uveitic	O
macular	O
edema	O
.	O

This	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
double-blinded	B-Blinding_Double_Blind
,	O
randomized	O
,	O
placebo-controlled	O
trial	O
is	O
the	O
first	O
evaluation	O
of	O
the	O
safety	O
and	O
activity	O
of	O
an	O
antisense	O
oligonucleotide	O
targeting	O
HBV	O
RNA	O
in	O
both	O
treatment-naïve	O
and	O
virally	O
suppressed	O
individuals	O
with	O
chronic	O
HBV	O
infection	O
.	O

Patients	B-Blinding_Object_Patients
,	O
physicians	B-Blinding_Object_Care_Providers
,	O
and	O
investigators	B-Blinding_Object_Investigators
were	O
masked	O
to	O
treatment	O
allocation	O
.	O

After	O
a	O
single-blind	O
placebo	O
run-in	O
period	O
,	O
490	B-Sample_Size_Actual_at_Enrollment
eligible	O
patients	O
were	O
randomized	O
to	O
the	O
double-blind	O
phase	O
,	O
with	O
409	B-Sample_Size_Actual_at_Outcome_Analysis
patients	O
completing	O
8	O
weeks	O
of	O
therapy	O
per	O
protocol	O
.	O

Recruitment	O
was	O
stopped	O
after	O
the	O
second	O
interim	O
analysis	O
,	O
when	O
the	O
Data	O
Monitoring	O
and	O
Ethics	O
Committee	O
reviewed	O
the	O
results	O
for	O
273	B-Sample_Size_Actual_at_Outcome_Analysis
patients	O
in	O
March	O
,	O
2010	O
.	O

Intranasal	B-Design_Parallel_Group
fentanyl	I-Design_Parallel_Group
spray	I-Design_Parallel_Group
versus	I-Design_Parallel_Group
intravenous	I-Design_Parallel_Group
opioids	I-Design_Parallel_Group
for	O
the	O
treatment	O
of	O
severe	O
pain	O
in	O
patients	O
with	O
cancer	O
in	O
the	O
emergency	O
department	O
setting	O
:	O
A	O
randomized	B-Randomization_Type_Simple
controlled	O
trial	O

All	O
patients	B-Blinding_Object_Patients
and	O
study	B-Blinding_Object_Others
personnel	I-Blinding_Object_Others
were	O
blinded	O
to	O
the	O
investigational	O
products	O
and	O
doses	O
.	O

A	O
sample	O
size	O
of	O
90	B-Sample_Size_Required
patients	I-Sample_Size_Required
in	I-Sample_Size_Required
each	I-Sample_Size_Required
treatment	I-Sample_Size_Required
group	I-Sample_Size_Required
was	O
expected	O
to	O
provide	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
difference	O
of	O
20	O
%	O
in	O
the	O
CSBM	O
responder	O
rate	O
between	O
the	O
placebo	O
group	O
and	O
at	O
least	O
one	O
of	O
the	O
tenapanor	O
treatment	O
groups	O
.	O

The	O
primary	B-Blinding_Object_Investigators
investigator/treating	I-Blinding_Object_Investigators
neurologist	I-Blinding_Object_Investigators
,	O
independent	B-Blinding_Object_Outcome_Assessors
evaluating	I-Blinding_Object_Outcome_Assessors
neurologist	I-Blinding_Object_Outcome_Assessors
,	O
physician	B-Blinding_Object_Outcome_Assessors
evaluating	I-Blinding_Object_Outcome_Assessors
cardiac	I-Blinding_Object_Outcome_Assessors
safety	I-Blinding_Object_Outcome_Assessors
assessments	I-Blinding_Object_Outcome_Assessors
,	O
care	B-Blinding_Object_Care_Providers
providers	I-Blinding_Object_Care_Providers
,	O
patients	B-Blinding_Object_Patients
and	O
sponsor	B-Blinding_Object_Others
were	O
blinded	O
to	O
the	O
treatment	O
.	O

Patients	B-Blinding_Object_Patients
and	O
evaluators	B-Blinding_Object_Outcome_Assessors
were	O
blinded	O
to	O
the	O
treatment	O
received	O
.	O

Seventeen	B-Sample_Size_Actual_at_Outcome_Analysis
completed	O
the	O
6-month	O
study	O
,	O
10	O
in	O
the	O
AI+WL	O
arm	O
and	O
7	O
in	O
the	O
PBO+WL	O
arm	O
.	O

The	O
trial	O
consisted	O
of	O
a	O
screening	O
phase	O
(	O
up	O
to	O
4	O
weeks	O
)	O
,	O
a	O
double-blind	O
phase	O
(	O
minimum	O
of	O
12	O
weeks	O
)	O
,	O
and	O
an	O
open-label	B-Blinding_Open_Label
phase	O
(	O
maximum	O
of	O
36	O
weeks	O
)	O
.	O

Allocation	O
was	O
concealed	O
in	O
sealed	B-Allocation_Concealment_Method
,	I-Allocation_Concealment_Method
opaque	I-Allocation_Concealment_Method
numbered	I-Allocation_Concealment_Method
envelopes	I-Allocation_Concealment_Method
that	O
were	O
opened	O
consecutively	O
after	O
informed	O
consent	O
was	O
obtained	O
.	O

Objective	O
A	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
,	O
double‐blind	B-Blinding_Double_Blind
,	O
placebo‐controlled	O
study	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
erenumab	O
for	O
the	O
prevention	O
of	O
episodic	O
migraine	O
in	O
Japanese	B-Settings_Location
patients	O
was	O
conducted	O
.	O

Statistical	O
analysis	O
The	O
planned	O
sample	O
size	O
was	O
120	B-Sample_Size_Required
patients	O
,	O
designed	O
to	O
provide	O
approximately	O
93	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
differences	O
of	O
100	O
mL	O
in	O
FEV1	O
AUC0–12	O
.	O

Study	O
design	O
A	O
randomized	O
,	O
multi-center	B-Settings_Multicenter
,	O
double-blinded	B-Blinding_Double_Blind
,	O
placebo-controlled	O
clinical	O
trial	O
was	O
conducted	O
in	O
21	B-Settings_Multicenter
centers	I-Settings_Multicenter
across	O
China	B-Settings_Location
.	O

Results	O
Sixty-nine	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
TCZ+MTX	O
and	O
sixty-three	B-Sample_Size_Actual_at_Enrollment
to	O
receive	O
placebo+MTX	O
(	O
figure	O
1	O
)	O
.	O

Results	O
Of	O
343	B-Sample_Size_Actual_at_Enrollment
randomized	O
patients	O
(	O
mean	O
age	O
,	O
41.8–42.5	O
years	O
)	O
,	O
the	O
majority	O
were	O
women	O
(	O
85.4–90.4	O
%	O
)	O
,	O
white	O
(	O
94.1–96.2	O
%	O
)	O
,	O
and	O
had	O
episodic	O
migraine	O
(	O
62.5–67.9	O
%	O
)	O
.	O

Randomisation	O
incorporated	O
minimisation	B-Randomization_Type_Minimization
for	O
age	B-Randomization_Minimization_Criteria
,	O
presence	B-Randomization_Minimization_Criteria
of	I-Randomization_Minimization_Criteria
diabetes	I-Randomization_Minimization_Criteria
mellitus	I-Randomization_Minimization_Criteria
,	O
extent	B-Randomization_Minimization_Criteria
of	I-Randomization_Minimization_Criteria
coronary	I-Randomization_Minimization_Criteria
artery	I-Randomization_Minimization_Criteria
disease	I-Randomization_Minimization_Criteria
,	O
renal	B-Randomization_Minimization_Criteria
function	I-Randomization_Minimization_Criteria
and	O
surgeon	B-Randomization_Minimization_Criteria
A	I-Randomization_Minimization_Criteria
or	I-Randomization_Minimization_Criteria
B	I-Randomization_Minimization_Criteria
.	O

Results	O
We	O
randomly	O
assigned	O
208	B-Sample_Size_Actual_at_Enrollment
patients	O
,	O
of	O
whom	O
5	O
(	O
1	O
rhEPO	O
and	O
4	O
placebo	O
)	O
withdrew	O
consent	O
and	O
3	O
(	O
placebo	O
)	O
became	O
ineligible	O
(	O
retinal	O
thrombosis	O
,	O
respiratory	O
insufficiency	O
,	O
SOD1	O
mutation	O
)	O
before	O
receiving	O
treatment	O
;	O
103	B-Sample_Size_Actual_at_Outcome_Analysis
receiving	I-Sample_Size_Actual_at_Outcome_Analysis
rhEPO	I-Sample_Size_Actual_at_Outcome_Analysis
and	I-Sample_Size_Actual_at_Outcome_Analysis
97	I-Sample_Size_Actual_at_Outcome_Analysis
placebo	I-Sample_Size_Actual_at_Outcome_Analysis
were	O
eligible	O
for	O
analysis	O
.	O

Anticipating	O
dropout	O
,	O
the	O
study	O
aimed	O
to	O
enroll	O
at	O
least	O
720	B-Sample_Size_Target
participants	O
.	O

This	O
update	O
set	O
the	O
goal	O
of	O
enrolling	O
at	O
least	O
71	B-Sample_Size_Target
participants	O
and	O
following	O
them	O
until	O
40	O
participants	O
had	O
received	O
a	O
diagnosis	O
of	O
type	O
1	O
diabetes	O
.	O

Safety	O
and	O
efficacy	O
of	O
iron	O
isomaltoside	O
1000/ferric	O
derisomaltose	O
versus	O
iron	O
sucrose	O
in	O
patients	O
with	O
chronic	O
kidney	O
disease	O
:	O
the	O
FERWON-NEPHRO	O
randomized	O
,	O
open-label	B-Blinding_Open_Label
,	O
comparative	O
trial	O

Assuming	O
a	O
treatment	O
effect	O
compared	O
to	O
placebo	O
of	O
−2.0	O
MMD	O
for	O
both	O
AMG	O
301	O
mg	O
treatment	O
groups	O
and	O
a	O
common	O
SD	O
of	O
4.7	O
MMD	O
,	O
the	O
planned	O
sample	O
size	O
of	O
135	B-Sample_Size_Required
patients	I-Sample_Size_Required
for	I-Sample_Size_Required
the	I-Sample_Size_Required
placebo	I-Sample_Size_Required
group	I-Sample_Size_Required
,	I-Sample_Size_Required
100	I-Sample_Size_Required
patients	I-Sample_Size_Required
for	I-Sample_Size_Required
the	I-Sample_Size_Required
AMG	I-Sample_Size_Required
301	I-Sample_Size_Required
420	I-Sample_Size_Required
mg	I-Sample_Size_Required
Q2W	I-Sample_Size_Required
,	I-Sample_Size_Required
and	I-Sample_Size_Required
100	I-Sample_Size_Required
patients	I-Sample_Size_Required
for	I-Sample_Size_Required
the	I-Sample_Size_Required
AMG	I-Sample_Size_Required
301	I-Sample_Size_Required
210	I-Sample_Size_Required
mg	I-Sample_Size_Required
Q4W	I-Sample_Size_Required
group	I-Sample_Size_Required
were	O
to	O
provide	O
≥80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
using	O
a	O
two-sample	O
t-test	O
for	O
each	O
AMG	O
301	O
group	O
versus	O
placebo	O
,	O
with	O
a	B-Sample_Size_Calculation_Alpha_Value
two-sided	I-Sample_Size_Calculation_Alpha_Value
significance	I-Sample_Size_Calculation_Alpha_Value
level	I-Sample_Size_Calculation_Alpha_Value
of	I-Sample_Size_Calculation_Alpha_Value
0.05	I-Sample_Size_Calculation_Alpha_Value
,	O
maintaining	O
a	O
family-wise	O
alpha	O
level	O
of	O
0.10	O
,	O
assuming	O
a	O
10	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
dropout	O
.	O

Study	O
design	O
and	O
treatment	O
This	O
was	O
a	O
randomized	O
,	O
incomplete-block	B-Randomization_Type_Block
,	O
crossover	B-Design_Crossover
,	O
placebo-	B-Blinding_Double_Blind
(	I-Blinding_Double_Blind
blinded	I-Blinding_Double_Blind
)	I-Blinding_Double_Blind
and	O
active-	B-Blinding_Open_Label
(	I-Blinding_Open_Label
open-label	I-Blinding_Open_Label
)	I-Blinding_Open_Label
control	O
study	O
(	O
NCT01566773	O
)	O
,	O
conducted	O
at	O
10	B-Settings_Multicenter
sites	I-Settings_Multicenter
in	O
the	O
USA	B-Settings_Location
from	O
11	O
April	O
2012	O
to	O
10	O
August	O
2012	O
.	O

Assuming	O
that	O
5	O
%	O
of	O
randomized	O
patients	O
do	O
not	O
receive	O
any	O
study	O
drug	O
and	O
with	O
a	O
common	O
SD	O
of	O
approximately	O
20	O
%	O
,	O
the	O
planned	O
sample	O
size	O
provided	O
at	O
least	O
93	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
treatment	O
effect	O
of	O
at	O
least	O
20	O
%	O
reduction	O
for	O
each	O
of	O
the	O
co-primary	O
endpoints	O
in	O
testing	O
the	O
superiority	O
of	O
evolocumab	O
over	O
ezetimibe	O
,	O
based	O
on	O
a	O
two-sided	B-Sample_Size_Calculation_Alpha_Value
t-test	I-Sample_Size_Calculation_Alpha_Value
with	I-Sample_Size_Calculation_Alpha_Value
a	I-Sample_Size_Calculation_Alpha_Value
significance	I-Sample_Size_Calculation_Alpha_Value
level	I-Sample_Size_Calculation_Alpha_Value
of	I-Sample_Size_Calculation_Alpha_Value
0.05	I-Sample_Size_Calculation_Alpha_Value
.	O

With	O
a	O
significance	O
level	O
of	O
5	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
and	O
a	O
power	O
of	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
,	O
a	O
sample	O
size	O
of	O
at	O
least	O
292	B-Sample_Size_Required
randomised	I-Sample_Size_Required
patients	I-Sample_Size_Required
per	I-Sample_Size_Required
treatment	I-Sample_Size_Required
group	I-Sample_Size_Required
was	O
required	O
in	O
order	O
to	O
reach	O
the	O
required	O
subject	O
size	O
for	O
the	O
PPS	O
.	O

Forty	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomized	O
to	O
either	O
IAsp	O
or	O
FA	O
.	O

Study	O
design	O
This	O
study	O
is	O
a	O
phase	B-Design_Phase_3
III	I-Design_Phase_3
,	O
randomised	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
multinational	O
,	O
multicentre	B-Settings_Multicenter
parallel	B-Design_Parallel_Group
group	I-Design_Parallel_Group
study	O
(	O
NCT01936181	O
,	O
EudraCT	O
2012-005733-37	O
)	O
.	O

The	O
randomisation	O
code	O
was	O
generated	O
by	O
the	O
contract	B-Randomization_Personnel
research	I-Randomization_Personnel
organisation	I-Randomization_Personnel
before	O
the	O
study	O
and	O
provided	O
to	O
the	O
study	O
centre	O
pharmacist	O
,	O
with	O
randomisation	O
numbers	O
assigned	O
on	O
day	O
−1	O
.	O

Methods	O
Participants	O
Between	O
Nov	O
4	O
and	O
Dec	O
4	O
,	O
2008	O
,	O
we	O
did	O
a	O
community	O
based	O
randomised	O
placebo-controlled	O
superiority	B-Design_Comparative_Intent_Superiority
trial	O
in	O
Kabul	B-Settings_Location
,	I-Settings_Location
Afghanistan	I-Settings_Location
,	O
within	O
the	O
catchment	O
area	O
of	O
the	O
Maiwand	O
Teaching	O
Hospital	O
,	O
which	O
serves	O
an	O
inner-city	O
population	O
.	O

MATERIALS	O
AND	O
METHODS	O
Trial	O
design	O
This	O
was	O
a	O
randomized	O
,	O
open-label	B-Blinding_Open_Label
,	I-Blinding_Open_Label
comparative	O
and	O
multi-centre	B-Settings_Multicenter
trial	O
conducted	O
from	O
November	O
2016	O
to	O
October	O
2018	O
.	O

This	O
was	O
a	O
prospective	O
,	O
randomized	O
,	O
single‐blind	B-Blinding_Single_Blind
study	O
in	O
troponin‐negative	O
ACS	O
patients	O
.	O

Patients	O
were	O
stratified	B-Randomization_Type_Stratified
at	O
randomisation	O
by	O
age	B-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
52	I-Randomization_Stratified_Criteria
vs	I-Randomization_Stratified_Criteria
≥52	I-Randomization_Stratified_Criteria
years	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
mean	B-Randomization_Stratified_Criteria
arterial	I-Randomization_Stratified_Criteria
blood	I-Randomization_Stratified_Criteria
pressure	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
93.3	I-Randomization_Stratified_Criteria
vs	I-Randomization_Stratified_Criteria
≥93.3	I-Randomization_Stratified_Criteria
mm	I-Randomization_Stratified_Criteria
Hg	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
and	O
CRP	B-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
1.66	I-Randomization_Stratified_Criteria
vs	I-Randomization_Stratified_Criteria
≥1.66	I-Randomization_Stratified_Criteria
mg/dL	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
.	O

Results	O
in	O
the	O
double-blind	B-Blinding_Double_Blind
phase	O
have	O
been	O
published	O
elsewhere	O
as	O
an	O
interim	O
report	O
(	O
Abo	O
,	O
M.	O
,	O
et	O
al.	O
,	O
Prog	O
.	O

Assuming	O
a	O
30	O
%	O
treatment	O
failure	O
rate	O
for	O
both	O
treatment	O
groups	O
,	O
we	O
needed	O
a	O
sample	O
of	O
128	B-Sample_Size_Required
patients	I-Sample_Size_Required
per	I-Sample_Size_Required
arm	I-Sample_Size_Required
for	O
a	O
one	O
sided	O
test	O
to	O
rule	O
out	O
the	O
pre-specified	O
difference	O
in	O
the	O
95	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
confidence	I-Sample_Size_Calculation_Alpha_Value
interval	I-Sample_Size_Calculation_Alpha_Value
of	O
the	O
difference	O
between	O
groups	O
,	O
allowing	O
for	O
10	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
non-evaluable	O
patients	O
(	O
α=0.05	O
,	O
β=0.8	O
)	O
.	O

Results	O
Patient	O
Population	O
Between	O
November	O
2016	O
and	O
January	O
2018	O
,	O
315	O
consecutive	O
patients	O
were	O
screened	O
;	O
of	O
these	O
,	O
100	B-Sample_Size_Actual_at_Enrollment
patients	O
met	O
the	O
inclusion	O
and	O
exclusion	O
criteria	O
and	O
were	O
randomized	O
to	O
CTIC	O
(	O
n=50	O
)	O
versus	O
eptifibatide	O
bolus	O
plus	O
clopidogrel	O
(	O
n=50	O
;	O
Figure	O
2	O
)	O
.	O

Methods	O
:	O
This	O
was	O
a	O
randomized	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
trial	O
of	O
patients	O
from	O
6	O
weeks	O
0	O
days	O
to	O
14	O
weeks	O
6	O
days	O
gestation	O
scheduled	O
to	O
receive	O
surgical	O
abortion	O
at	O
the	O
Duke	B-Settings_Single_Center
Family	I-Settings_Single_Center
Planning	I-Settings_Single_Center
Clinic	I-Settings_Single_Center
.	O

Randomization	O
followed	O
a	B-Randomization_Sequence_Generation_Method
computer-generated	I-Randomization_Sequence_Generation_Method
number	I-Randomization_Sequence_Generation_Method
sequence	I-Randomization_Sequence_Generation_Method
and	O
allocation	O
was	O
conducted	O
by	O
telephone	B-Allocation_Concealment_Method
.	O

The	O
surgeon	B-Blinding_Object_Care_Providers
performing	O
the	O
operation	O
was	O
informed	O
of	O
patient	O
participation	O
in	O
the	O
study	O
but	O
group	O
allocation	O
was	O
not	O
revealed	O
.	O

Patients	O
and	O
methods	O
A	O
multicenter	B-Settings_Multicenter
,	O
open-label	B-Blinding_Open_Label
,	O
phase	B-Design_Phase_1
I	I-Design_Phase_1
trial	O
of	O
abemaciclib	O
in	O
Chinese	O
patients	O
with	O
advanced	O
and/or	O
metastatic	O
cancers	O
was	O
conducted	O
.	O

Results	O
Patients	O
disposition	O
and	O
baseline	O
characteristics	O
A	O
total	O
of	O
44	B-Sample_Size_Actual_at_Enrollment
patients	O
with	O
PsA	O
enroled	O
at	O
11	B-Settings_Multicenter
trial	I-Settings_Multicenter
centres	I-Settings_Multicenter
were	O
randomised	O
.	O

Study	O
Conduct	O
Using	O
a	O
preprogrammed	B-Randomization_Sequence_Generation_Method
interactive	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
technology	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
,	O
participants	O
were	O
randomized	O
in	O
a	O
1:1	B-Randomization_Ratio
ratio	O
to	O
be	O
vaccinated	O
by	O
intramuscular	O
injection	O
with	O
a	O
half	B-Design_Parallel_Group
or	I-Design_Parallel_Group
full	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
of	I-Design_Parallel_Group
IIV4	I-Design_Parallel_Group
.	O

Secondary	O
efficacy	O
analysis	O
for	O
the	O
primary	O
efficacy	O
endpoint	O
assessed	O
the	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
of	O
each	O
treatment	O
group	O
to	O
open-label	O
tiotropium	O
using	O
a	O
margin	O
for	O
clinical	O
relevance	O
of	O
100	O
mL	O
.	O

Randomization	O
:	O
Patients	O
were	O
randomized	O
to	O
receive	O
periocular	B-Design_Parallel_Group
triamcinolone	I-Design_Parallel_Group
acetonide	I-Design_Parallel_Group
,	I-Design_Parallel_Group
intravitreal	I-Design_Parallel_Group
triamcinolone	I-Design_Parallel_Group
acetonide	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
intravitreal	I-Design_Parallel_Group
dexamethasone	I-Design_Parallel_Group
implant	I-Design_Parallel_Group
injections	I-Design_Parallel_Group
in	O
an	O
eligible	O
eye	O
.	O

Participants	B-Blinding_Object_Patients
and	O
investigators	B-Blinding_Object_Investigators
involved	O
in	O
the	O
patient	O
’	O
s	O
follow-up	O
and	O
outcome	O
measurements	O
were	O
masked	O
to	O
treatment	O
allocation	O
during	O
the	O
entire	O
study	O
duration	O
by	O
using	O
identical	B-Allocation_Concealment_Method
envelopes	I-Allocation_Concealment_Method
for	I-Allocation_Concealment_Method
pills	I-Allocation_Concealment_Method
.	O

Setting	O
99	B-Settings_Multicenter
general	I-Settings_Multicenter
practices	I-Settings_Multicenter
in	O
England	B-Settings_Location
,	O
with	O
participants	O
recruited	O
in	O
2009-11	O
.	O

Because	O
of	O
slower-than-expected	O
rates	O
of	O
enrollment	O
,	O
the	O
original	O
protocol	O
(	O
which	O
called	O
for	O
the	O
enrollment	O
of	O
144	O
participants	O
)	O
was	O
revised	O
to	O
detect	O
a	O
60	O
%	O
(	O
previously	O
50	O
%	O
)	O
lower	O
risk	O
in	O
the	O
teplizumab	O
group	O
than	O
in	O
the	O
placebo	O
group	O
(	O
i.e.	O
,	O
a	O
hazard	O
ratio	O
of	O
0.4	O
)	O
with	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
statistical	O
power	O
at	O
an	O
alpha	O
level	O
of	O
0.025	B-Sample_Size_Calculation_Alpha_Value
(	I-Sample_Size_Calculation_Alpha_Value
one-sided	I-Sample_Size_Calculation_Alpha_Value
)	I-Sample_Size_Calculation_Alpha_Value
.	O

An	O
additional	B-Design_Parallel_Group
160	I-Design_Parallel_Group
U	I-Design_Parallel_Group
onabotulinumtoxinA	I-Design_Parallel_Group
(	I-Design_Parallel_Group
400	I-Design_Parallel_Group
U	I-Design_Parallel_Group
group	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
(	I-Design_Parallel_Group
240	I-Design_Parallel_Group
U	I-Design_Parallel_Group
group	I-Design_Parallel_Group
)	I-Design_Parallel_Group
was	O
injected	O
in	O
the	O
elbow	O
flexors	O
.	O

We	O
randomly	O
allocated	O
participants	O
(	O
1:1	B-Randomization_Ratio
)	O
to	O
either	O
perioperative	B-Design_Parallel_Group
intravenous	I-Design_Parallel_Group
(	I-Design_Parallel_Group
IV	I-Design_Parallel_Group
)	I-Design_Parallel_Group
iron	I-Design_Parallel_Group
administration	I-Design_Parallel_Group
(	I-Design_Parallel_Group
intervention	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
usual	I-Design_Parallel_Group
care	I-Design_Parallel_Group
.	O

Results	O
Patients	O
Of	O
1659	O
initially	O
screened	O
patients	O
,	O
996	O
were	O
enrolled	O
in	O
the	O
placebo-run-in	O
period	O
,	O
and	O
490	B-Sample_Size_Actual_at_Enrollment
were	O
randomized	O
(	O
Figure	O
1	O
)	O
.	O

Primary	O
outcome	O
data	O
were	O
available	O
for	O
379	B-Sample_Size_Actual_at_Outcome_Analysis
participants	O
at	O
one	O
year	O
follow-up	O
(	O
182	O
(	O
68	O
%	O
)	O
in	O
the	O
intensive	O
target	O
arm	O
and	O
197	O
(	O
75	O
%	O
)	O
in	O
the	O
standard	O
target	O
arm	O
)	O
.	O

The	O
total	O
sample	O
size	O
planned	O
for	O
this	O
study	O
was	O
~495	B-Sample_Size_Target
randomized	O
patients	O
.	O

Statistical	O
Analysis	O
The	O
sample	O
size	O
(	O
target	O
number	O
,	O
approximately	O
275	B-Sample_Size_Target
patients	O
)	O
was	O
based	O
mainly	O
on	O
prior	O
study	O
results	O
,	O
including	O
TCS	O
use	O
,	O
which	O
defined	O
an	O
estimated	O
sample	O
size	O
of	O
approximately	O
75	O
patients	O
for	O
active	O
groups	O
and	O
50	O
for	O
the	O
placebo	O
group	O
to	O
adequately	O
power	O
the	O
study	O
.	O

The	O
fieldworkers	O
obtained	O
written	O
informed	O
consent	O
from	O
the	O
mother	O
,	O
father	O
,	O
or	O
another	O
senior	O
family	O
member	O
before	O
recruitment	O
;	O
allocated	O
the	O
unique	O
identification	O
number	O
(	O
sequentially	O
)	O
;	O
and	O
gave	O
the	O
first	O
dose	O
of	O
vitamin	B-Design_Parallel_Group
D3	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
.	O

Results	O
Demographics	O
A	O
total	O
of	O
614	B-Sample_Size_Actual_at_Enrollment
participants	O
were	O
randomized	O
in	O
this	O
study	O
across	O
9	O
different	O
countries	O
(	O
Fig	O
.	O

A	O
total	O
of	O
305	B-Sample_Size_Actual_at_Outcome_Analysis
patients	O
(	O
88.9	O
%	O
)	O
completed	O
the	O
double-blind	O
treatment	O
phase	O
;	O
124	O
patients	O
(	O
90.5	O
%	O
)	O
receiving	O
placebo	O
,	O
94	O
patients	O
(	O
90.4	O
%	O
)	O
receiving	O
AMG	O
301	O
210	O
mg	O
Q4W	O
,	O
and	O
87	O
patients	O
(	O
85.3	O
%	O
)	O
receiving	O
AMG	O
301	O
420	O
mg	O
Q2W	O
.	O

Patients	O
were	O
centrally	O
randomised	O
in	O
blocks	B-Randomization_Type_Block
of	O
4	B-Randomization_Block_Size
(	I-Randomization_Block_Size
2:2	I-Randomization_Block_Size
)	I-Randomization_Block_Size
by	O
computer-generated	B-Randomization_Sequence_Generation_Method
random	O
sequence	O
to	O
receive	O
subcutaneous	O
injections	O
of	O
50	O
mg	O
golimumab	B-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
,	O
administrated	O
every	O
4	O
weeks	O
for	O
24	O
weeks	O
,	O
both	O
in	O
combination	O
with	O
MTX	O
.	O

TRIAL	O
DESIGN	O
AND	O
INTERVENTION	O
Participants	O
were	O
randomly	O
assigned	O
in	O
a	O
1:1	B-Randomization_Ratio
ratio	O
to	O
receive	O
either	O
teplizumab	B-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
.	O

Methods	O
Study	O
Design	O
:	O
The	O
POINT	O
Trial	O
was	O
a	O
multicenter	B-Settings_Multicenter
,	O
randomized	O
(	O
allocation	O
ratio	O
1:1:1	B-Randomization_Ratio
)	O
,	O
parallel-treatment	B-Design_Parallel_Group
,	O
comparative	O
trial	O
(	O
clinicaltrial.gov	O
identifier	O
:	O
NCT02374060	O
)	O
.	O

METHODS	O
Study	O
Design	O
and	O
Participants	O
Protocol	O
MK-1986-002	O
(	O
Ventilated	O
Pneumonia	O
Treatment	O
with	O
Tedizolid	O
Phosphate	O
and	O
Linezolid	O
[	O
VITAL	O
]	O
)	O
was	O
a	O
randomized	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
double-dummy	O
,	O
phase	B-Design_Phase_3
3	I-Design_Phase_3
,	O
noninferiority	B-Design_Comparative_Intent_NonInferiority
trial	O
conducted	O
at	O
122	B-Settings_Multicenter
global	I-Settings_Multicenter
study	I-Settings_Multicenter
sites	I-Settings_Multicenter
in	O
32	B-Settings_Location
countries	I-Settings_Location
from	O
June	O
2014	O
to	O
June	O
2018	O
.	O

The	O
statistical	O
testing	O
for	O
the	O
primary	O
outcome	O
was	O
conducted	O
at	O
the	O
1-sided	B-Sample_Size_Calculation_Alpha_Value
α	I-Sample_Size_Calculation_Alpha_Value
=	I-Sample_Size_Calculation_Alpha_Value
.025	I-Sample_Size_Calculation_Alpha_Value
level	O
using	O
the	O
upper	O
bound	O
of	O
a	O
stratified	O
by	O
site	O
Newcombe	O
binomial	O
confidence	O
interval	O
with	O
Cochran-Mantel-Haenszel	O
(	O
CMH	O
)	O
weighting	O
with	O
a	O
noninferiority	O
margin	O
of	O
5	O
%	O
.	O

The	O
most	O
common	O
adverse	O
events	O
were	O
diarrhea	O
(	O
9.5	O
%	O
)	O
and	O
nasopharyngitis	O
(	O
12.5	O
%	O
)	O
in	O
the	O
ezetimibe	O
and	O
evolocumab	O
groups	O
,	O
respectively	O
,	O
during	O
the	O
double-blind	B-Blinding_Double_Blind
period	O
and	O
nasopharyngitis	O
(	O
29	O
%	O
)	O
during	O
the	O
open-label	O
extension	O
.	O

The	O
change	O
in	O
mean	O
carotid	O
artery	O
wall	O
area	O
was	O
–3.37	O
mm2	O
after	O
12	O
months	O
with	O
canakinumab	B-Design_Parallel_Group
versus	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
.	O

The	O
study	O
was	O
conducted	O
between	O
August	O
2014	O
and	O
June	O
2017	O
in	O
11	B-Settings_Multicenter
rheumatology	I-Settings_Multicenter
centres	I-Settings_Multicenter
in	O
Portugal	B-Settings_Location
.	O

Sample	O
size	O
For	O
the	O
planned	O
factorial	B-Design_Factorial
trial	O
,	O
we	O
estimated	O
that	O
a	O
provisional	O
sample	O
size	O
would	O
be	O
1498	B-Sample_Size_Required
women	O
(	O
749	O
per	O
group	O
)	O
.	O

METHODS	O
We	O
conducted	O
a	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
,	O
randomized	O
,	O
placebo-controlled	O
,	O
double-blind	B-Blinding_Double_Blind
trial	O
of	O
teplizumab	O
(	O
an	O
Fc	O
receptor–nonbinding	O
anti-CD3	O
monoclonal	O
antibody	O
)	O
involving	O
relatives	O
of	O
patients	O
with	O
type	O
1	O
diabetes	O
who	O
did	O
not	O
have	O
diabetes	O
but	O
were	O
at	O
high	O
risk	O
for	O
development	O
of	O
clinical	O
disease	O
.	O

Randomisation	O
and	O
masking	O
An	B-Randomization_Personnel
independent	I-Randomization_Personnel
statistician	I-Randomization_Personnel
(	O
Shabbar	O
Jaffar	O
,	O
London	O
School	O
of	O
Hygiene	O
and	O
Tropical	O
Medicine	O
,	O
London	O
,	O
UK	O
)	O
randomised	O
unique	O
identification	O
numbers	O
individually	O
in	O
fixed	O
blocks	B-Randomization_Block_Size
of	I-Randomization_Block_Size
20	I-Randomization_Block_Size
to	O
the	O
vitamin	B-Design_Parallel_Group
D3	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
group	O
by	O
use	O
of	O
a	B-Randomization_Sequence_Generation_Method
random	I-Randomization_Sequence_Generation_Method
number	I-Randomization_Sequence_Generation_Method
generator	I-Randomization_Sequence_Generation_Method
with	O
the	O
SAS	O
routine	O
.	O

Methods	O
In	O
this	O
randomized	B-Randomization_Type_Simple
,	O
active-controlled	O
,	O
double-blinded	B-Blinding_Double_Blind
trial	O
,	O
444	B-Sample_Size_Actual_at_Enrollment
adults	I-Sample_Size_Actual_at_Enrollment
60	I-Sample_Size_Actual_at_Enrollment
through	I-Sample_Size_Actual_at_Enrollment
64	I-Sample_Size_Actual_at_Enrollment
years	I-Sample_Size_Actual_at_Enrollment
of	I-Sample_Size_Actual_at_Enrollment
age	I-Sample_Size_Actual_at_Enrollment
were	O
randomized	O
to	O
receive	O
either	O
a	B-Design_Parallel_Group
single	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
of	I-Design_Parallel_Group
PCV20	I-Design_Parallel_Group
followed	I-Design_Parallel_Group
1	I-Design_Parallel_Group
month	I-Design_Parallel_Group
later	I-Design_Parallel_Group
by	I-Design_Parallel_Group
saline	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
or	I-Design_Parallel_Group
a	I-Design_Parallel_Group
single	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
of	I-Design_Parallel_Group
PCV13	I-Design_Parallel_Group
followed	I-Design_Parallel_Group
1	I-Design_Parallel_Group
month	I-Design_Parallel_Group
later	I-Design_Parallel_Group
by	I-Design_Parallel_Group
23-valent	I-Design_Parallel_Group
polysaccharide	I-Design_Parallel_Group
vaccine	I-Design_Parallel_Group
.	O

After	O
an	O
initial	O
screening	O
period	O
of	O
≤	O
3	O
weeks	O
followed	O
by	O
a	O
baseline	O
period	O
of	O
4	O
weeks	O
,	O
during	O
which	O
patients	O
were	O
required	O
to	O
complete	O
a	O
daily	O
electronic	O
headache	O
diary	O
,	O
investigators	O
confirmed	O
that	O
patients	O
met	O
eligibility	O
criteria	O
and	O
had	O
provided	O
informed	O
consent	O
,	O
patients	O
were	O
enrolled	O
in	O
the	O
trial	O
and	O
randomized	O
4:3:3	B-Randomization_Ratio
to	O
placebo	B-Design_Parallel_Group
,	I-Design_Parallel_Group
AMG	I-Design_Parallel_Group
301	I-Design_Parallel_Group
210	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
every	I-Design_Parallel_Group
4	I-Design_Parallel_Group
weeks	I-Design_Parallel_Group
(	I-Design_Parallel_Group
Q4W	I-Design_Parallel_Group
)	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
AMG	I-Design_Parallel_Group
301	I-Design_Parallel_Group
420	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
every	I-Design_Parallel_Group
2	I-Design_Parallel_Group
weeks	I-Design_Parallel_Group
(	I-Design_Parallel_Group
Q2W	I-Design_Parallel_Group
)	I-Design_Parallel_Group
for	I-Design_Parallel_Group
12	I-Design_Parallel_Group
weeks	I-Design_Parallel_Group
(	O
Figure	O
1	O
)	O
;	O
to	O
maintain	O
blinding	O
,	O
patients	O
received	O
a	O
total	O
of	O
six	O
subcutaneous	O
injections	O
Q2W	O
.	O

This	O
case	O
provided	O
at	O
least	O
85	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
(	O
93	O
%	O
×93	O
%	O
)	O
power	O
to	O
detect	O
significant	O
treatment	O
effects	O
of	O
the	O
co-primary	O
endpoints	O
.	O

Participants	O
received	O
6.25	B-Design_Parallel_Group
mg	I-Design_Parallel_Group
SHP465	I-Design_Parallel_Group
MAS	I-Design_Parallel_Group
once	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
for	O
4	O
weeks	O
.	O

In	O
total	O
,	O
343	B-Sample_Size_Actual_at_Enrollment
patients	O
from	O
46	B-Settings_Multicenter
sites	I-Settings_Multicenter
were	O
randomized	O
to	O
treatment	O
.	O

STAIRWAY	O
was	O
a	O
patient-	O
and	O
outcome	B-Blinding_Object_Outcome_Assessors
assessor	I-Blinding_Object_Outcome_Assessors
(	O
BCVA	O
and	O
central	O
reading	O
center	O
)	O
–masked	O
trial	O
that	O
allowed	O
for	O
a	O
single	O
investigator	O
per	O
site	O
while	O
fulfilling	O
masking	O
requirements	O
.	O

Randomisation	O
and	O
masking	O
The	B-Randomization_Personnel
central	I-Randomization_Personnel
study	I-Randomization_Personnel
team	I-Randomization_Personnel
at	I-Randomization_Personnel
the	I-Randomization_Personnel
University	I-Randomization_Personnel
of	I-Randomization_Personnel
Birmingham	I-Randomization_Personnel
randomised	O
patients	O
,	O
with	O
minimisation	B-Randomization_Type_Minimization
based	O
on	O
age	B-Randomization_Minimization_Criteria
,	O
sex	B-Randomization_Minimization_Criteria
,	O
diabetes	B-Randomization_Minimization_Criteria
mellitus	I-Randomization_Minimization_Criteria
,	O
atrial	B-Randomization_Minimization_Criteria
fibrillation	I-Randomization_Minimization_Criteria
,	O
baseline	B-Randomization_Minimization_Criteria
systolic	I-Randomization_Minimization_Criteria
blood	I-Randomization_Minimization_Criteria
pressure	I-Randomization_Minimization_Criteria
,	O
and	O
general	B-Randomization_Minimization_Criteria
practice	I-Randomization_Minimization_Criteria
.	O

Patients	O
were	O
randomly	O
assigned	O
in	O
a	O
1:1	B-Randomization_Ratio
ratio	O
by	O
a	B-Randomization_Sequence_Generation_Method
centralised	I-Randomization_Sequence_Generation_Method
24	I-Randomization_Sequence_Generation_Method
h	I-Randomization_Sequence_Generation_Method
telephone	I-Randomization_Sequence_Generation_Method
or	I-Randomization_Sequence_Generation_Method
web-based	I-Randomization_Sequence_Generation_Method
randomisation	I-Randomization_Sequence_Generation_Method
service	I-Randomization_Sequence_Generation_Method
(	O
University	O
of	O
Aberdeen	O
,	O
UK	B-Settings_Location
)	O
.	O

Neither	B-Blinding_Open_Label
participants	I-Blinding_Open_Label
nor	I-Blinding_Open_Label
clinicians	I-Blinding_Open_Label
were	I-Blinding_Open_Label
blinded	I-Blinding_Open_Label
to	I-Blinding_Open_Label
treatment	I-Blinding_Open_Label
allocation	I-Blinding_Open_Label
.	O

All	O
participants	B-Blinding_Object_Patients
,	O
caregivers	B-Blinding_Object_Care_Providers
,	O
and	O
investigators	B-Blinding_Object_Investigators
were	O
masked	O
to	O
group	O
allocation	O
.	O

Patients	O
must	O
meet	O
the	O
LDL-C	O
threshold	O
based	O
on	O
their	O
management	O
category	O
in	O
the	O
2012	O
Japan	B-Settings_Location
Atherosclerosis	O
Society	O
Guidelines	O
for	O
the	O
Diagnosis	O
and	O
Prevention	O
of	O
ASCVD	O
in	O
Japan	B-Settings_Location
)	O
.	O

Investigators	B-Blinding_Object_Investigators
and	O
patients	B-Blinding_Object_Patients
were	O
blinded	O
to	O
GP	O
MDI	O
and	O
placebo	O
MDI	O
treatment	O
using	O
non-distinguishable	O
MDIs	O
.	O

Setting	O
Four	B-Settings_Multicenter
acute	I-Settings_Multicenter
care	I-Settings_Multicenter
hospitals	I-Settings_Multicenter
in	O
Israel	B-Settings_Location
.	O

METHODS	O
This	O
was	O
a	O
26‐week	O
,	O
double‐blind	B-Blinding_Double_Blind
,	O
placebo‐controlled	O
,	O
multicentre	B-Settings_Multicenter
,	O
randomized	O
,	O
parallel‐group	B-Design_Parallel_Group
,	O
phase	B-Design_Phase_3
III	I-Design_Phase_3
study	O
in	O
Asian	B-Settings_Location
patients	O
with	O
T2DM	O
and	O
inadequate	O
glycaemic	O
control	O
on	O
metformin	O
monotherapy	O
.	O

Of	O
these	O
,	O
195	B-Sample_Size_Actual_at_Outcome_Analysis
patients	O
(	O
93.3	O
%	O
)	O
completed	O
the	O
12-week	O
study	O
.	O

Methods	O
We	O
did	O
a	O
randomised	O
placebo-controlled	O
trial	O
to	O
compare	O
oral	B-Design_Parallel_Group
100	I-Design_Parallel_Group
000	I-Design_Parallel_Group
IU	I-Design_Parallel_Group
(	I-Design_Parallel_Group
2·5	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
)	I-Design_Parallel_Group
vitamin	I-Design_Parallel_Group
D3	I-Design_Parallel_Group
with	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
given	O
to	O
children	O
aged	O
1–11	O
months	O
in	O
Kabul	B-Settings_Location
,	I-Settings_Location
Afghanistan	I-Settings_Location
.	O

Results	O
:	O
Sixty-one	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomized	O
to	O
evolocumab	O
(	O
n	O
=	O
40	O
)	O
or	O
ezetimibe	O
(	O
n	O
=	O
21	O
)	O
.	O

At	O
the	O
time	O
of	O
study	O
termination	O
,	O
72	B-Sample_Size_Actual_at_Enrollment
eligible	O
patients	O
were	O
enrolled	O
and	O
randomized	O
(	O
intervention	O
group	O
n	O
=	O
40	O
,	O
usual	O
care	O
group	O
n	O
=	O
32	O
)	O
(	O
see	O
Supplemental	O
Digital	O
Content	O
eFigure	O
1	O
)	O
.	O

Subjects	B-Blinding_Object_Patients
,	O
investigators	B-Blinding_Object_Investigators
,	O
all	B-Blinding_Object_Others
other	I-Blinding_Object_Others
study	I-Blinding_Object_Others
staff	I-Blinding_Object_Others
,	O
laboratories	B-Blinding_Object_Others
,	O
and	O
the	O
rest	B-Blinding_Object_Others
of	I-Blinding_Object_Others
the	I-Blinding_Object_Others
Sponsor	I-Blinding_Object_Others
study	I-Blinding_Object_Others
team	I-Blinding_Object_Others
were	O
blinded	O
to	O
subject	O
treatment	O
assignment	O
until	O
the	O
database	O
was	O
locked	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

Patients	O
and	O
Methods	O
Study	O
Design	O
This	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
,	O
randomized	O
,	O
double‐blind	B-Blinding_Double_Blind
,	O
placebo‐controlled	O
study	O
was	O
conducted	O
in	O
Japan	B-Settings_Location
at	O
43	B-Settings_Multicenter
centers	I-Settings_Multicenter
with	O
on‐site	O
headache	O
specialists	O
and	O
enrolled	O
adult	O
Japanese	O
patients	O
with	O
a	O
history	O
of	O
episodic	O
migraine	O
.	O

This	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
study	O
(	O
V114-008	O
;	O
NCT02987972	O
;	O
EudraCT	O
2016-001117-25	O
)	O
compared	O
safety	O
and	O
immunogenicity	O
of	O
2	O
clinical	O
lots	O
of	O
V114	O
(	O
investigational	O
15-valent	O
pneumococcal	O
vaccine	O
:	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6A	O
,	O
6B	O
,	O
7F	O
,	O
9V	O
,	O
14	O
,	O
18C	O
,	O
19F	O
,	O
19A	O
,	O
22F*	O
,	O
23F	O
,	O
33F*	O
)	O
to	O
13-valent	O
pneumococcal	O
conjugate	O
vaccine	O
(	O
PCV13	O
)	O
in	O
healthy	O
infants	O
(	O
*serotypes	O
unique	O
to	O
V114	O
)	O
.	O

Fifty-eight	B-Sample_Size_Actual_at_Outcome_Analysis
patients	O
(	O
95	O
%	O
)	O
completed	O
the	O
12-week	O
double-blind	O
period	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
a	O
single	O
14-day	O
course	O
of	O
teplizumab	B-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
,	O
and	O
follow-up	O
for	O
progression	O
to	O
clinical	O
type	O
1	O
diabetes	O
was	O
performed	O
with	O
the	O
use	O
of	O
oral	O
glucose-tolerance	O
tests	O
at	O
6-month	O
intervals	O
.	O

Assuming	O
for	O
each	O
strain	O
the	O
same	O
expected	O
seroconversion	O
rates	O
for	O
each	O
vaccine	O
dosing	O
group	O
(	O
90.9	O
%	O
for	O
A/H1N1	O
,	O
95.4	O
%	O
for	O
A/H3N2	O
,	O
72	O
%	O
for	O
B/Victoria	O
and	O
57.5	O
%	O
for	O
B/Yamagata	O
)	O
and	O
a	O
noninferiority	O
margin	O
of	O
10	O
%	O
for	O
each	O
strain	O
,	O
the	O
planned	O
study	O
power	O
was	O
approximately	O
93.2	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
to	O
demonstrate	O
noninferiority	O
for	O
seroconversion	O
rates	O
.	O

The	O
primary	O
objective	O
was	O
to	O
demonstrate	O
the	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
in	O
efficacy	O
of	O
tofacitinib	O
MR	O
11	O
mg	O
QD	O
relative	O
to	O
IR	O
5	O
mg	O
BID	O
.	O

In	O
the	O
CTIC	O
group	O
,	O
the	O
lesion	O
could	O
not	O
be	O
crossed	O
in	O
1	O
patient	O
,	O
and	O
PCI	B-Sample_Size_Actual_at_Outcome_Analysis
was	I-Sample_Size_Actual_at_Outcome_Analysis
performed	I-Sample_Size_Actual_at_Outcome_Analysis
in	I-Sample_Size_Actual_at_Outcome_Analysis
49	I-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
.	O

Study	B-Blinding_Object_Patients
participants	I-Blinding_Object_Patients
and	O
BCVA	B-Blinding_Object_Outcome_Assessors
examiners	I-Blinding_Object_Outcome_Assessors
were	O
masked	O
to	O
treatment	O
assignment	O
.	O

Methods	O
Patients	O
were	O
randomized	O
to	O
placebo	B-Design_Parallel_Group
or	I-Design_Parallel_Group
erenumab	I-Design_Parallel_Group
28	I-Design_Parallel_Group
,	I-Design_Parallel_Group
70	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
140	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
administered	O
subcutaneously	O
once	O
per	O
month	O
for	O
6	O
months	O
.	O

Treatment	O
was	O
allocated	O
by	O
a	B-Randomization_Sequence_Generation_Method
web-based	I-Randomization_Sequence_Generation_Method
randomisation	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
,	O
available	O
24	O
h	O
a	O
day	O
.	O

Objective	O
This	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
,	O
dose-finding	O
phase	B-Design_Phase_2
IIb	I-Design_Phase_2
study	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
ponesimod	O
,	O
an	O
oral	O
selective	O
S1P1	O
receptor	O
modulator	O
,	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
relapsing–remitting	O
multiple	O
sclerosis	O
(	O
RRMS	O
)	O
.	O

A	O
sample	O
size	O
of	O
726	B-Sample_Size_Required
randomized	O
patients	O
(	O
363	O
per	O
group	O
)	O
was	O
selected	O
to	O
provide	O
92	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
at	O
a	B-Sample_Size_Calculation_Alpha_Value
1-sided	I-Sample_Size_Calculation_Alpha_Value
significance	I-Sample_Size_Calculation_Alpha_Value
level	I-Sample_Size_Calculation_Alpha_Value
of	I-Sample_Size_Calculation_Alpha_Value
0.025	I-Sample_Size_Calculation_Alpha_Value
,	O
assuming	O
a	O
day	O
28	O
ACM	O
rate	O
of	O
20	O
%	O
in	O
both	O
groups	O
.	O

Patients	O
were	O
randomized	O
1:1	B-Randomization_Ratio
to	O
receive	O
oral	B-Design_Parallel_Group
tofacitinib	I-Design_Parallel_Group
MR	I-Design_Parallel_Group
11	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
QD	I-Design_Parallel_Group
or	I-Design_Parallel_Group
IR	I-Design_Parallel_Group
5	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
BID	I-Design_Parallel_Group
,	O
both	O
with	O
stable	O
background	O
MTX	O
(	O
6–16	O
mg/week	O
for	O
⩾6	O
weeks	O
before	O
baseline	O
;	O
supplemented	O
with	O
folic	O
acid	O
or	O
folinic	O
acid	O
)	O
,	O
using	O
an	B-Randomization_Sequence_Generation_Method
automated	I-Randomization_Sequence_Generation_Method
Web/telephone	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
provided	O
by	O
Pfizer	O
Inc	O
.	O

Based	O
on	O
a	O
fixed	O
effects	O
meta-analysis	O
of	O
five	O
historical	O
reference	O
studies	O
selected	O
for	O
their	O
applicability	O
to	O
this	O
study	O
,	O
a	O
sample	O
size	O
of	O
300	O
randomized	O
subjects	O
per	O
group	O
(	O
600	B-Sample_Size_Required
total	O
)	O
was	O
chosen	O
to	O
provide	O
adequate	O
power	O
for	O
the	O
proposed	O
analyses	O
.	O

Methods	O
and	O
Results	O
A	O
total	O
of	O
100	B-Sample_Size_Actual_at_Enrollment
P2Y12	I-Sample_Size_Actual_at_Enrollment
naïve	I-Sample_Size_Actual_at_Enrollment
,	I-Sample_Size_Actual_at_Enrollment
troponin‐negative	I-Sample_Size_Actual_at_Enrollment
patients	I-Sample_Size_Actual_at_Enrollment
with	O
acute	O
coronary	O
syndrome	O
were	O
randomized	O
to	O
CTIC	O
(	O
180	O
mg	O
)	O
versus	O
eptifibatide	O
bolus	O
(	O
180	O
μg/kg×2	O
intravenous	O
boluses	O
)	O
plus	O
clopidogrel	O
(	O
600	O
mg	O
)	O
at	O
the	O
time	O
of	O
percutaneous	O
coronary	O
intervention	O
.	O

We	O
conducted	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
comparisons	O
(	O
non-inferiority	O
margin	O
=	O
0.9	O
)	O
of	O
pain	O
change	O
from	O
treatment	O
initiation	O
(	O
T0	O
)	O
to	O
one	O
hour	O
later	O
(	O
T60	O
)	O
.	O

Randomisation	O
for	O
both	O
comparisons	O
within	O
the	O
trial	O
was	O
in	O
a	O
1	B-Randomization_Ratio
to	I-Randomization_Ratio
1	I-Randomization_Ratio
allocation	O
ratio	O
.	O

Results	O
Figure	O
1	O
shows	O
the	O
trial	O
profile	O
;	O
529	B-Sample_Size_Actual_at_Enrollment
patients	O
from	O
99	B-Settings_Multicenter
general	I-Settings_Multicenter
practices	I-Settings_Multicenter
(	O
range	O
1-16	O
per	O
practice	O
)	O
entered	O
the	O
trial	O
,	O
and	O
84	O
patients	O
withdrew	O
from	O
the	O
trial	O
in	O
the	O
12	O
months	O
after	O
randomisation	O
(	O
52	O
(	O
20	O
%	O
)	O
in	O
the	O
intensive	O
target	O
arm	O
and	O
32	O
(	O
12	O
%	O
)	O
in	O
the	O
standard	O
target	O
arm	O
;	O
P=0.02	O
)	O
.	O

Randomization	O
was	O
stratified	B-Randomization_Type_Stratified
by	O
screening	O
the	O
LDL-C	B-Randomization_Stratified_Criteria
level	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
or	I-Randomization_Stratified_Criteria
≥	I-Randomization_Stratified_Criteria
180	I-Randomization_Stratified_Criteria
mg/dL	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
and	O
baseline	B-Randomization_Stratified_Criteria
statin	I-Randomization_Stratified_Criteria
use	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
yes	I-Randomization_Stratified_Criteria
or	I-Randomization_Stratified_Criteria
no	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
.	O

Methods	O
and	O
results	O
In	O
a	O
randomised	O
double-blind	B-Blinding_Double_Blind
placebo-controlled	O
parallel	B-Design_Parallel_Group
group	I-Design_Parallel_Group
clinical	O
trial	O
,	O
87	B-Sample_Size_Actual_at_Enrollment
patients	O
undergoing	O
CABG	O
surgery	O
were	O
randomised	O
1:1	B-Randomization_Ratio
to	O
intravenous	O
elafin	I-Design_Parallel_Group
200	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
or	I-Design_Parallel_Group
saline	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
administered	O
after	O
induction	O
of	O
anaesthesia	O
and	O
prior	O
to	O
sternotomy	O
.	O

In	O
the	O
subsequent	O
open-label	B-Blinding_Open_Label
phase	O
,	O
all	O
participants	O
received	O
repeat	O
injections	O
of	O
400	O
U	O
onabotulinumtoxinA	O
(	O
target	O
muscles	O
and	O
doses	O
per	O
muscle	O
determined	O
by	O
the	O
physician	O
)	O
.	O

Non-inferiority	B-Design_Comparative_Intent_NonInferiority
of	O
MR	O
11	O
mg	O
QD	O
to	O
IR	O
5	O
mg	O
BID	O
was	O
not	O
met	O
.	O

To	O
ensure	O
blinding	O
,	O
study	O
drugs	O
were	O
prepared	O
by	O
staff	O
independent	O
of	O
the	O
study	B-Blinding_Object_Investigators
investigators	I-Blinding_Object_Investigators
or	O
clinical	B-Blinding_Object_Care_Providers
team	I-Blinding_Object_Care_Providers
responsible	O
for	O
the	O
patient	O
’	O
s	O
care	O
.	O

Aromatase	O
Inhibitor	O
Therapy	O
Participants	O
were	O
randomized	O
by	O
the	B-Randomization_Personnel
MEDVAMC	I-Randomization_Personnel
pharmacy	I-Randomization_Personnel
from	O
a	B-Randomization_Sequence_Generation_Method
list	I-Randomization_Sequence_Generation_Method
generated	I-Randomization_Sequence_Generation_Method
by	I-Randomization_Sequence_Generation_Method
a	I-Randomization_Sequence_Generation_Method
research	I-Randomization_Sequence_Generation_Method
biostatistician	I-Randomization_Sequence_Generation_Method
to	O
one	O
of	O
two	O
treatment	O
groups	O
for	O
a	O
total	O
of	O
26	O
weeks	O
:	O
AI	B-Design_Parallel_Group
(	I-Design_Parallel_Group
anastrozole	I-Design_Parallel_Group
1	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
)	I-Design_Parallel_Group
+	I-Design_Parallel_Group
WL	I-Design_Parallel_Group
or	I-Design_Parallel_Group
PBO	I-Design_Parallel_Group
+	I-Design_Parallel_Group
WL	I-Design_Parallel_Group
.	O

In	O
the	O
double-blind	O
phase	O
,	O
patients	O
were	O
randomly	O
allocated	O
in	O
a	O
1:1	B-Randomization_Ratio
ratio	O
to	O
either	O
400	B-Design_Parallel_Group
U	I-Design_Parallel_Group
onabotulinumtoxinA	I-Design_Parallel_Group
or	I-Design_Parallel_Group
240	I-Design_Parallel_Group
U	I-Design_Parallel_Group
onabotulinumtoxinA	I-Design_Parallel_Group
.	O

The	O
investigator	B-Blinding_Object_Investigators
,	O
study	B-Blinding_Object_Others
staff	I-Blinding_Object_Others
at	I-Blinding_Object_Others
the	I-Blinding_Object_Others
site	I-Blinding_Object_Others
,	O
and	O
patient	B-Blinding_Object_Patients
were	O
blinded	O
to	O
the	O
study	O
treatment	O
allocated	O
to	O
each	O
individual	O
patient	O
during	O
the	O
overall	O
study	O
period	O
.	O

Of	O
154	O
screened	O
participants	O
,	O
130	B-Sample_Size_Actual_at_Enrollment
were	O
randomised	O
to	O
treatment	O
(	O
65	O
per	O
group	O
)	O
and	O
were	O
included	O
in	O
the	O
mITT	O
and	O
safety	O
populations	O
;	O
129	B-Sample_Size_Actual_at_Outcome_Analysis
participants	O
completed	O
the	O
study	O
(	O
Fig	O
.	O

To	O
detect	O
an	O
assumed	O
treatment	O
difference	O
of	O
11.9	O
points	O
for	O
ADHD-RS-5-HV	O
total	O
score	O
change	O
from	O
baseline	O
at	O
week	O
4	O
(	O
assumed	O
common	O
standard	O
deviation	O
[	O
SD	O
]	O
,	O
14	O
)	O
,	O
26	B-Sample_Size_Required
participants	I-Sample_Size_Required
in	I-Sample_Size_Required
each	I-Sample_Size_Required
treatment	I-Sample_Size_Required
arm	I-Sample_Size_Required
(	O
52	B-Sample_Size_Required
total	O
participants	O
)	O
needed	O
to	O
complete	O
the	O
study	O
to	O
provide	O
85	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
for	O
a	B-Sample_Size_Calculation_Alpha_Value
two-sided	I-Sample_Size_Calculation_Alpha_Value
t	I-Sample_Size_Calculation_Alpha_Value
test	I-Sample_Size_Calculation_Alpha_Value
(	I-Sample_Size_Calculation_Alpha_Value
α	I-Sample_Size_Calculation_Alpha_Value
=	I-Sample_Size_Calculation_Alpha_Value
0.05	I-Sample_Size_Calculation_Alpha_Value
)	I-Sample_Size_Calculation_Alpha_Value
.	O

Patient	O
groups	O
were	O
assigned	O
centrally	O
according	O
to	O
a	B-Randomization_Sequence_Generation_Method
validated	I-Randomization_Sequence_Generation_Method
computer-generated	I-Randomization_Sequence_Generation_Method
randomization	I-Randomization_Sequence_Generation_Method
code	I-Randomization_Sequence_Generation_Method
,	O
stratified	B-Randomization_Type_Stratified
according	O
to	O
glycemic	B-Randomization_Stratified_Criteria
status	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
T2DM	I-Randomization_Stratified_Criteria
or	I-Randomization_Stratified_Criteria
IGT	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
.	O

treatment	O
groups	O
were	O
compared	O
with	O
the	O
placebo	O
group	O
using	O
a	O
5	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
significance	O
level	O
.	O

Methods	O
We	O
did	O
a	O
multicentre	B-Settings_Multicenter
,	O
placebo-controlled	O
,	O
parallel-group	B-Design_Parallel_Group
,	O
randomised	O
trial	O
at	O
46	B-Settings_Multicenter
UK	B-Settings_Location
intensive-care	I-Settings_Multicenter
units	I-Settings_Multicenter
between	O
December	O
,	O
2006	O
,	O
and	O
March	O
,	O
2010	O
.	O

Methods	O
Study	O
design	O
and	O
setting	O
This	O
was	O
a	O
single-center	B-Settings_Single_Center
,	O
randomized	B-Randomization_Type_Simple
,	O
open-label	B-Blinding_Open_Label
clinical	O
trial	O
designed	O
to	O
compare	O
IN	B-Design_Parallel_Group
fentanyl	I-Design_Parallel_Group
versus	I-Design_Parallel_Group
IV	I-Design_Parallel_Group
opioids	I-Design_Parallel_Group
in	O
pain	O
intensity	O
reduction	O
by	O
1	O
hour	O
after	O
drug	O
delivery	O
.	O

Procedures	O
This	O
two-arm	O
,	O
randomised	O
,	O
multicentre	B-Settings_Multicenter
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
,	O
parallel-group	B-Design_Parallel_Group
,	O
phase	B-Design_Phase_3
III	I-Design_Phase_3
study	O
was	O
conducted	O
in	O
the	O
USA	B-Settings_Location
,	I-Settings_Location
Canada	I-Settings_Location
and	I-Settings_Location
the	I-Settings_Location
UK	I-Settings_Location
(	O
figure	O
1	O
)	O
at	O
34	B-Settings_Multicenter
sites	I-Settings_Multicenter
(	O
the	O
MEASURE	O
study	O
)	O
.	O

Results	O
A	O
total	O
of	O
627	B-Sample_Size_Actual_at_Enrollment
subjects	O
were	O
randomized	O
1:1	B-Randomization_Ratio
to	O
MB02	O
(	O
n	O
=	O
315	O
)	O
or	O
EU-bevacizumab	O
(	O
n	O
=	O
312	O
)	O
.	O

Of	O
the	O
394	O
on	O
study	O
at	O
delivery	O
,	O
368	B-Sample_Size_Actual_at_Outcome_Analysis
(	O
94	O
%	O
)	O
had	O
either	O
screening	O
or	O
entry	O
plasma	O
HIV-1	O
RNA	O
viral	O
load	O
≥200	O
copies	O
per	O
mL	O
and	O
were	O
thus	O
eligible	O
for	O
the	O
primary	O
efficacy	O
analysis	O
.	O

Statistical	O
Analysis	O
The	O
target	O
sample	O
size	O
of	O
334	B-Sample_Size_Required
evaluable	I-Sample_Size_Required
women	I-Sample_Size_Required
provided	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
difference	O
in	O
response	O
proportions	O
of	O
75	O
%	O
vs.	O
60	O
%	O
with	O
a	B-Sample_Size_Calculation_Alpha_Value
two-sided	I-Sample_Size_Calculation_Alpha_Value
type	I-Sample_Size_Calculation_Alpha_Value
I	I-Sample_Size_Calculation_Alpha_Value
error	I-Sample_Size_Calculation_Alpha_Value
rate	I-Sample_Size_Calculation_Alpha_Value
of	I-Sample_Size_Calculation_Alpha_Value
0·05	I-Sample_Size_Calculation_Alpha_Value
and	O
allowing	O
for	O
two	O
interim	O
efficacy	O
analyses	O
.	O

Study	O
participants	O
were	O
enrolled	O
in	O
25	B-Settings_Multicenter
sites	I-Settings_Multicenter
in	O
the	O
US	B-Settings_Location
from	O
January	O
and	O
March	O
2017	O
with	O
treatment-naive	O
choroidal	O
neovascularization	O
secondary	O
to	O
neovascular	O
age-related	O
macular	O
degeneration	O
and	O
best-corrected	O
visual	O
acuity	O
(	O
BCVA	O
)	O
Early	O
Treatment	O
Diabetic	O
Retinopathy	O
Study	O
letter	O
score	O
of	O
73	O
(	O
approximate	O
Snellen	O
equivalent	O
,	O
20/40	O
)	O
to	O
24	O
(	O
approximate	O
Snellen	O
equivalent	O
,	O
20/320	O
)	O
.	O

Of	O
71	B-Sample_Size_Actual_at_Outcome_Analysis
participants	O
,	O
64	O
(	O
90.1	O
%	O
)	O
attended	O
the	O
primary	O
end	O
point	O
week-40	O
visit	O
,	O
and	O
65	O
(	O
91.5	O
%	O
)	O
completed	O
the	O
study	O
through	O
week	O
52	O
.	O

Methods	O
In	O
this	O
randomized	O
,	O
open-label	B-Blinding_Open_Label
and	O
multi-centre	B-Settings_Multicenter
trial	O
conducted	O
in	O
the	O
USA	B-Settings_Location
,	O
patients	O
were	O
randomized	O
2:1	B-Randomization_Ratio
to	O
a	O
single	B-Design_Parallel_Group
dose	I-Design_Parallel_Group
of	I-Design_Parallel_Group
1000	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
IIM	I-Design_Parallel_Group
or	I-Design_Parallel_Group
iron	I-Design_Parallel_Group
sucrose	I-Design_Parallel_Group
(	I-Design_Parallel_Group
IS	I-Design_Parallel_Group
)	I-Design_Parallel_Group
administered	O
as	O
200	O
mg	O
IV	O
injections	O
up	O
to	O
five	O
times	O
within	O
a	O
2-week	O
period	O
.	O

Statistical	O
Analysis	O
The	O
planned	O
sample	O
size	O
of	O
at	O
least	O
668	B-Sample_Size_Required
evaluable	O
participants	O
(	O
334	O
per	O
group	O
across	O
all	O
sites	O
)	O
provided	O
at	O
least	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
reject	O
the	O
null	O
hypothesis	O
that	O
the	O
proportion	O
of	O
participants	O
with	O
moderate-to-severe	O
injection-site	O
pain	O
after	O
aIIV3	O
is	O
inferior	O
to	O
HD-IIV3	O
during	O
days	O
1	O
to	O
8	O
(	O
US	O
Food	O
and	O
Drug	O
Administration	O
package	O
inserts	O
)	O
.	O

Based	O
on	O
our	O
sample	O
size	O
calculation	O
,	O
we	O
planned	O
to	O
recruit	O
and	O
enroll	O
a	O
total	O
of	O
ninety-six	B-Sample_Size_Required
women	I-Sample_Size_Required
with	O
equal	O
allocation	O
to	O
the	O
placebo	O
and	O
gabapentin	O
groups	O
.	O

Eligible	O
patients	O
were	O
randomised	O
1:1	B-Randomization_Ratio
to	O
receive	O
either	O
filgotinib	B-Design_Parallel_Group
or	I-Design_Parallel_Group
lanraplenib	I-Design_Parallel_Group
in	O
a	O
blinded	O
fashion	O
for	O
up	O
to	O
52	O
weeks	O
.	O

A	O
sufficient	O
number	O
of	O
participants	O
were	O
to	O
be	O
screened	O
to	O
randomise	O
approximately	O
130	B-Sample_Size_Required
(	O
65	O
per	O
group	O
)	O
,	O
to	O
ensure	O
60	O
evaluable	O
participants	O
per	O
group	O
completed	O
the	O
study	O
.	O

After	O
a	O
2-week	O
screening	O
period	O
,	O
eligible	O
patients	O
were	O
randomly	O
assigned	O
in	O
a	O
1:1:1:1	B-Randomization_Ratio
ratio	O
to	O
one	O
of	O
four	O
treatment	O
groups	O
:	O
tenapanor	B-Design_Parallel_Group
5	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
,	I-Design_Parallel_Group
20	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
50	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
twice	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
(	I-Design_Parallel_Group
b.i.d	I-Design_Parallel_Group
.	I-Design_Parallel_Group

The	O
sample	O
size	O
required	O
for	O
the	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
hypothesis	O
dictated	O
the	O
final	O
sample	O
size	O
for	O
the	O
trial	O
.	O

A	O
Phase	B-Design_Phase_3
3	I-Design_Phase_3
,	O
Randomized	O
,	O
Double-Blind	B-Blinding_Double_Blind
Study	O
Comparing	O
Tedizolid	O
Phosphate	O
and	O
Linezolid	O
for	O
Treatment	O
of	O
Ventilated	O
Gram-Positive	O
Hospital-Acquired	O
or	O
Ventilator-Associated	O
Bacterial	O
Pneumonia	O

Sample	O
size	O
estimation	O
On	O
the	O
basis	O
of	O
the	O
results	O
of	O
our	O
pilot	O
study	O
(	O
ie	O
,	O
observed	O
rates	O
of	O
0.56	O
for	O
death	O
and	O
0.33	O
for	O
tracheotomy	O
at	O
18	O
months	O
in	O
the	O
placebo	O
group	O
)	O
,	O
we	O
estimated	O
that	O
we	O
would	O
need	O
a	O
sample	O
size	O
of	O
203	B-Sample_Size_Required
patients	O
followed	O
up	O
for	O
12	O
months	O
to	O
give	O
97	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
significant	O
difference	O
between	O
rhEPO	O
and	O
placebo	O
corresponding	O
to	O
a	O
67	O
%	O
relative	O
reduction	O
of	O
risk	O
of	O
death	O
and	O
74	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
70	O
%	O
relative	O
reduction	O
of	O
risk	O
of	O
respiratory	O
events	O
(	O
tracheotomy	O
or	O
>	O
23	O
h	O
NIV	O
)	O
,	O
with	O
a	B-Sample_Size_Calculation_Alpha_Value
two-sided	I-Sample_Size_Calculation_Alpha_Value
type	I-Sample_Size_Calculation_Alpha_Value
1	I-Sample_Size_Calculation_Alpha_Value
error	I-Sample_Size_Calculation_Alpha_Value
of	I-Sample_Size_Calculation_Alpha_Value
5	I-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
and	O
given	O
an	O
anticipated	O
dropout	O
rate	O
of	O
10	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
.	O

Assuming	O
a	O
2-sided	B-Sample_Size_Calculation_Alpha_Value
type	I-Sample_Size_Calculation_Alpha_Value
I	I-Sample_Size_Calculation_Alpha_Value
error	I-Sample_Size_Calculation_Alpha_Value
rate	I-Sample_Size_Calculation_Alpha_Value
of	I-Sample_Size_Calculation_Alpha_Value
5	I-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
and	O
a	O
standard	O
deviation	O
(	O
SD	O
)	O
of	O
3.5	O
mm	O
Hg	O
,	O
it	O
was	O
determined	O
that	O
50	O
subjects	O
per	O
treatment	O
arm	O
(	O
total	O
of	O
100	B-Sample_Size_Required
subjects	O
)	O
would	O
have	O
an	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
2.0	O
mm	O
Hg	O
between-treatment	O
difference	O
.	O

Women	O
were	O
then	O
randomised	O
to	O
receive	O
raltegravir	B-Design_Parallel_Group
400	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
twice	I-Design_Parallel_Group
a	I-Design_Parallel_Group
day	I-Design_Parallel_Group
or	I-Design_Parallel_Group
efavirenz	I-Design_Parallel_Group
600	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
each	I-Design_Parallel_Group
night	I-Design_Parallel_Group
in	O
addition	O
to	O
lamivudine	O
150	O
mg/zidovudine	O
300	O
mg	O
twice	O
a	O
day	O
(	O
or	O
an	O
alternative	O
,	O
locally	O
supplied	O
NRTI	O
regimen	O
)	O
from	O
study	O
entry	O
through	O
delivery	O
.	O

Statistical	O
Analyses	O
Assuming	O
a	O
change	O
from	O
baseline	O
in	O
mean	O
MMD	O
over	O
months	O
4‐6	O
of	O
–1.12	O
days	O
and	O
–1.30	O
days	O
for	O
the	O
70‐	O
and	O
140‐mg	O
dose	O
groups	O
,	O
respectively	O
,	O
vs	O
placebo	O
and	O
a	O
common	O
standard	O
deviation	O
of	O
2.8	O
days	O
(	O
based	O
on	O
a	O
clinical	O
study	O
of	O
topiramate	O
in	O
Japanese	O
patients	O
with	O
migraine	O
,	O
NCT01081795	O
)	O
,	O
the	O
planned	O
sample	O
size	O
was	O
131	B-Sample_Size_Target
patients	I-Sample_Size_Target
for	I-Sample_Size_Target
the	I-Sample_Size_Target
placebo	I-Sample_Size_Target
,	I-Sample_Size_Target
and	I-Sample_Size_Target
erenumab	I-Sample_Size_Target
70‐	I-Sample_Size_Target
and	I-Sample_Size_Target
140‐mg	I-Sample_Size_Target
dose	I-Sample_Size_Target
groups	I-Sample_Size_Target
,	O
providing	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
and	O
96	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
,	O
respectively	O
,	O
for	O
a	O
2‐sided	B-Sample_Size_Calculation_Alpha_Value
test	I-Sample_Size_Calculation_Alpha_Value
with	I-Sample_Size_Calculation_Alpha_Value
significance	I-Sample_Size_Calculation_Alpha_Value
level	I-Sample_Size_Calculation_Alpha_Value
of	I-Sample_Size_Calculation_Alpha_Value
.05	I-Sample_Size_Calculation_Alpha_Value
to	O
demonstrate	O
the	O
superiority	B-Design_Comparative_Intent_Superiority
of	O
erenumab	O
.	O

Randomisation	O
was	O
balanced	O
by	O
permuted	O
blocks	B-Randomization_Type_Block
and	O
stratified	B-Randomization_Type_Stratified
by	O
day	B-Randomization_Stratified_Criteria
−1	I-Randomization_Stratified_Criteria
body	I-Randomization_Stratified_Criteria
weight	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
≥80	I-Randomization_Stratified_Criteria
kg	I-Randomization_Stratified_Criteria
vs.	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
80	I-Randomization_Stratified_Criteria
kg	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
sex	B-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
male	I-Randomization_Stratified_Criteria
vs.	I-Randomization_Stratified_Criteria
female	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
and	O
study	B-Randomization_Stratified_Criteria
centre	I-Randomization_Stratified_Criteria
.	O

Participants	O
with	O
CHB	O
infection	O
≥6	O
months	O
and	O
serum	O
HBsAg	O
≥50	O
IU	O
ml−1	O
were	O
enrolled	O
from	O
seven	O
centers	O
across	O
Hong	O
Kong	O
and	O
the	O
Republic	O
of	O
Korea	O
and	O
randomized	O
(	O
3:1	B-Randomization_Ratio
within	I-Randomization_Ratio
each	I-Randomization_Ratio
dose	I-Randomization_Ratio
cohort	I-Randomization_Ratio
)	O
to	O
receive	O
bepirovirsen	B-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
via	O
subcutaneous	O
injection	O
twice	O
weekly	O
during	O
weeks	O
1	O
and	O
2	O
(	O
days	O
1	O
,	O
4	O
,	O
8	O
and	O
11	O
)	O
and	O
once	O
weekly	O
during	O
weeks	O
3	O
and	O
4	O
(	O
days	O
15	O
and	O
22	O
)	O
.	O

Methods	O
:	O
Randomized	O
subjects	O
(	O
1:1	B-Randomization_Ratio
)	O
received	O
omidenepag	O
isopropyl	O
0.002	O
%	O
QD	O
(	O
n=50	O
)	O
or	O
BID	O
(	O
n=48	O
)	O
for	O
6	O
weeks	O
(	O
after	O
a	O
≤4-week	O
washout	O
period	O
)	O
.	O

For	O
full	O
analysis	O
population	O
1	O
,	O
378	B-Sample_Size_Actual_at_Outcome_Analysis
received	I-Sample_Size_Actual_at_Outcome_Analysis
aIIV3	I-Sample_Size_Actual_at_Outcome_Analysis
and	I-Sample_Size_Actual_at_Outcome_Analysis
377	I-Sample_Size_Actual_at_Outcome_Analysis
received	I-Sample_Size_Actual_at_Outcome_Analysis
HD-IIV3	I-Sample_Size_Actual_at_Outcome_Analysis
because	O
2	O
participants	O
were	O
missing	O
symptom	O
diary	O
data	O
(	O
Figure	O
1	O
)	O
.	O

By	O
the	O
end	O
of	O
our	O
trial	O
2616	B-Sample_Size_Actual_at_Outcome_Analysis
of	O
the	O
3046	B-Sample_Size_Actual_at_Enrollment
recruited	O
children	O
were	O
present	O
in	O
our	O
study	O
and	O
17	O
had	O
died	O
.	O

METHODS	O
Study	O
Design	O
This	O
was	O
a	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
,	O
randomized	O
,	O
double-masked	B-Blinding_Double_Blind
,	O
multicenter	B-Settings_Multicenter
,	O
parallel-arm	B-Design_Parallel_Group
study	O
assessing	O
the	O
safety	O
and	O
efficacy	O
of	O
omidenepag	O
isopropyl	O
0.002	O
%	O
QD	O
and	O
BID	O
in	O
subjects	O
with	O
POAG	O
or	O
OHT	O
(	O
NCT03858894	O
)	O
.	O

Interventions	O
Intensive	B-Design_Parallel_Group
systolic	I-Design_Parallel_Group
blood	I-Design_Parallel_Group
pressure	I-Design_Parallel_Group
target	I-Design_Parallel_Group
(	I-Design_Parallel_Group
<	I-Design_Parallel_Group
130	I-Design_Parallel_Group
mm	I-Design_Parallel_Group
Hg	I-Design_Parallel_Group
or	I-Design_Parallel_Group
10	I-Design_Parallel_Group
mm	I-Design_Parallel_Group
Hg	I-Design_Parallel_Group
reduction	I-Design_Parallel_Group
from	I-Design_Parallel_Group
baseline	I-Design_Parallel_Group
if	I-Design_Parallel_Group
this	I-Design_Parallel_Group
was	I-Design_Parallel_Group
<	I-Design_Parallel_Group
140	I-Design_Parallel_Group
mm	I-Design_Parallel_Group
Hg	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
standard	I-Design_Parallel_Group
target	I-Design_Parallel_Group
(	I-Design_Parallel_Group
<	I-Design_Parallel_Group
140	I-Design_Parallel_Group
mm	I-Design_Parallel_Group
Hg	I-Design_Parallel_Group
)	I-Design_Parallel_Group
.	O

Effect	O
of	O
intravenous	O
β-2	O
agonist	O
treatment	O
on	O
clinical	O
outcomes	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
BALTI-2	O
)	O
:	O
a	O
multicentre	B-Settings_Multicenter
,	O
randomised	O
controlled	O
trial	O

Results	O
In	O
total	O
,	O
17	B-Sample_Size_Actual_at_Outcome_Analysis
participants	O
completed	O
the	O
study	O
.	O

Randomization	O
to	O
treatment	O
was	O
stratified	B-Randomization_Type_Stratified
by	O
age	B-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
6–8	I-Randomization_Stratified_Criteria
and	I-Randomization_Stratified_Criteria
9–12	I-Randomization_Stratified_Criteria
years	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
.	O

The	O
randomisation	O
sequence	O
was	O
computer-generated	B-Randomization_Sequence_Generation_Method
by	O
blocks	B-Randomization_Type_Block
,	O
stratified	B-Randomization_Type_Stratified
by	O
centre	B-Randomization_Stratified_Criteria
,	O
disease	B-Randomization_Stratified_Criteria
severity	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
ALSFRS-R	I-Randomization_Stratified_Criteria
cut-off	I-Randomization_Stratified_Criteria
score	I-Randomization_Stratified_Criteria
of	I-Randomization_Stratified_Criteria
33	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
and	O
onset	B-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
spinal	I-Randomization_Stratified_Criteria
or	I-Randomization_Stratified_Criteria
bulbar	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
.	O

Methods	O
Trial	O
design	O
A	O
phase	B-Design_Phase_2
2a	I-Design_Phase_2
,	O
multicenter	B-Settings_Multicenter
,	O
randomized	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
trial	O
of	O
subcutaneous	O
AMG	O
301	O
was	O
undertaken	O
in	O
adults	O
with	O
CM	O
or	O
EM	O
who	O
were	O
considered	O
eligible	O
for	O
preventive	O
treatment	O
and	O
fulfilled	O
eligibility	O
criteria	O
(	O
more	O
detailed	O
eligibility	O
criteria	O
are	O
provided	O
in	O
the	O
Patients	O
section	O
below	O
;	O
ClinicalTrials.gov	O
:	O
NCT03238781	O
)	O
.	O

This	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
study	O
evaluated	O
safety	O
,	O
tolerability	O
,	O
and	O
immunogenicity	O
of	O
PCV20	O
in	O
adults	O
without	O
prior	O
pneumococcal	O
vaccination	O
.	O

Patients	O
with	O
moderate	O
to	O
severe	O
RA	O
despite	O
methotrexate	O
therapy	O
were	O
randomised	O
in	O
a	O
1:1	B-Randomization_Ratio
ratio	O
to	O
receive	O
either	O
SB2	O
or	O
INF	O
of	O
3	O
mg/kg	O
.	O

Within	O
each	O
investigation	O
site	O
,	O
patients	O
were	O
randomised	O
in	O
a	O
1:1:1:1	B-Randomization_Ratio
ratio	O
to	O
once-daily	B-Design_Parallel_Group
treatment	I-Design_Parallel_Group
with	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
or	I-Design_Parallel_Group
ponesimod	I-Design_Parallel_Group
10	I-Design_Parallel_Group
,	I-Design_Parallel_Group
20	I-Design_Parallel_Group
or	I-Design_Parallel_Group
40	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
for	O
24	O
weeks	O
.	O

Design	O
:	O
Randomized	O
double-blind	B-Blinding_Double_Blind
placebo-controlled	O
pilot	O
trial	O
.	O

Results	O
Between	O
August	O
2010	O
and	O
November	O
2012	O
,	O
208	B-Sample_Size_Actual_at_Enrollment
of	O
545	O
eligible	O
patients	O
(	O
38	O
%	O
)	O
were	O
randomly	O
allocated	O
to	O
the	O
treatment	O
arms	O
(	O
104	O
in	O
the	O
rhEPO	O
arm	O
and	O
104	O
in	O
the	O
placebo	O
arm	O
;	O
figure	O
1	O
)	O
.	O

In	O
the	O
double-blind	B-Blinding_Double_Blind
phase	O
of	O
this	O
randomized	B-Randomization_Type_Simple
,	O
controlled	O
trial	O
,	O
we	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
400	O
vs.	O
240	O
U	O
onabotulinumtoxinA	O
in	O
patients	O
with	O
post-stroke	O
upper	O
limb	O
spasticity	O
.	O

By	O
use	O
of	O
the	O
randomisation	O
list	O
,	O
a	O
pharmacist	O
in	O
the	O
Department	O
of	O
Pharmacy	O
,	O
Aga	O
Khan	O
University	O
Hospital	O
,	O
Karachi	O
prepared	O
100	O
000	O
IU	O
(	O
2·5	O
mg	O
)	O
of	O
vitamin	O
D3	O
(	O
cholecalciferol	O
)	O
in	O
olive	O
oil	O
(	O
Sinochem	O
Ningbo	O
Laboratory	O
,	O
China	O
)	O
or	O
placebo	O
(	O
olive	O
oil	O
)	O
in	O
sealed	B-Allocation_Concealment_Method
2	I-Allocation_Concealment_Method
mL	I-Allocation_Concealment_Method
plastic	I-Allocation_Concealment_Method
syringes	I-Allocation_Concealment_Method
labelled	I-Allocation_Concealment_Method
with	I-Allocation_Concealment_Method
the	I-Allocation_Concealment_Method
unique	I-Allocation_Concealment_Method
identification	I-Allocation_Concealment_Method
numbers	I-Allocation_Concealment_Method
.	O

Precis	O
In	O
a	O
6-month	O
multicenter	B-Settings_Multicenter
,	O
randomized	O
,	O
comparative	O
trial	O
,	O
both	O
intravitreal	O
triamcinolone	O
and	O
intravitreal	O
dexamethasone	O
implant	O
were	O
superior	B-Design_Comparative_Intent_Superiority
to	O
periocular	O
triamcinolone	O
for	O
treating	O
uveitic	O
macular	O
edema	O
.	O

Results	O
Baseline	O
characteristics	O
As	O
depicted	O
in	O
the	O
trial	O
and	O
participant	O
flowchart	O
,	O
a	O
total	O
of	O
1009	B-Sample_Size_Actual_at_Enrollment
women	I-Sample_Size_Actual_at_Enrollment
were	O
randomised	O
and	O
exposed	O
,	O
of	O
whom	O
499	O
were	O
treated	O
with	O
follitropin	O
delta	O
in	O
its	O
individualised	O
fixed-dose	O
regimen	O
and	O
510	O
with	O
follitropin	O
alfa	O
in	O
a	O
conventional	O
and	O
adjustable	O
dosing	O
regimen	O
(	O
Fig	O
.	O

Four	B-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
in	I-Sample_Size_Actual_at_Outcome_Analysis
the	I-Sample_Size_Actual_at_Outcome_Analysis
filgotinib	I-Sample_Size_Actual_at_Outcome_Analysis
group	I-Sample_Size_Actual_at_Outcome_Analysis
and	I-Sample_Size_Actual_at_Outcome_Analysis
one	I-Sample_Size_Actual_at_Outcome_Analysis
patient	I-Sample_Size_Actual_at_Outcome_Analysis
in	I-Sample_Size_Actual_at_Outcome_Analysis
the	I-Sample_Size_Actual_at_Outcome_Analysis
lanraplenib	I-Sample_Size_Actual_at_Outcome_Analysis
group	I-Sample_Size_Actual_at_Outcome_Analysis
completed	O
week	O
16	O
.	O

The	O
primary	O
endpoint	O
was	O
change	O
from	O
baseline	O
in	O
mean	O
monthly	O
migraine	O
days	O
over	O
months	O
4‐6	O
of	O
the	O
double‐blind	B-Blinding_Double_Blind
treatment	O
phase	O
.	O

Of	O
the	O
1538	O
patients	O
enrolled	O
,	O
1447	B-Sample_Size_Actual_at_Outcome_Analysis
(	O
94	O
%	O
)	O
completed	O
the	O
trial	O
.	O

The	O
target	O
sample	O
size	O
of	O
the	O
initial	O
phase	O
was	O
determined	O
to	O
be	O
about	O
90	B-Sample_Size_Target
participants	O
to	O
allow	O
reasonably	O
precise	O
estimates	O
of	O
the	O
variables	O
for	O
the	O
main	O
trial	O
.	O

Methods	O
Randomised	O
,	O
multicentre	B-Settings_Multicenter
,	O
two-part	O
,	O
phase	B-Design_Phase_3
III	I-Design_Phase_3
trial	O
(	O
24-week	O
double-blind	B-Blinding_Double_Blind
,	O
80-week	O
open-label	B-Blinding_Open_Label
)	O
,	O
MEASURE	O
,	O
evaluated	O
lipid	O
and	O
lipoprotein	O
levels	O
,	O
high-density	O
lipoprotein	O
(	O
HDL	O
)	O
particle	O
composition	O
,	O
markers	O
of	O
coagulation	O
,	O
thrombosis	O
and	O
vascular	O
function	O
by	O
pulse	O
wave	O
velocity	O
(	O
PWV	O
)	O
in	O
132	B-Sample_Size_Actual_at_Enrollment
patients	O
with	O
RA	O
who	O
received	O
TCZ	B-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
.	O

At	O
the	O
start	O
of	O
the	O
treatment	O
period	O
,	O
participants	O
were	O
randomized	O
1:1	B-Randomization_Ratio
to	O
double-blind	B-Blinding_Double_Blind
treatment	O
with	O
either	O
faster	O
aspart	O
or	O
IAsp	O
delivered	O
in	O
a	O
basal-bolus	O
regimen	O
with	O
once-daily	O
insulin	O
degludec	O
with	O
or	O
without	O
metformin	O
.	O

Results	O
Nine	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomised	O
to	O
receive	O
filgotinib	O
(	O
n=5	O
)	O
or	O
lanraplenib	O
(	O
n=4	O
)	O
.	O

Evolocumab	O
vs.	O
Ezetimibe	O
in	O
Statin-Intolerant	O
Hyperlipidemic	O
Japanese	B-Settings_Location
Patients	O
:	O
Phase	B-Design_Phase_3
3	I-Design_Phase_3
GAUSS-4	O
Trial	O

Subjects	O
were	O
randomised	O
(	O
1:1	B-Randomization_Ratio
)	O
to	O
receive	O
CT‐P17	O
AI	O
or	O
CT‐P17	O
PFS	O
(	O
day	O
1	O
)	O
followed	O
by	O
PK	O
,	O
safety	O
and	O
immunogenicity	O
assessment	O
over	O
the	O
10‐week	O
study	O
period	O
(	O
until	O
end‐of‐study	O
visit	O
[	O
day	O
71	O
]	O
)	O
.	O

RESULTS	O
PARTICIPANTS	O
Of	O
the	O
112	O
potential	O
participants	O
who	O
were	O
screened	O
for	O
eligibility	O
,	O
76	B-Sample_Size_Actual_at_Enrollment
underwent	O
randomization	O
—	O
44	O
to	O
the	O
teplizumab	O
group	O
and	O
32	O
to	O
the	O
placebo	O
group	O
(	O
Fig	O
.	O

This	O
would	O
give	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
,	O
α	O
0.05	B-Sample_Size_Calculation_Alpha_Value
,	O
to	O
show	O
a	O
reduction	O
in	O
the	O
primary	O
composite	O
endpoint	O
(	O
fetal	O
death	O
or	O
severe	O
morbidity	O
)	O
from	O
6	O
%	O
to	O
3	O
%	O
.	O

Methods	O
This	O
was	O
a	O
randomized	O
,	O
multi-center	B-Settings_Multicenter
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
clinical	O
trial	O
conducted	O
in	O
21	B-Settings_Multicenter
centers	I-Settings_Multicenter
across	O
China	B-Settings_Location
.	O

Methods	O
Study	O
design	O
GO-DACT	O
was	O
a	O
multicentre	B-Settings_Multicenter
,	O
investigator-initiated	O
,	O
randomised	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
,	O
phase	B-Design_Phase_3
3b	I-Design_Phase_3
trial	O
of	O
golimumab	B-Design_Parallel_Group
plus	I-Design_Parallel_Group
MTX	I-Design_Parallel_Group
versus	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
plus	I-Design_Parallel_Group
MTX	I-Design_Parallel_Group
,	O
in	O
MTX-naive	O
and	O
bDMARDs-naive	O
patients	O
with	O
PsA	O
and	O
active	O
dactylitis	O
.	O

Using	O
a	O
permuted	O
block	B-Randomization_Type_Block
randomization	I-Randomization_Type_Block
method	O
,	O
children	O
were	O
assigned	O
in	O
a	O
2:1	B-Randomization_Ratio
ratio	O
to	O
receive	O
a	O
single	O
dose	O
of	O
oral	O
baloxavir	O
on	O
day	O
1	O
(	O
2	O
mg/kg	O
for	O
those	O
weighing	O
<	O
20	O
kg	O
and	O
a	O
single	O
dose	O
of	O
40	O
mg	O
for	O
those	O
weighing	O
≥20	O
kg	O
)	O
,	O
or	O
oral	O
oseltamivir	O
twice	O
daily	O
according	O
to	O
prescribing	O
information	O
(	O
30	O
mg	O
for	O
patients	O
weighing	O
≤15	O
kg	O
,	O
45	O
mg	O
for	O
>	O
15–≤23	O
kg	O
,	O
60	O
mg	O
for	O
>	O
23–≤40	O
kg	O
,	O
and	O
75	O
mg	O
for	O
>	O
40	O
kg	O
)	O
on	O
days	O
1–5	O
.	O

The	O
interactive	B-Randomization_Sequence_Generation_Method
web	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
determined	O
which	O
drug	O
package	O
the	O
center	O
should	O
administer	O
to	O
the	O
patient	O
based	O
on	O
a	O
randomization	O
schedule	O
where	O
each	O
treatment	O
was	O
allocated	O
once	O
using	O
a	O
block	B-Randomization_Type_Block
size	O
of	O
four	B-Randomization_Block_Size
within	O
each	O
study	O
site	O
.	O

Primary	O
immunogenicity	O
endpoint	O
was	O
to	O
demonstrate	O
noninferiority	B-Design_Comparative_Intent_NonInferiority
of	O
V114	O
Lot	O
1	O
and	O
V114	O
Lot	O
2	O
relative	O
to	O
PCV13	O
based	O
on	O
proportion	O
of	O
infants	O
achieving	O
serotype-specific	O
IgG	O
concentration	O
≥0.35	O
µg/mL	O
for	O
13	O
serotypes	O
shared	O
with	O
PCV13	O
at	O
1	O
month	O
postdose	O
3	O
(	O
PD3	O
)	O
.	O

Interventions	O
Ursodeoxycholic	B-Design_Parallel_Group
acid	I-Design_Parallel_Group
500	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
twice	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
increased	O
as	O
necessary	O
for	O
symptomatic	O
or	O
biochemical	O
improvement	O
until	O
delivery	O
;	O
early	O
term	O
delivery	O
(	O
induction	O
or	O
delivery	O
started	O
between	O
37+0	O
and	O
37+6	O
)	O
or	O
expectant	O
management	O
(	O
spontaneous	O
labour	O
awaited	O
until	O
40	O
weeks	O
’	O
gestation	O
or	O
caesarean	O
section	O
undertaken	O
by	O
normal	O
obstetric	O
guidelines	O
,	O
usually	O
after	O
39	O
weeks	O
’	O
gestation	O
)	O
.	O

Materials	O
and	O
methods	O
A	O
26‐week	O
,	O
double‐blind	O
study	O
of	O
506	B-Sample_Size_Actual_at_Enrollment
Asian	B-Settings_Location
patients	O
(	O
80.2	O
%	O
from	O
mainland	O
China	B-Settings_Location
)	O
,	O
randomized	O
1:1:1	B-Randomization_Ratio
to	O
placebo	B-Design_Parallel_Group
,	I-Design_Parallel_Group
ertugliflozin	I-Design_Parallel_Group
5‐	I-Design_Parallel_Group
or	I-Design_Parallel_Group
15	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
,	O
was	O
performed	O
.	O

Design	O
First	B-Design_Phase_1
phase	I-Design_Phase_1
of	O
a	O
semifactorial	B-Design_Factorial
randomised	O
controlled	O
trial	O
.	O

It	O
was	O
ultimately	O
limited	O
to	O
nine	B-Sample_Size_Actual_at_Enrollment
patients	O
who	O
were	O
randomised	O
to	O
receive	O
filgotinib	O
(	O
five	O
patients	O
)	O
or	O
lanraplenib	O
(	O
four	O
patients	O
)	O
(	O
figure	O
1	O
)	O
.	O

This	O
is	O
a	O
single-center	B-Settings_Single_Center
randomized	B-Randomization_Type_Simple
open	B-Blinding_Open_Label
label	I-Blinding_Open_Label
active-controlled	O
crossover	B-Design_Crossover
trial	O
comparing	O
efficacy	O
and	O
safety	O
of	O
fast	O
acting	O
insulin	O
aspart	O
(	O
FA	O
)	O
(	O
FIASP®	O
)	O
versus	O
insulin	O
aspart	O
(	O
IAsp	O
)	O
(	O
NovoLog®	O
)	O
when	O
used	O
in	O
the	O
Medtronic	O
670G	O
system	O
in	O
auto	O
mode	O
in	O
patients	O
with	O
type	O
1	O
diabetes	O
.	O

Four	B-Sample_Size_Actual_at_Enrollment
hundred	I-Sample_Size_Actual_at_Enrollment
forty	I-Sample_Size_Actual_at_Enrollment
adults	I-Sample_Size_Actual_at_Enrollment
with	O
knee	O
OA	O
received	O
a	B-Design_Parallel_Group
single	I-Design_Parallel_Group
6	I-Design_Parallel_Group
ml	I-Design_Parallel_Group
Hylan	I-Design_Parallel_Group
G-F	I-Design_Parallel_Group
20	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
injection	I-Design_Parallel_Group
and	O
were	O
evaluated	O
for	O
clinical	O
efficacy	O
and	O
safety	O
outcomes	O
over	O
26	O
weeks	O
.	O

Materials	O
and	O
Methods	O
Study	O
Design	O
This	O
clinical	O
study	O
was	O
a	O
multicenter	B-Settings_Multicenter
,	O
open-label	B-Blinding_Open_Label
,	O
phase	B-Design_Phase_1
I	I-Design_Phase_1
study	O
of	O
oral	O
abemaciclib	O
(	O
LY2835219	O
;	O
Eli	O
Lilly	O
and	O
Company	O
,	O
Indianapolis	O
,	O
IN	O
,	O
USA	O
)	O
,	O
in	O
Chinese	O
patients	O
with	O
advanced	O
and/or	O
metastatic	O
cancers	O
.	O

Materials	O
and	O
Methods	O
Study	O
design	O
This	O
is	O
a	O
single-center	B-Settings_Single_Center
randomized	B-Randomization_Type_Simple
open	B-Blinding_Open_Label
label	I-Blinding_Open_Label
active-controlled	O
crossover	B-Design_Crossover
trial	O
with	O
a	O
2-week	O
run	O
in	O
period	O
and	O
two	B-Design_Crossover_Period_Treatment
7-week	I-Design_Crossover_Period_Treatment
treatment	I-Design_Crossover_Period_Treatment
periods	I-Design_Crossover_Period_Treatment
comparing	O
FA	O
versus	O
IAsp	O
in	O
the	O
Medtronic	O
MiniMed	O
670G	O
system	O
in	O
participants	O
with	O
T1DM	O
.	O

Nearly	B-Sample_Size_Actual_at_Outcome_Analysis
all	I-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
(	I-Sample_Size_Actual_at_Outcome_Analysis
96	I-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
)	I-Sample_Size_Actual_at_Outcome_Analysis
completed	O
all	O
protocol-defined	O
study	O
visits	O
,	O
with	O
similar	O
discontinuation	O
and	O
withdrawal	O
rates	O
between	O
treatment	O
groups	O
(	O
Fig	O
.	O

Safety	O
endpoints	O
of	O
a	O
priori	O
interest	O
(	O
Tier	O
1	O
AEs	O
of	O
GMI	O
by	O
gender	O
,	O
UTI	O
,	O
symptomatic	O
hypoglycaemia	O
and	O
hypovolaemia	O
)	O
were	O
assessed	O
using	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
,	O
and	O
P‐values	O
provided	O
without	O
multiplicity	O
control	O
using	O
the	O
Miettinen	O
and	O
Nurminen	O
method.23	O
RESULTS	O
Patient	O
disposition	O
and	O
baseline	O
characteristics	O
In	O
total	O
,	O
506	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomized	O
(	O
Supporting	O
Information	O
Table	O
S1	O
)	O
,	O
including	O
406	O
patients	O
in	O
mainland	O
China	O
.	O

A	O
closed	O
testing	O
procedure	O
was	O
used	O
to	O
control	O
the	O
experiment-wise	O
type	O
I	O
error	O
rate	O
at	O
the	O
5	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
significance	O
level	O
.	O

The	O
trial	O
was	O
composed	O
of	O
a	O
double-blinded	B-Blinding_Double_Blind
,	O
randomized	O
,	O
placebo-controlled	O
,	O
dose-escalation	O
study	O
in	O
treatment-naïve	O
patients	O
(	O
n	O
=	O
24	B-Sample_Size_Actual_at_Enrollment
)	O
and	O
an	O
add-on	O
exploratory	O
cohort	O
of	O
patients	O
already	O
receiving	O
stable	O
NA	O
regimens	O
(	O
on-NA	O
patients	O
;	O
n	O
=	O
7	B-Sample_Size_Actual_at_Enrollment
)	O
(	O
Supplementary	O
Fig	O
.	O

Based	O
on	O
a	O
prespecified	O
non-inferiority	O
limit	O
of	O
−10.0	O
%	O
(	O
absolute	O
)	O
and	O
an	O
assumed	O
ongoing	O
pregnancy	O
rate	O
of	O
32.2	O
%	O
in	O
both	O
treatment	O
groups	O
,	O
the	O
trial	O
was	O
designed	O
to	O
have	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
achieving	O
the	O
primary	O
objective	O
.	O

Women	O
who	O
were	O
eligible	O
for	O
both	O
were	O
permitted	O
to	O
participate	O
in	O
either	O
or	O
both	O
factorial	B-Design_Factorial
comparisons	O
.	O

Design	O
:	O
Multicenter	B-Settings_Multicenter
randomized	O
clinical	O
trial	O
Participants	O
:	O
Patients	O
with	O
uveitic	O
macular	O
edema	O
Methods	O
:	O
Patients	O
were	O
randomized	O
1:1:1	B-Randomization_Ratio
to	O
receive	O
one	O
of	O
the	O
three	O
therapies	O
.	O

RESULTS	O
Patient	O
Disposition	O
and	O
Characteristics	O
This	O
study	O
was	O
performed	O
between	O
November	O
20	O
,	O
2018	O
and	O
August	O
27	O
,	O
2019	O
at	O
36	O
sites	O
across	O
6	O
countries	O
(	O
USA	B-Settings_Location
,	I-Settings_Location
Poland	I-Settings_Location
,	I-Settings_Location
Spain	I-Settings_Location
,	I-Settings_Location
Costa	I-Settings_Location
Rica	I-Settings_Location
,	I-Settings_Location
Mexico	I-Settings_Location
and	I-Settings_Location
Russia	I-Settings_Location
)	O
.	O

The	O
vitamin	B-Design_Parallel_Group
D3	I-Design_Parallel_Group
and	I-Design_Parallel_Group
the	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
were	O
the	O
same	O
colour	O
(	O
pale	O
yellow	O
)	O
,	O
taste	O
,	O
and	O
quantity	O
(	O
0·5	O
mL	O
)	O
and	O
therefore	O
the	O
study	B-Blinding_Object_Others
staff	I-Blinding_Object_Others
and	O
the	O
families	B-Blinding_Object_Others
did	O
not	O
know	O
to	O
which	O
group	O
the	O
children	O
were	O
assigned	O
.	O

At	O
the	O
start	O
of	O
the	O
double-blind	O
treatment	O
period	O
,	O
participants	O
were	O
randomized	O
1:1	B-Randomization_Ratio
to	O
6.25	B-Design_Parallel_Group
mg	I-Design_Parallel_Group
SHP465	I-Design_Parallel_Group
MAS	I-Design_Parallel_Group
once	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
.	O

Overall	O
,	O
295	B-Sample_Size_Actual_at_Outcome_Analysis
(	I-Sample_Size_Actual_at_Outcome_Analysis
80.6	I-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
)	I-Sample_Size_Actual_at_Outcome_Analysis
and	I-Sample_Size_Actual_at_Outcome_Analysis
293	I-Sample_Size_Actual_at_Outcome_Analysis
(	I-Sample_Size_Actual_at_Outcome_Analysis
81.4	I-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
)	I-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
in	I-Sample_Size_Actual_at_Outcome_Analysis
the	I-Sample_Size_Actual_at_Outcome_Analysis
tedizolid	I-Sample_Size_Actual_at_Outcome_Analysis
and	I-Sample_Size_Actual_at_Outcome_Analysis
linezolid	I-Sample_Size_Actual_at_Outcome_Analysis
groups	I-Sample_Size_Actual_at_Outcome_Analysis
,	O
respectively	O
,	O
received	O
any	O
adjunctive	O
gram-negative	O
therapy	O
(	O
Table	O
1	O
)	O
.	O

All	B-Blinding_Object_Outcome_Assessors
site	I-Blinding_Object_Outcome_Assessors
personnel	I-Blinding_Object_Outcome_Assessors
involved	I-Blinding_Object_Outcome_Assessors
in	I-Blinding_Object_Outcome_Assessors
efficacy	I-Blinding_Object_Outcome_Assessors
and	I-Blinding_Object_Outcome_Assessors
safety	I-Blinding_Object_Outcome_Assessors
assessments	I-Blinding_Object_Outcome_Assessors
were	O
also	O
blinded	O
to	O
assigned	O
treatment	O
during	O
the	O
study	O
.	O

The	O
study	O
was	O
conducted	O
in	O
73	B-Settings_Multicenter
centres	I-Settings_Multicenter
in	O
11	B-Settings_Location
countries	I-Settings_Location
from	I-Settings_Location
Europe	I-Settings_Location
and	I-Settings_Location
Asia	I-Settings_Location
.	O

Patients	O
were	O
randomized	O
to	O
tofacitinib	B-Design_Parallel_Group
MR	I-Design_Parallel_Group
11	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
QD	I-Design_Parallel_Group
(	I-Design_Parallel_Group
n	I-Design_Parallel_Group
=	I-Design_Parallel_Group
104	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
IR	I-Design_Parallel_Group
5	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
BID	I-Design_Parallel_Group
(	I-Design_Parallel_Group
n	I-Design_Parallel_Group
=	I-Design_Parallel_Group
105	I-Design_Parallel_Group
)	I-Design_Parallel_Group
,	O
with	O
stable	O
MTX	O
.	O

Raltegravir	O
Versus	O
Efavirenz	O
in	O
Antiretroviral-Naive	O
Pregnant	O
Women	O
Living	O
With	O
HIV	O
(	O
NICHD	O
P1081	O
)	O
:	O
An	O
Open-Label	B-Blinding_Open_Label
,	O
Randomised	O
,	O
Controlled	O
,	O
Phase	B-Design_Phase_4
4	I-Design_Phase_4
Trial	O

Randomisation	O
was	O
by	O
use	O
of	O
a	B-Randomization_Sequence_Generation_Method
computer-generated	I-Randomization_Sequence_Generation_Method
list	I-Randomization_Sequence_Generation_Method
.	O

The	O
random	O
allocation	O
sequence	O
for	O
each	O
comparison	O
was	O
generated	O
by	O
using	O
a	O
specific	O
function	O
(	O
-ralloc-	O
)	O
in	O
Stata	O
(	O
StataCorp	O
,	O
College	O
Station	O
,	O
TX	O
)	O
software	O
within	O
the	O
clinical	O
unit	O
using	O
randomly	O
varying	O
block	B-Randomization_Type_Block
sizes	O
of	O
two	B-Randomization_Block_Size
,	I-Randomization_Block_Size
four	I-Randomization_Block_Size
,	I-Randomization_Block_Size
and	I-Randomization_Block_Size
six	I-Randomization_Block_Size
.	O

The	O
proportion	O
of	O
patients	O
who	O
had	O
achieved	O
onset	O
of	O
action	O
by	O
15	O
min	O
post-dose	O
ranged	O
from	O
7	O
%	O
with	O
GP	O
MDI	O
0.6	O
μg	O
to	O
30	O
%	O
with	O
GP	O
MDI	O
9	O
μg	O
(	O
29	O
%	O
with	O
GP	O
MDI	O
18	O
μg	O
)	O
,	O
and	O
39	O
%	O
for	O
open-label	B-Blinding_Open_Label
tiotropium	O
,	O
compared	O
with	O
4	O
%	O
for	O
placebo	O
MDI	O
.	O

Randomisation	O
and	O
Masking	O
Participants	O
were	O
randomly	O
allocated	O
to	O
one	B-Design_Parallel_Group
of	I-Design_Parallel_Group
two	I-Design_Parallel_Group
ART	I-Design_Parallel_Group
regimens	I-Design_Parallel_Group
,	I-Design_Parallel_Group
one	I-Design_Parallel_Group
raltegravir-based	I-Design_Parallel_Group
and	I-Design_Parallel_Group
one	I-Design_Parallel_Group
efavirenz	I-Design_Parallel_Group
-based	I-Design_Parallel_Group
.	O

Material	O
and	O
Methods	O
Study	O
Design	O
and	O
Participants	O
This	O
multinational	B-Settings_Multicenter
,	O
double-blind	B-Blinding_Double_Blind
,	O
randomized	O
,	O
parallel	B-Design_Parallel_Group
group	I-Design_Parallel_Group
,	O
phase	B-Design_Phase_3
III	I-Design_Phase_3
clinical	O
comparability	O
study	O
(	O
STELLA	O
)	O
was	O
conducted	O
in	O
93	B-Settings_Multicenter
centers	I-Settings_Multicenter
in	O
the	O
following	O
16	B-Settings_Location
countries	I-Settings_Location
:	I-Settings_Location
Brazil	I-Settings_Location
,	I-Settings_Location
Bulgaria	I-Settings_Location
,	I-Settings_Location
Chile	I-Settings_Location
,	I-Settings_Location
Georgia	I-Settings_Location
,	I-Settings_Location
Greece	I-Settings_Location
,	I-Settings_Location
Hungary	I-Settings_Location
,	I-Settings_Location
India	I-Settings_Location
,	I-Settings_Location
Lebanon	I-Settings_Location
,	I-Settings_Location
Malaysia	I-Settings_Location
,	I-Settings_Location
Mexico	I-Settings_Location
,	I-Settings_Location
Philippines	I-Settings_Location
,	I-Settings_Location
Russia	I-Settings_Location
,	I-Settings_Location
Serbia	I-Settings_Location
,	I-Settings_Location
Thailand	I-Settings_Location
,	I-Settings_Location
Turkey	I-Settings_Location
,	I-Settings_Location
and	I-Settings_Location
Ukraine	I-Settings_Location
.	O

Participants	O
were	O
administered	O
600mg	O
of	O
oral	B-Design_Parallel_Group
gabapentin	I-Design_Parallel_Group
versus	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
with	O
usual	O
oral	O
pain	O
management	O
.	O

Patients	O
were	O
randomized	O
(	O
3:1	B-Randomization_Ratio
within	I-Randomization_Ratio
each	I-Randomization_Ratio
dose	I-Randomization_Ratio
cohort	I-Randomization_Ratio
)	O
to	O
bepirovirsen	B-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
according	O
to	O
the	O
randomization	O
schedule	O
(	O
permuted	O
block	B-Randomization_Type_Block
)	O
.	O

Overall	O
,	O
465	B-Sample_Size_Actual_at_Outcome_Analysis
(	O
92	O
%	O
)	O
patients	O
completed	O
the	O
study	O
medication	O
.	O

Randomisation	O
was	O
minimised	B-Randomization_Type_Minimization
by	O
centre	B-Randomization_Minimization_Criteria
,	O
PaO2/FIO2	B-Randomization_Minimization_Criteria
ratio	I-Randomization_Minimization_Criteria
(	I-Randomization_Minimization_Criteria
≤50	I-Randomization_Minimization_Criteria
,	I-Randomization_Minimization_Criteria
51–99	I-Randomization_Minimization_Criteria
,	I-Randomization_Minimization_Criteria
or	I-Randomization_Minimization_Criteria
≥100	I-Randomization_Minimization_Criteria
mm	I-Randomization_Minimization_Criteria
Hg	I-Randomization_Minimization_Criteria
)	I-Randomization_Minimization_Criteria
,	O
and	O
age	B-Randomization_Minimization_Criteria
(	I-Randomization_Minimization_Criteria
<	I-Randomization_Minimization_Criteria
64	I-Randomization_Minimization_Criteria
,	I-Randomization_Minimization_Criteria
65–84	I-Randomization_Minimization_Criteria
,	I-Randomization_Minimization_Criteria
≥85	I-Randomization_Minimization_Criteria
years	I-Randomization_Minimization_Criteria
)	I-Randomization_Minimization_Criteria
.	O

A	O
Randomized	O
Phase	B-Design_Phase_2
2	I-Design_Phase_2
Study	O
of	O
Erenumab	O
for	O
the	O
Prevention	O
of	O
Episodic	O
Migraine	O
in	O
Japanese	B-Settings_Location
Adults	O

Patients	B-Blinding_Object_Patients
,	O
the	O
study	B-Blinding_Object_Others
sponsor	I-Blinding_Object_Others
,	O
site	B-Blinding_Object_Investigators
investigators	I-Blinding_Object_Investigators
,	O
and	O
study	B-Blinding_Object_Care_Providers
staff	I-Blinding_Object_Care_Providers
involved	I-Blinding_Object_Care_Providers
in	I-Blinding_Object_Care_Providers
clinical	I-Blinding_Object_Care_Providers
care/evaluations	I-Blinding_Object_Care_Providers
were	O
all	O
blinded	O
to	O
treatment	O
assignments	O
.	O

(	O
Clinicaltrials.gov	O
:	O
NCT01618305	O
)	O
Findings	O
From	O
September	O
2013	O
to	O
December	O
2018	O
,	O
408	B-Sample_Size_Actual_at_Enrollment
women	I-Sample_Size_Actual_at_Enrollment
were	O
randomized	O
(	O
206	O
RAL	O
,	O
202	O
EFV	O
)	O
and	O
394	O
delivered	O
on-study	O
(	O
200	O
RAL	O
,	O
194	O
EFV	O
)	O
;	O
307	B-Sample_Size_Actual_at_Outcome_Analysis
were	O
included	O
in	O
the	O
primary	O
efficacy	O
analysis	O
(	O
153	O
RAL	O
,	O
154	O
EFV	O
)	O
.	O

Participants	O
125	B-Sample_Size_Actual_at_Enrollment
women	I-Sample_Size_Actual_at_Enrollment
with	O
intrahepatic	O
cholestasis	O
of	O
pregnancy	O
(	O
pruritus	O
and	O
raised	O
levels	O
of	O
serum	O
bile	O
acids	O
)	O
or	O
pruritus	O
and	O
raised	O
alanine	O
transaminase	O
levels	O
(	O
>	O
100	O
IU/L	O
)	O
recruited	O
after	O
24	O
weeks	O
’	O
gestation	O
and	O
followed	O
until	O
delivery	O
.	O

Blinded	B-Allocation_Concealment_Method
,	I-Allocation_Concealment_Method
coded	I-Allocation_Concealment_Method
kits	I-Allocation_Concealment_Method
with	I-Allocation_Concealment_Method
study	I-Allocation_Concealment_Method
drug	I-Allocation_Concealment_Method
in	I-Allocation_Concealment_Method
prefilled	I-Allocation_Concealment_Method
syringes	I-Allocation_Concealment_Method
and	I-Allocation_Concealment_Method
boxes	I-Allocation_Concealment_Method
masked	O
the	O
treatment	O
assignments	O
.	O

Results	O
Trial	O
population	O
The	O
ITT	O
population	O
included	O
800	B-Sample_Size_Actual_at_Enrollment
patients	O
who	O
underwent	O
randomization	O
(	O
FF/UMEC/VI	O
,	O
N	O
=	O
400	O
;	O
TIO	O
,	O
N	O
=	O
400	O
;	O
Fig	O
.	O

treatment	O
group	O
was	O
compared	O
with	O
the	O
placebo	O
group	O
using	O
a	O
5	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
significance	O
level	O
.	O

It	O
was	O
conducted	O
from	O
March	O
21	O
,	O
2017	O
,	O
through	O
July	O
9	O
,	O
2019	O
,	O
at	O
47	B-Settings_Multicenter
sites	I-Settings_Multicenter
(	O
Finland	B-Settings_Location
[	I-Settings_Location
8	I-Settings_Location
]	I-Settings_Location
,	I-Settings_Location
Spain	I-Settings_Location
[	I-Settings_Location
2	I-Settings_Location
]	I-Settings_Location
,	I-Settings_Location
Israel	I-Settings_Location
[	I-Settings_Location
3	I-Settings_Location
]	I-Settings_Location
,	I-Settings_Location
Denmark	I-Settings_Location
[	I-Settings_Location
2	I-Settings_Location
]	I-Settings_Location
,	I-Settings_Location
Canada	I-Settings_Location
[	I-Settings_Location
3	I-Settings_Location
]	I-Settings_Location
and	I-Settings_Location
the	I-Settings_Location
United	I-Settings_Location
States	I-Settings_Location
[	I-Settings_Location
29	I-Settings_Location
]	I-Settings_Location
)	O
.	O

Patients	O
were	O
randomised	O
in	O
a	O
1:1	B-Randomization_Ratio
ratio	O
to	O
receive	O
either	B-Design_Parallel_Group
SB2	I-Design_Parallel_Group
or	I-Design_Parallel_Group
INF	I-Design_Parallel_Group
of	I-Design_Parallel_Group
3	I-Design_Parallel_Group
mg/kg	I-Design_Parallel_Group
intravenously	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
This	O
multicenter	B-Settings_Multicenter
,	O
double-blind	B-Blinding_Double_Blind
,	O
treat-to-target	O
trial	O
randomized	B-Randomization_Type_Simple
participants	O
to	O
faster	O
aspart	B-Design_Parallel_Group
(	I-Design_Parallel_Group
n	I-Design_Parallel_Group
=	I-Design_Parallel_Group
546	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
IAsp	I-Design_Parallel_Group
(	I-Design_Parallel_Group
n	I-Design_Parallel_Group
=	I-Design_Parallel_Group
545	I-Design_Parallel_Group
)	I-Design_Parallel_Group
.	O

Randomisation	O
and	O
treatment	O
allocation	O
was	O
implemented	O
through	O
an	B-Randomization_Sequence_Generation_Method
interactive	I-Randomization_Sequence_Generation_Method
web	I-Randomization_Sequence_Generation_Method
responsive	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
(	O
Cenduit	O
LLC	O
,	O
see	O
online	O
supplementary	O
appendix	O
S3-1	O
)	O
.	O

Assuming	O
a	O
20	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
loss	O
to	O
follow-up	O
and	O
allowing	O
for	O
protocol	O
violations	O
we	O
intended	O
to	O
recruit	O
3050	B-Sample_Size_Target
children	O
for	O
18	O
months	O
follow-up	O
.	O

In	O
the	O
open-label	B-Blinding_Open_Label
phase	O
,	O
patients	O
received	O
400	O
U	O
of	O
onabotulinumtoxinA	O
up	O
to	O
3	O
times	O
with	O
a	O
minimum	O
interval	O
of	O
12	O
weeks	O
between	O
injections	O
.	O

Erythropoietin	O
in	O
amyotrophic	O
lateral	O
sclerosis	O
:	O
a	O
multicentre	B-Settings_Multicenter
,	O
randomised	O
,	O
double	B-Blinding_Double_Blind
blind	I-Blinding_Double_Blind
,	O
placebo	O
controlled	O
,	O
phase	B-Design_Phase_3
III	I-Design_Phase_3
study	O

All	O
investigators	B-Blinding_Object_Investigators
,	O
embryologists	B-Blinding_Object_Others
and	O
central	B-Blinding_Object_Others
laboratory	I-Blinding_Object_Others
personnel	I-Blinding_Object_Others
were	O
blinded	O
to	O
the	O
individual	O
treatment	O
allocation	O
.	O

The	O
rest	O
of	O
the	O
research	O
team	O
including	O
the	O
principal	B-Blinding_Object_Investigators
investigator	I-Blinding_Object_Investigators
,	O
research	B-Blinding_Object_Others
coordinator	I-Blinding_Object_Others
,	O
dietitian	B-Blinding_Object_Others
,	O
and	O
exercise	B-Blinding_Object_Others
physiologist	I-Blinding_Object_Others
were	O
blinded	O
as	O
to	O
the	O
randomization	O
of	O
the	O
participants	O
until	O
the	O
end	O
of	O
the	O
study	O
.	O

Randomization	O
tables	O
were	O
prepared	O
by	O
the	B-Randomization_Personnel
coordinating	I-Randomization_Personnel
center	O
and	O
assignments	O
were	O
revealed	O
via	O
a	B-Randomization_Sequence_Generation_Method
web	I-Randomization_Sequence_Generation_Method
portal	I-Randomization_Sequence_Generation_Method
after	O
patients	O
were	O
enrolled	O
in	O
the	O
trial	O
and	O
all	O
baseline	O
data	O
were	O
collected	O
.	O

Non-inferiority	B-Design_Comparative_Intent_NonInferiority
was	O
only	O
determined	O
for	O
a	O
treatment	O
group	O
if	O
the	O
lower	O
bound	O
of	O
the	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
for	O
the	O
difference	O
was	O
above	O
−100	O
mL	O
and	O
if	O
all	O
higher	O
dose	O
levels	O
were	O
statistically	O
significantly	O
non-inferior	B-Design_Comparative_Intent_NonInferiority
to	O
open-label	B-Blinding_Open_Label
tiotropium	O
.	O

Methods	O
This	O
26-week	O
,	O
randomised	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
phase	B-Design_Phase_2
IIb	I-Design_Phase_2
study	O
enrolled	O
symptomatic	O
patients	O
with	O
mild-to-moderate	O
COPD	O
at	O
risk	O
for	O
exacerbations	O
.	O

MATERIALS	O
AND	O
METHODS	O
Trial	O
Design	O
and	O
Participants	O
This	O
was	O
a	O
global	O
,	O
multicenter	B-Settings_Multicenter
,	O
double-blind	B-Blinding_Double_Blind
,	O
randomized	O
,	O
active	O
controlled	O
trial	O
of	O
the	O
safety	O
,	O
pharmacokinetics	O
and	O
efficacy	O
of	O
a	O
single	O
oral	O
dose	O
of	O
baloxavir	O
versus	O
twice-daily	O
(	O
for	O
5	O
days	O
)	O
oral	O
oseltamivir	O
,	O
in	O
otherwise	O
healthy	O
children	O
with	O
influenza	O
.	O

Accounting	O
for	O
10	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
dropouts	O
,	O
a	O
total	O
of	O
40	B-Sample_Size_Actual_at_Enrollment
subjects	O
were	O
randomized	O
.	O

24	O
,	O
25	O
Fast	O
Acting	O
Insulin	O
Aspart	O
Compared	O
with	O
Insulin	O
Aspart	O
in	O
the	O
Medtronic	O
670G	O
Hybrid	O
Closed	O
Loop	O
System	O
in	O
Type	O
1	O
Diabetes	O
:	O
An	O
Open	B-Blinding_Open_Label
Label	I-Blinding_Open_Label
Crossover	B-Design_Crossover
Study	O

All	O
participants	B-Blinding_Object_Patients
,	O
study	B-Blinding_Object_Others
monitors	I-Blinding_Object_Others
,	O
study	B-Blinding_Object_Care_Providers
center	I-Blinding_Object_Care_Providers
personnel	I-Blinding_Object_Care_Providers
and	O
contract	B-Blinding_Object_Others
research	I-Blinding_Object_Others
organization	I-Blinding_Object_Others
personnel	I-Blinding_Object_Others
were	O
blinded	O
to	O
treatment	O
assignment	O
.	O

Fieldworkers	O
allocated	O
children	O
to	O
randomisation	O
groups	O
during	O
recruitment	O
and	O
gave	O
vitamin	B-Design_Parallel_Group
D	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
.	O

Following	O
a	O
prespecified	O
blinded	O
sample	O
size	O
reestimation	O
(	O
based	O
on	O
an	O
overall	O
SD=8.8	O
mm	O
Hg	O
observed	O
in	O
the	O
first	O
119	O
patients	O
)	O
,	O
the	O
size	O
of	O
the	O
per-protocol	O
set	O
was	O
reduced	O
to	O
66	B-Sample_Size_Required
patients	I-Sample_Size_Required
per	I-Sample_Size_Required
group	I-Sample_Size_Required
.	O

The	O
sample	O
size	O
was	O
selected	O
to	O
provide	O
a	O
minimum	O
of	O
90	O
%	O
power	O
for	O
the	O
superiority	B-Design_Comparative_Intent_Superiority
hypotheses	O
(	O
intravitreal	O
triamcinolone	O
injection	O
and	O
dexamethasone	O
implant	O
superior	O
to	O
periocular	O
injection	O
)	O
and	O
80	O
%	O
power	O
for	O
the	O
non-inferiority	O
hypothesis	O
(	O
intravitreal	O
dexamethasone	O
implant	O
non-inferior	O
to	O
intravitreal	O
triamcinolone	O
injection	O
)	O
.	O

Consecutive	O
patients	O
were	O
screened	O
for	O
eligibility	O
at	O
all	O
the	O
25	B-Settings_Multicenter
Italian	B-Settings_Location
ALS	I-Settings_Multicenter
centres	I-Settings_Multicenter
.	O

RESULTS	O
Patients	O
A	O
total	O
of	O
2560	O
patients	O
were	O
screened	O
,	O
of	O
whom	O
1538	B-Sample_Size_Actual_at_Enrollment
were	O
randomized	O
2:1	O
to	O
IIM	O
(	O
n	O
=	O
1027	O
)	O
or	O
IS	O
(	O
n	O
=	O
511	O
)	O
.	O

A	O
total	O
of	O
305	B-Sample_Size_Actual_at_Outcome_Analysis
patients	O
completed	O
treatment	O
(	O
placebo	O
,	O
n	O
=	O
124	O
;	O
AMG	O
301	O
210	O
mg	O
,	O
n	O
=	O
94	O
;	O
AMG	O
301	O
420	O
mg	O
,	O
n	O
=	O
87	O
)	O
.	O

Assuming	O
a	O
standard	O
deviation	O
(	O
SD	O
)	O
of	O
1.0	O
%	O
,	O
a	O
sample	O
size	O
of	O
105	O
patients	O
from	O
mainland	O
China	O
per	O
group	O
(	O
315	O
in	O
total	O
)	O
provided	O
~95	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
difference	O
in	O
HbA1c	O
change	O
from	O
baseline	O
of	O
0.5	O
%	O
between	O
each	O
ertugliflozin	O
dose	O
and	O
placebo	O
(	O
and	O
~90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
for	O
detecting	O
this	O
difference	O
for	O
both	O
doses	O
vs.	O
placebo	O
)	O
using	O
a	O
two‐sided	O
0.05	B-Sample_Size_Calculation_Alpha_Value
alpha	O
level	O
test	O
.	O

Treatment	O
protocol	O
Subjects	O
were	O
randomised	O
in	O
a	O
1:1	B-Randomization_Ratio
ratio	O
to	O
receive	O
once	O
daily	O
oral	O
doses	O
of	O
either	O
filgotinib	B-Design_Parallel_Group
200	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
(	I-Design_Parallel_Group
plus	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
to	I-Design_Parallel_Group
match	I-Design_Parallel_Group
(	I-Design_Parallel_Group
PTM	I-Design_Parallel_Group
)	I-Design_Parallel_Group
lanraplenib	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
lanraplenib	I-Design_Parallel_Group
30	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
(	I-Design_Parallel_Group
plus	I-Design_Parallel_Group
PTM	I-Design_Parallel_Group
filgotinib	I-Design_Parallel_Group
)	I-Design_Parallel_Group
.	O

Participants	B-Blinding_Object_Patients
,	O
investigator	B-Blinding_Object_Investigators
site	I-Blinding_Object_Investigators
staff	I-Blinding_Object_Investigators
and	O
the	O
sponsor	B-Blinding_Object_Others
study	I-Blinding_Object_Others
team	I-Blinding_Object_Others
were	O
blinded	O
to	O
the	O
study	O
treatment	O
.	O

To	O
maintain	O
double-blinding	O
for	O
both	O
investigators	B-Blinding_Object_Investigators
and	O
participants	B-Blinding_Object_Patients
,	O
individuals	B-Randomization_Personnel
not	I-Randomization_Personnel
associated	I-Randomization_Personnel
with	I-Randomization_Personnel
study	I-Randomization_Personnel
conduct	I-Randomization_Personnel
created	O
the	O
randomization	O
sequence	O
and	O
allocation	O
containers	O
.	O

The	O
target	O
sample	O
size	O
of	O
1334	B-Sample_Size_Required
gave	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
at	O
p	B-Sample_Size_Calculation_Alpha_Value
<	I-Sample_Size_Calculation_Alpha_Value
0·05	I-Sample_Size_Calculation_Alpha_Value
to	O
detect	O
a	O
risk	O
ratio	O
(	O
RR	O
)	O
of	O
0·8	O
for	O
28-day	O
mortality	O
between	O
the	O
salbutamol	O
and	O
placebo	O
groups	O
with	O
a	O
3	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
loss	O
of	O
patients	O
for	O
the	O
primary	O
outcome	O
,	O
with	O
the	O
assumption	O
that	O
the	O
28-day	O
mortality	O
in	O
the	O
placebo	O
group	O
was	O
44	O
%	O
.	O

For	O
our	O
primary	O
outcome	O
we	O
assumed	O
a	O
standard	O
deviation	O
of	O
26-mm	O
on	O
the	O
100-mm	O
VAS	O
for	O
pain	O
,	O
as	O
reported	O
from	O
prior	O
abortion	O
pain	O
research	O
studies	O
,	O
and	O
a	O
type	O
I	O
error	O
rate	O
of	O
0.05	B-Sample_Size_Calculation_Alpha_Value
,	O
and	O
determined	O
the	O
number	O
of	O
participants	O
needed	O
to	O
achieve	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
15-mm	O
difference	O
in	O
pain	O
at	O
five	O
minutes	O
post-procedure	O
.	O

Noninferiority	B-Design_Comparative_Intent_NonInferiority
of	O
both	O
hemagglutination	O
inhibition	O
geometric	O
mean	O
titers	O
and	O
seroconversion	O
rates	O
was	O
demonstrated	O
for	O
all	O
4	O
vaccine	O
strains	O
for	O
the	O
full	O
dose	O
versus	O
the	O
half	O
dose	O
.	O

Declarations	O
CXCR2	O
antagonist	O
for	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
with	O
chronic	O
mucus	O
hypersecretion	O
:	O
a	O
phase	B-Design_Phase_2
2b	I-Design_Phase_2
trial	O

326	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
salbutamol	B-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
.	O

Participants	O
were	O
stratified	B-Randomization_Type_Stratified
according	O
to	O
baseline	B-Randomization_Stratified_Criteria
MGI	I-Randomization_Stratified_Criteria
score	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
low	I-Randomization_Stratified_Criteria
:	I-Randomization_Stratified_Criteria
≤	I-Randomization_Stratified_Criteria
2.00	I-Randomization_Stratified_Criteria
;	I-Randomization_Stratified_Criteria
high	I-Randomization_Stratified_Criteria
:	I-Randomization_Stratified_Criteria
>	I-Randomization_Stratified_Criteria
2.00	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
and	O
sex	B-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
female/male	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
.	O

RESULTS	O
Subject	O
Disposition	O
A	O
total	O
of	O
98	B-Sample_Size_Actual_at_Enrollment
subjects	O
were	O
randomized	O
into	O
the	O
study	O
and	O
were	O
included	O
in	O
the	O
intention-to-treat	O
population	O
(	O
QD	O
,	O
n	O
=	O
50	O
;	O
BID	O
,	O
n	O
=	O
48	O
)	O
.	O

High-sensitivity	O
C-reactive	O
protein	O
was	O
significantly	O
reduced	O
by	O
canakinumab	B-Design_Parallel_Group
compared	I-Design_Parallel_Group
with	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
at	O
3	O
months	O
(	O
geometric	O
mean	O
ratio	O
[	O
GMR	O
]	O
:	O
0.568	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
0.436	O
to	O
0.740	O
;	O
p	O
<	O
0.0001	O
)	O
and	O
12	O
months	O
(	O
GMR	O
:	O
0.56	O
;	O
95	O
%	O
CI	O
:	O
0.414	O
to	O
0.758	O
;	O
p	O
=	O
0.0002	O
)	O
.	O

Sample	O
size	O
and	O
statistical	O
analysis	O
It	O
was	O
calculated	O
that	O
there	O
is	O
at	O
least	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
treatment	O
difference	O
with	O
36	B-Sample_Size_Required
subjects	O
.	O

Results	O
Of	O
76	B-Sample_Size_Actual_at_Enrollment
participants	O
enrolled	O
(	O
mean	O
[	O
SD	O
]	O
age	O
,	O
78.5	O
[	O
8.5	O
]	O
years	O
;	O
age	O
range	O
,	O
56-94	O
years	O
;	O
41	O
women	O
[	O
58	O
%	O
]	O
;	O
69	O
white	O
[	O
97	O
%	O
]	O
)	O
,	O
16	O
(	O
21.0	O
%	O
)	O
were	O
randomized	O
to	O
ranibizumab	O
every	O
4	O
weeks	O
,	O
29	O
(	O
38.2	O
%	O
)	O
to	O
faricimab	O
every	O
12	O
weeks	O
,	O
and	O
31	O
(	O
40.8	O
%	O
)	O
to	O
faricimab	O
every	O
16	O
weeks	O
.	O

Based	O
upon	O
these	O
assumptions	O
,	O
a	O
sample	O
size	O
of	O
89	O
independent	O
eyes	O
per	O
treatment	O
group	O
provided	O
80	O
%	O
power	O
to	O
demonstrate	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
of	O
the	O
intravitreal	O
dexamethasone	O
implant	O
as	O
compared	O
to	O
intravitreal	O
triamcinolone	O
injection	O
with	O
a	O
one-sided	O
type	O
I	O
error	O
rate	O
of	O
0.01667	O
.	O

Research	O
Design	O
and	O
Methods	O
Trial	O
Design	O
In	O
this	O
phase	B-Design_Phase_3
3b	I-Design_Phase_3
,	O
multicenter	B-Settings_Multicenter
,	O
active-controlled	O
,	O
treat-to-target	O
,	O
randomized	B-Randomization_Type_Simple
,	O
parallel-group	B-Design_Parallel_Group
trial	O
(	O
ClinicalTrials.gov	O
:	O
NCT03268005	O
)	O
,	O
faster	O
aspart	O
was	O
compared	O
with	O
IAsp	O
,	O
both	O
in	O
combination	O
with	O
insulin	O
degludec	O
with	O
or	O
without	O
metformin	O
,	O
in	O
adults	O
with	O
type	O
2	O
diabetes	O
not	O
optimally	O
controlled	O
with	O
basal-bolus	O
treatment	O
(	O
Supplementary	O
Fig	O
.	O

Participants	O
received	O
both	O
usual	O
perioperative	O
pain	O
management	O
and	O
either	O
oral	B-Design_Parallel_Group
placebo	I-Design_Parallel_Group
or	I-Design_Parallel_Group
gabapentin	I-Design_Parallel_Group
600	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
one	O
to	O
two	O
hours	O
prior	O
to	O
uterine	O
aspiration	O
allocated	O
by	O
the	O
clinic	O
nurse	O
,	O
as	O
is	O
standard	O
practice	O
in	O
our	O
clinic	O
.	O

Tenapanor	O
Treatment	O
of	O
Patients	O
With	O
Constipation-Predominant	O
Irritable	O
Bowel	O
Syndrome	O
:	O
A	O
Phase	B-Design_Phase_2
2	I-Design_Phase_2
,	O
Randomized	O
,	O
Placebo-Controlled	O
Efficacy	O
and	O
Safety	O
Trial	O

Other	O
secondary	O
efficacy	O
analyses	O
involved	O
superiority	O
comparisons	O
of	O
secondary	O
endpoints	O
for	O
each	O
treatment	O
group	O
versus	O
placebo	O
MDI	O
and	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
comparisons	O
versus	O
open-label	B-Blinding_Open_Label
tiotropium	O
.	O

;	I-Design_Parallel_Group
dosed	I-Design_Parallel_Group
as	I-Design_Parallel_Group
the	I-Design_Parallel_Group
hydrochloride	I-Design_Parallel_Group
salt	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
b.i.d	I-Design_Parallel_Group
.	O

Randomization	O
was	O
implemented	O
by	O
Interactive	B-Randomization_Sequence_Generation_Method
Response	I-Randomization_Sequence_Generation_Method
Technology	I-Randomization_Sequence_Generation_Method
and	O
performed	O
using	O
a	O
central	B-Randomization_Sequence_Generation_Method
randomization	I-Randomization_Sequence_Generation_Method
list	I-Randomization_Sequence_Generation_Method
,	O
unstratified	O
and	O
with	O
a	O
block	B-Randomization_Type_Block
size	I-Randomization_Type_Block
of	O
6	B-Randomization_Block_Size
,	O
generated	O
and	O
kept	O
by	O
a	O
group	B-Randomization_Personnel
external	I-Randomization_Personnel
to	I-Randomization_Personnel
the	I-Randomization_Personnel
study	I-Randomization_Personnel
sponsor	I-Randomization_Personnel
.	O

A	O
total	O
of	O
430	B-Sample_Size_Actual_at_Outcome_Analysis
patients	O
completed	O
the	O
8-week	O
treatment	O
period	O
.	O

In	O
total	O
,	O
169	B-Sample_Size_Actual_at_Outcome_Analysis
children	I-Sample_Size_Actual_at_Outcome_Analysis
(	O
96	O
%	O
)	O
completed	O
the	O
trial	O
(	O
Fig	O
.	O

A	O
single	B-Settings_Single_Center
center	I-Settings_Single_Center
parallel	B-Design_Parallel_Group
double-blind	B-Blinding_Double_Blind
randomized	O
clinical	O
trial	O
with	O
6	O
months	O
of	O
follow-up	O
was	O
performed	O
in	O
patients	O
with	O
persistent	O
IGT	O
after	O
12	O
months	O
of	O
treatment	O
with	O
metformin	O
and	O
lifestyle	O
;	O
patients	O
were	O
randomized	B-Randomization_Type_Simple
to	O
continue	O
with	O
metformin	O
850	O
mg	O
twice	O
daily	O
(	O
M	O
group	O
,	O
n	O
=	O
12	O
)	O
or	O
linagliptin/metformin	O
2.5/850	O
mg	O
twice	O
daily	O
(	O
LM	O
group	O
,	O
n	O
=	O
19	O
)	O
.	O

RESULTS	O
Study	O
Population	O
Of	O
the	O
1051	B-Sample_Size_Actual_at_Enrollment
participants	O
randomized	O
,	O
1044	O
participants	O
received	O
at	O
least	O
1	O
dose	O
of	O
study	O
vaccine	O
,	O
927	O
(	O
88.2	O
%	O
)	O
completed	O
the	O
4-dose	O
vaccine	O
regimen	O
and	O
921	B-Sample_Size_Actual_at_Outcome_Analysis
completed	O
the	O
final	O
study	O
visit	O
(	O
87.6	O
%	O
)	O
(	O
Figure	O
,	O
Supplemental	O
Digital	O
Content	O
2	O
,	O
http	O
:	O
//links.lww.com/INF/E54	O
)	O
.	O

After	O
a	O
screening	O
period	O
not	O
exceeding	O
30	O
days	O
and	O
after	O
eligibility	O
requirements	O
were	O
confirmed	O
on	O
day	O
1	O
(	O
baseline	O
)	O
,	O
screening	O
numbers	O
were	O
entered	O
into	O
an	O
interactive	B-Randomization_Sequence_Generation_Method
web	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
,	O
and	O
patients	O
were	O
randomized	B-Randomization_Type_Simple
2:3:3:3	B-Randomization_Ratio
to	O
matching	O
placebo	O
every	O
2	O
weeks	O
or	O
to	O
subcutaneous	O
injections	O
of	O
lebrikizumab	O
at	O
the	O
following	O
doses	O
:	O
125	O
mg	O
every	O
4	O
weeks	O
(	O
250-mg	O
loading	O
dose	O
[	O
LD	O
]	O
)	O
,	O
250	O
mg	O
every	O
4	O
weeks	O
(	O
500-mg	O
LD	O
)	O
,	O
or	O
250	O
mg	O
every	O
2	O
weeks	O
(	O
500-mg	O
LD	O
at	O
baseline	O
and	O
week	O
2	O
)	O
.	O

Materials	O
and	O
methods	O
Trial	O
design	O
This	O
was	O
a	O
randomised	O
,	O
controlled	O
,	O
assessor-blind	B-Blinding_Single_Blind
,	O
parallel	B-Design_Parallel_Group
groups	I-Design_Parallel_Group
,	O
multi-centre	B-Settings_Multicenter
,	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
trial	O
comparing	O
the	O
efficacy	O
and	O
safety	O
of	O
follitropin	O
delta	O
in	O
its	O
individualised	O
fixed-dose	O
regimen	O
with	O
follitropin	O
alfa	O
in	O
a	O
conventional	O
adjustable	O
dosing	O
regimen	O
in	O
Asian	O
women	O
undergoing	O
their	O
first	O
ovarian	O
stimulation	O
cycle	O
.	O

Masking	O
RhEPO	O
(	O
Eprex	O
)	O
was	O
purchased	O
from	O
Janssen-Cilag	O
SpA	O
(	O
Cologno	O
Monzese	O
,	O
Italy	O
)	O
by	O
the	O
coordinating	O
centre	O
and	O
directly	O
shipped	O
to	O
the	O
company	O
(	O
Pierrel	O
Research	O
IMP	O
srl	O
,	O
Cantù	O
,	O
Italy	O
)	O
in	O
charge	O
of	O
preparing	O
the	O
investigational	O
drug	O
(	O
rhEPO	O
or	O
1	O
cc	O
of	O
saline	O
)	O
in	O
syringes	O
of	O
identical	O
appearance	O
,	O
sealed	B-Allocation_Concealment_Method
in	I-Allocation_Concealment_Method
sequentially	I-Allocation_Concealment_Method
numbered	I-Allocation_Concealment_Method
identical	I-Allocation_Concealment_Method
containers	I-Allocation_Concealment_Method
according	O
to	O
the	O
allocation	O
sequence	O
.	O

Study	B-Blinding_Object_Patients
participants	I-Blinding_Object_Patients
,	O
investigators	B-Blinding_Object_Investigators
,	O
and	O
site	O
and	O
sponsor	B-Blinding_Object_Others
staff	I-Blinding_Object_Others
were	O
all	O
blinded	O
to	O
the	O
treatment	O
assignment	O
.	O

Of	O
the	O
31	B-Sample_Size_Actual_at_Enrollment
patients	O
enrolled	O
in	O
the	O
study	O
,	O
12	O
were	O
randomly	O
assigned	O
to	O
Metformin	O
group	O
(	O
7	O
with	O
isolated	O
IGT	O
and	O
5	O
with	O
combined	O
IFG	O
+	O
IGT	O
)	O
and	O
19	O
to	O
linagliptin	O
+	O
metformin	O
group	O
(	O
9	O
with	O
isolated	O
IGT	O
and	O
10	O
with	O
combined	O
IFG	O
+	O
IGT	O
)	O
;	O
however	O
,	O
2	O
patients	O
in	O
the	O
metformin	O
group	O
and	O
4	O
in	O
the	O
linagliptin	O
+	O
metformin	O
group	O
were	O
excluded	O
from	O
the	O
study	O
because	O
they	O
did	O
not	O
attend	O
their	O
follow-up	O
appointments	O
(	O
Fig	O
.	O

Results	O
:	O
Overall	O
,	O
356	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomized	O
(	O
mean	O
age	O
:	O
45.7	O
years	O
;	O
86.8	O
%	O
women	O
)	O
and	O
304	B-Sample_Size_Actual_at_Outcome_Analysis
completed	O
the	O
study	O
.	O

Twenty-nine	B-Settings_Multicenter
centers	I-Settings_Multicenter
in	O
5	O
countries	O
randomized	O
at	O
least	O
one	O
participant	O
:	O
8	O
centers	O
in	O
the	O
Russian	B-Settings_Location
Federation	I-Settings_Location
,	O
7	O
each	O
in	O
Spain	B-Settings_Location
and	O
the	O
United	B-Settings_Location
States	I-Settings_Location
,	O
4	O
in	O
Canada	B-Settings_Location
,	O
and	O
3	O
in	O
Germany	B-Settings_Location
.	O

Results	O
:	O
The	O
study	O
included	O
1950	B-Sample_Size_Actual_at_Enrollment
children	I-Sample_Size_Actual_at_Enrollment
.	O

Results	O
Of	O
193	B-Sample_Size_Actual_at_Enrollment
subjects	O
who	O
were	O
randomised	O
(	O
98	O
CT‐P17	O
AI	O
;	O
95	O
CT‐P17	O
PFS	O
)	O
,	O
180	B-Sample_Size_Actual_at_Outcome_Analysis
received	O
study	O
drug	O
.	O

For	O
the	O
1600	B-Sample_Size_Actual_at_Enrollment
participants	O
who	O
were	O
to	O
be	O
randomly	O
assigned	O
to	O
the	O
immunogenicity	O
subset	O
,	O
assuming	O
an	O
attrition	O
rate	O
of	O
20	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
,	O
a	O
1-sided	B-Sample_Size_Calculation_Alpha_Value
alpha	I-Sample_Size_Calculation_Alpha_Value
of	I-Sample_Size_Calculation_Alpha_Value
2.5	I-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
for	O
each	O
test	O
,	O
the	O
same	O
expected	O
GMTs	O
for	O
each	O
dose	O
group	O
,	O
a	O
standard	O
deviation	O
of	O
log	O
titers	O
against	O
each	O
strain	O
of	O
0.7	O
and	O
a	O
noninferiority	B-Design_Comparative_Intent_NonInferiority
margin	O
of	O
0.667	O
,	O
the	O
study	O
power	O
was	O
approximately	O
97.6	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
to	O
demonstrate	O
noninferiority	O
for	O
GMTs	O
.	O

Results	O
Patient	O
population	O
Of	O
211	O
patients	O
screened	O
,	O
103	B-Sample_Size_Actual_at_Enrollment
(	O
49	O
%	O
)	O
met	O
the	O
eligibility	O
criteria	O
and	O
were	O
randomized	O
to	O
the	O
placebo	O
group	O
(	O
n	O
=	O
20	O
)	O
or	O
one	O
of	O
the	O
four	O
daprodustat	O
cohorts	O
(	O
n	O
=	O
83	O
in	O
total	O
)	O
(	O
Fig	O
.	O

Methods	O
Patients	O
with	O
probable	O
laboratory-supported	O
,	O
probable	O
or	O
definite	O
ALS	O
were	O
enrolled	O
by	O
25	B-Settings_Multicenter
Italian	B-Settings_Location
centres	I-Settings_Multicenter
and	O
randomly	O
assigned	O
(	O
1:1	B-Randomization_Ratio
)	O
to	O
receive	O
intravenous	B-Design_Parallel_Group
rhEPO	I-Design_Parallel_Group
40	I-Design_Parallel_Group
000	I-Design_Parallel_Group
IU	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
fortnightly	O
as	O
add-on	O
treatment	O
to	O
riluzole	O
100	O
mg	O
daily	O
for	O
12	O
months	O
.	O

Patients	O
who	O
,	O
despite	O
scheduled	O
infusions	O
of	O
double-blind	O
study	O
medication	O
at	O
weeks	O
8	O
and	O
12	O
,	O
did	O
not	O
achieve	O
≥20	O
%	O
improvement	O
from	O
baseline	O
in	O
SJC	O
and	O
TJC	O
at	O
week	O
16	O
were	O
offered	O
escape	O
therapy	O
with	O
open-label	B-Blinding_Open_Label
TCZ	O
8	O
mg/kg	O
.	O

In	O
85	B-Sample_Size_Actual_at_Enrollment
of	O
the	O
87	O
patients	O
,	O
the	O
trial	O
infusion	O
was	O
administered	O
as	O
planned	O
.	O

Methods	O
:	O
This	O
study	O
was	O
conducted	O
in	O
a	O
12-week	O
,	O
double-blind	B-Blinding_Double_Blind
period	O
followed	O
by	O
an	O
open-label	B-Blinding_Open_Label
extension	O
designed	O
to	O
characterize	O
1	O
year	O
of	O
evolocumab	O
treatment	O
.	O

Eligible	O
patients	O
were	O
randomized	O
at	O
2:2:1:1	B-Randomization_Ratio
into	O
four	O
groups	O
:	O
420	O
mg	O
evolocumab	O
every	O
4	O
weeks	O
(	O
Q4W	O
)	O
+	O
oral	O
placebo	O
daily	O
,	O
140	O
mg	O
evolocumab	O
every	O
2	O
weeks	O
(	O
Q2W	O
)	O
+	O
oral	O
placebo	O
daily	O
,	O
subcutaneous	O
(	O
SC	O
)	O
placebo	O
Q4W	O
+	O
10	O
mg	O
ezetimibe	O
daily	O
,	O
and	O
SC	O
placebo	O
Q2W	O
+	O
10	O
mg	O
ezetimibe	O
daily	O
.	O

Randomisation	O
was	O
stratified	B-Randomization_Type_Stratified
by	O
centre	B-Randomization_Stratified_Criteria
,	O
disease	B-Randomization_Stratified_Criteria
severity	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
ALSFRS-R	I-Randomization_Stratified_Criteria
≤33	I-Randomization_Stratified_Criteria
vs	I-Randomization_Stratified_Criteria
>	I-Randomization_Stratified_Criteria
33	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
and	O
onset	B-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
spinal	I-Randomization_Stratified_Criteria
or	I-Randomization_Stratified_Criteria
bulbar	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
with	O
a	O
block	B-Randomization_Type_Block
size	O
of	O
four	B-Randomization_Block_Size
within	O
each	O
centre	O
.	O

Interventions	O
Trimethoprim-sulfamethoxazole	B-Design_Parallel_Group
320	I-Design_Parallel_Group
mg/1600	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
twice	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
versus	I-Design_Parallel_Group
vancomycin	I-Design_Parallel_Group
1	I-Design_Parallel_Group
g	I-Design_Parallel_Group
twice	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
for	O
a	O
minimum	O
of	O
seven	O
days	O
and	O
then	O
by	O
indication	O
.	O

Week	O
16	O
completion	O
rates	O
were	O
greater	O
for	O
lebrikizumab-treated	O
patients	O
vs	O
placebo-treated	O
patients	O
(	O
44.2	B-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
[	I-Sample_Size_Actual_at_Outcome_Analysis
23	I-Sample_Size_Actual_at_Outcome_Analysis
of	I-Sample_Size_Actual_at_Outcome_Analysis
52	I-Sample_Size_Actual_at_Outcome_Analysis
]	I-Sample_Size_Actual_at_Outcome_Analysis
for	I-Sample_Size_Actual_at_Outcome_Analysis
placebo	I-Sample_Size_Actual_at_Outcome_Analysis
and	I-Sample_Size_Actual_at_Outcome_Analysis
79.5	I-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
[	I-Sample_Size_Actual_at_Outcome_Analysis
58	I-Sample_Size_Actual_at_Outcome_Analysis
of	I-Sample_Size_Actual_at_Outcome_Analysis
73	I-Sample_Size_Actual_at_Outcome_Analysis
]	I-Sample_Size_Actual_at_Outcome_Analysis
,	I-Sample_Size_Actual_at_Outcome_Analysis
77.5	I-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
[	I-Sample_Size_Actual_at_Outcome_Analysis
62	I-Sample_Size_Actual_at_Outcome_Analysis
of	I-Sample_Size_Actual_at_Outcome_Analysis
80	I-Sample_Size_Actual_at_Outcome_Analysis
]	I-Sample_Size_Actual_at_Outcome_Analysis
,	I-Sample_Size_Actual_at_Outcome_Analysis
and	I-Sample_Size_Actual_at_Outcome_Analysis
77.3	I-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
[	I-Sample_Size_Actual_at_Outcome_Analysis
58	I-Sample_Size_Actual_at_Outcome_Analysis
of	I-Sample_Size_Actual_at_Outcome_Analysis
75	I-Sample_Size_Actual_at_Outcome_Analysis
]	I-Sample_Size_Actual_at_Outcome_Analysis
for	I-Sample_Size_Actual_at_Outcome_Analysis
125	I-Sample_Size_Actual_at_Outcome_Analysis
mg	I-Sample_Size_Actual_at_Outcome_Analysis
of	I-Sample_Size_Actual_at_Outcome_Analysis
lebrikizumab	I-Sample_Size_Actual_at_Outcome_Analysis
every	I-Sample_Size_Actual_at_Outcome_Analysis
4	I-Sample_Size_Actual_at_Outcome_Analysis
weeks	I-Sample_Size_Actual_at_Outcome_Analysis
,	I-Sample_Size_Actual_at_Outcome_Analysis
250	I-Sample_Size_Actual_at_Outcome_Analysis
mg	I-Sample_Size_Actual_at_Outcome_Analysis
every	I-Sample_Size_Actual_at_Outcome_Analysis
4	I-Sample_Size_Actual_at_Outcome_Analysis
weeks	I-Sample_Size_Actual_at_Outcome_Analysis
,	I-Sample_Size_Actual_at_Outcome_Analysis
and	I-Sample_Size_Actual_at_Outcome_Analysis
250	I-Sample_Size_Actual_at_Outcome_Analysis
mg	I-Sample_Size_Actual_at_Outcome_Analysis
every	I-Sample_Size_Actual_at_Outcome_Analysis
2	I-Sample_Size_Actual_at_Outcome_Analysis
weeks	I-Sample_Size_Actual_at_Outcome_Analysis
[	O
hereinafter	O
,	O
the	O
3	O
lebrikizumab	O
groups	O
,	O
respectively	O
]	O
)	O
.	O

Overall	O
,	O
94.8	O
%	O
of	O
subjects	O
completed	O
the	O
visit	O
occurring	O
1	O
month	O
after	O
vaccination	O
2	O
,	O
95.3	O
%	O
completed	O
the	O
6-month	O
telephone	O
visit	O
,	O
and	O
91.0	B-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
completed	O
the	O
study	O
.	O

Results	O
Characteristics	O
at	O
Enrollment	O
:	O
Between	O
June	O
2015	O
and	O
July	O
2017	O
,	O
192	B-Sample_Size_Actual_at_Enrollment
patients	O
(	O
235	O
eyes	O
with	O
uveitic	O
macular	O
edema	O
)	O
were	O
enrolled	O
.	O

Methods	O
Trial	O
design	O
Study	O
207626	O
(	O
NCT03474081	O
)	O
was	O
a	O
12-week	O
,	O
Phase	B-Design_Phase_4
IV	I-Design_Phase_4
,	O
parallel-group	B-Design_Parallel_Group
,	O
active-controlled	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
double-dummy	O
,	O
randomized	O
,	O
multicenter	B-Settings_Multicenter
study	O
comparing	O
once-daily	O
single-inhaler	O
FF/UMEC/VI	O
with	O
TIO	O
monotherapy	O
in	O
patients	O
with	O
symptomatic	O
COPD	O
and	O
moderate-to-very-severe	O
airflow	O
limitation	O
.	O

A	O
total	O
of	O
1,062	O
participants	O
(	O
97.3	O
%	O
)	O
completed	O
the	O
trial	O
,	O
while	O
1,053	B-Sample_Size_Actual_at_Outcome_Analysis
participants	O
(	O
96.5	O
%	O
)	O
completed	O
the	O
16-week	O
treatment	O
period	O
without	O
premature	O
discontinuation	O
of	O
randomized	O
treatment	O
(	O
Supplementary	O
Fig	O
.	O

Interventions	O
Women	O
in	O
the	O
first	O
comparison	O
were	O
randomised	O
to	O
ursodeoxycholic	B-Design_Parallel_Group
acid	I-Design_Parallel_Group
(	I-Design_Parallel_Group
250	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
;	I-Design_Parallel_Group
Ursofalk	I-Design_Parallel_Group
,	I-Design_Parallel_Group
Dr	I-Design_Parallel_Group
Falk	I-Design_Parallel_Group
Pharma	I-Design_Parallel_Group
,	I-Design_Parallel_Group
Buckinghamshire	I-Design_Parallel_Group
)	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
to	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
capsules	I-Design_Parallel_Group
(	O
Dr	O
Falk	O
Pharma	O
)	O
identical	O
in	O
appearance	O
and	O
taste	O
to	O
the	O
study	O
drug	O
(	O
white	O
,	O
opaque	O
,	O
hard	O
gelatin	O
capsule	O
)	O
.	O

The	O
trial	O
enrolled	O
participants	O
at	O
19	B-Settings_Multicenter
clinic	I-Settings_Multicenter
and	I-Settings_Multicenter
hospital	I-Settings_Multicenter
sites	I-Settings_Multicenter
in	O
Brazil	B-Settings_Location
(	I-Settings_Location
7	I-Settings_Location
)	I-Settings_Location
,	I-Settings_Location
Tanzania	I-Settings_Location
(	I-Settings_Location
1	I-Settings_Location
)	I-Settings_Location
,	I-Settings_Location
South	I-Settings_Location
Africa	I-Settings_Location
(	I-Settings_Location
1	I-Settings_Location
)	I-Settings_Location
,	I-Settings_Location
Thailand	I-Settings_Location
(	I-Settings_Location
3	I-Settings_Location
)	I-Settings_Location
,	I-Settings_Location
Argentina	I-Settings_Location
(	I-Settings_Location
2	I-Settings_Location
)	I-Settings_Location
,	I-Settings_Location
and	I-Settings_Location
the	I-Settings_Location
US	I-Settings_Location
(	I-Settings_Location
5	I-Settings_Location
)	I-Settings_Location
.	O

Non-inferiority	B-Design_Comparative_Intent_NonInferiority
was	O
declared	O
if	O
the	O
upper	O
bound	O
of	O
the	O
two-sided	O
95	O
%	O
CI	O
for	O
the	O
difference	O
in	O
change	O
from	O
baseline	O
in	O
DAS28-4	O
(	O
CRP	O
)	O
at	O
week	O
12	O
was	O
<	O
0.6	O
.	O

Results	O
Patient	O
Disposition	O
A	O
total	O
of	O
61	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomized	O
(	O
evolocumab	O
,	O
n	O
=	O
40	O
;	O
ezetimibe	O
,	O
n	O
=	O
21	O
)	O
(	O
Fig	O
.	O

Noninferiority	B-Design_Comparative_Intent_NonInferiority
with	O
respect	O
to	O
fever	O
was	O
considered	O
demonstrated	O
if	O
the	O
upper	O
bound	O
of	O
the	O
2-sided	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
of	O
the	O
fever	O
rate	O
difference	O
between	O
participants	O
receiving	O
full-dose	O
vaccine	O
and	O
participants	O
receiving	O
half-dose	O
vaccine	O
was	O
<	O
5	O
%	O
.	O

Patients	B-Blinding_Object_Patients
,	O
neurologists	B-Blinding_Object_Care_Providers
,	O
laboratory	B-Blinding_Object_Others
biologists/technicians	I-Blinding_Object_Others
(	O
two	O
at	O
each	O
centre	O
)	O
and	O
a	O
statistician	B-Blinding_Object_Others
were	O
masked	O
to	O
treatment	O
allocation	O
and	O
did	O
not	O
have	O
access	O
to	O
any	O
data	O
related	O
to	O
rhEPO	O
haematopoietic	O
activity	O
.	O

Patients	B-Blinding_Object_Patients
were	O
blinded	O
to	O
the	O
study	O
drugs	O
.	O

RESULTS	O
Study	O
Population	O
Among	O
444	B-Sample_Size_Actual_at_Enrollment
subjects	O
randomized	O
(	O
n	O
=	O
222	O
,	O
PCV20/saline	O
;	O
n	O
=	O
222	O
,	O
PCV13/PPSV23	O
)	O
,	O
443	O
received	O
vaccination	O
1	O
and	O
427	O
received	O
vaccination	O
2	O
(	O
Figure	O
2	O
)	O
.	O

Of	O
the	O
176	B-Sample_Size_Actual_at_Enrollment
children	I-Sample_Size_Actual_at_Enrollment
enrolled	O
,	O
117	O
(	O
66.5	O
%	O
)	O
and	O
59	O
(	O
33.5	O
%	O
)	O
patients	O
were	O
randomized	O
into	O
the	O
baloxavir	O
and	O
oseltamivir	O
groups	O
,	O
respectively	O
.	O

Eligible	O
patients	O
were	O
then	O
randomly	O
assigned	O
to	O
placebo	B-Design_Parallel_Group
,	I-Design_Parallel_Group
aprocitentan	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
lisinopril	I-Design_Parallel_Group
treatment	I-Design_Parallel_Group
groups	I-Design_Parallel_Group
.	O

Power	O
and	O
statistical	O
methods	O
With	O
1000	O
patients	O
treated	O
with	O
IIM	O
and	O
500	O
patients	O
treated	O
with	O
IS	O
,	O
there	O
was	O
100	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
demonstrate	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
of	O
IIM	O
versus	O
IS	O
in	O
the	O
co-primary	O
efficacy	O
endpoint	O
,	O
change	O
in	O
Hb	O
from	O
baseline	O
to	O
Week	O
8	O
,	O
using	O
a	O
non-inferiority	O
margin	O
of	O
–0.5	O
g/dL	O
and	O
assuming	O
a	O
common	O
SD	O
of	O
1.5	O
g/dL	O
in	O
Hb	O
.	O

Statistical	O
methods	O
A	O
computer-generated	B-Randomization_Sequence_Generation_Method
randomization	O
scheme	O
was	O
made	O
available	O
to	O
all	O
clinical	O
centers	O
participating	O
in	O
the	O
study	O
via	O
an	B-Randomization_Sequence_Generation_Method
interactive	I-Randomization_Sequence_Generation_Method
web	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
.	O

Patient	O
randomisation	O
was	O
stratified	B-Randomization_Type_Stratified
by	O
centre	B-Randomization_Stratified_Criteria
using	O
a	O
block	B-Randomization_Type_Block
size	O
of	O
four	B-Randomization_Block_Size
for	I-Randomization_Block_Size
the	I-Randomization_Block_Size
first	I-Randomization_Block_Size
two	I-Randomization_Block_Size
blocks	I-Randomization_Block_Size
and	I-Randomization_Block_Size
eight	I-Randomization_Block_Size
thereafter	I-Randomization_Block_Size
.	O

At	O
the	O
start	O
of	O
the	O
double-blind	B-Blinding_Double_Blind
phase	O
(	O
week	O
0	O
)	O
,	O
patients	O
in	O
both	O
groups	O
received	O
an	O
injection	O
of	O
240	O
U	O
in	O
6	O
forearm	O
muscles	O
(	O
flexor	O
carpi	O
radialis	O
,	O
flexor	O
carpi	O
ulnaris	O
,	O
flexor	O
digitorum	O
profundus	O
,	O
flexor	O
digitorum	O
superficialis	O
,	O
flexor	O
pollicis	O
longus	O
,	O
and	O
adductor	O
pollicis	O
)	O
.	O

Key	O
Points	O
Question	O
How	O
does	O
extended	O
dosing	O
with	O
faricimab	O
compare	O
with	O
monthly	O
ranibizumab	O
in	O
treating	O
patients	O
with	O
neovascular	O
age-related	O
macular	O
degeneration	O
?	O
Findings	O
In	O
this	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
randomized	O
clinical	O
trial	O
of	O
faricimab	O
in	O
76	B-Sample_Size_Actual_at_Enrollment
patients	O
,	O
vision	O
gains	O
from	O
baseline	O
were	O
+9.6	O
,	O
+10.1	O
,	O
and	O
+11.4	O
letters	O
for	O
the	O
monthly	O
ranibizumab	O
,	O
faricimab	O
every-12-weeks	O
,	O
and	O
faricimab	O
every-16-weeks	O
arms	O
,	O
respectively	O
,	O
at	O
week	O
52	O
.	O

Design	O
,	O
Setting	O
,	O
and	O
Participants	O
A	O
phase	B-Design_Phase_2
2b	I-Design_Phase_2
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
,	O
dose-ranging	O
randomized	O
clinical	O
trial	O
of	O
lebrikizumab	O
injections	O
every	O
4	O
weeks	O
or	O
every	O
2	O
weeks	O
was	O
conducted	O
from	O
January	O
23	O
,	O
2018	O
,	O
to	O
May	O
23	O
,	O
2019	O
,	O
at	O
57	B-Settings_Multicenter
US	B-Settings_Location
centers	I-Settings_Multicenter
.	O

Randomization	O
was	O
stratified	B-Randomization_Type_Stratified
according	O
to	O
TrialNet	B-Randomization_Stratified_Criteria
site	I-Randomization_Stratified_Criteria
,	O
age	B-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
18	I-Randomization_Stratified_Criteria
years	I-Randomization_Stratified_Criteria
or	I-Randomization_Stratified_Criteria
≥18	I-Randomization_Stratified_Criteria
years	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
and	O
second	B-Randomization_Stratified_Criteria
oral	I-Randomization_Stratified_Criteria
glucose-tolerance	I-Randomization_Stratified_Criteria
test	I-Randomization_Stratified_Criteria
result	I-Randomization_Stratified_Criteria
before	I-Randomization_Stratified_Criteria
treatment	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
impaired	I-Randomization_Stratified_Criteria
tolerance	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
normal	I-Randomization_Stratified_Criteria
tolerance	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
or	I-Randomization_Stratified_Criteria
diabetes	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
.	O

Assuming	O
a	O
dropout	O
rate	O
of	O
20	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
at	O
week	O
26	O
(	O
i.e	O
.	O

Results	O
Participants	O
In	O
total	O
,	O
18	B-Sample_Size_Actual_at_Enrollment
eligible	O
participants	O
were	O
assigned	O
to	O
the	O
study	O
treatment	O
,	O
and	O
17	B-Sample_Size_Actual_at_Outcome_Analysis
(	O
94.4	O
%	O
)	O
completed	O
the	O
double‐blind	O
treatment	O
and	O
follow‐up	O
period	O
(	O
Fig	O
.	O

A	O
phase	B-Design_Phase_1
I	I-Design_Phase_1
,	O
randomized	O
,	O
double‐blind	B-Blinding_Double_Blind
study	O
to	O
assess	O
the	O
safety	O
,	O
tolerability	O
and	O
efficacy	O
of	O
the	O
topical	O
RORC2	O
inverse	O
agonist	O
PF‐06763809	O
in	O
participants	O
with	O
mild‐to‐moderate	O
plaque	O
psoriasis	O

Methods	O
Phase	B-Design_Phase_3
III	I-Design_Phase_3
,	O
randomized	B-Randomization_Type_Simple
,	O
double-blind	B-Blinding_Double_Blind
,	O
double-dummy	O
,	O
12-week	O
study	O
.	O

Interactive	B-Randomization_Sequence_Generation_Method
web	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
technology	I-Randomization_Sequence_Generation_Method
automatically	O
assigned	O
a	O
treatment	O
to	O
each	O
individual	O
.	O

A	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
margin	O
of	O
0.6	O
for	O
the	O
treatment	O
difference	O
of	O
tofacitinib	O
MR	O
11	O
mg	O
QD	O
vs	O
IR	O
5	O
mg	O
BID	O
was	O
requested	O
by	O
the	O
Japanese	O
Pharmaceuticals	O
and	O
Medical	O
Devices	O
Agency	O
.	O

Patients	O
with	O
PsA	O
along	O
with	O
active	O
dactylitis	O
and	O
naive	O
to	O
MTX	O
and	O
biologic	O
disease-modifying	O
antirheumatic	O
drugs	O
(	O
bDMARDs	O
)	O
were	O
randomly	O
assigned	O
to	O
golimumab	B-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
,	O
both	O
in	O
combination	O
with	O
MTX	O
.	O

In	O
the	O
double-blind	B-Blinding_Double_Blind
phase	O
,	O
the	O
regimen	O
and	O
frequency/intensity	O
of	O
concurrent	O
rehabilitation	O
therapy	O
were	O
not	O
to	O
be	O
changed	O
.	O

Safety	O
,	O
tolerability	O
and	O
antiviral	O
activity	O
of	O
the	O
antisense	O
oligonucleotide	O
bepirovirsen	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
:	O
a	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
randomized	O
controlled	O
trial	O

Assuming	O
a	O
maximum	O
difference	O
versus	O
placebo	O
of	O
5	O
mm	O
Hg	O
and	O
an	O
SD	O
of	O
9	O
mm	O
Hg	O
for	O
the	O
change	O
from	O
baseline	O
in	O
SiDBP	O
,	O
we	O
calculated	O
that	O
70	O
patients	O
per	O
group	O
would	O
provide	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
dose-response	O
with	O
MCP-Modeling	O
in	O
the	O
per-protocol	O
set	O
(	O
420	O
patients	O
)	O
.	O

The	O
study	O
was	O
conducted	O
between	O
September	O
2016	O
and	O
March	O
2017	O
at	O
38	B-Settings_Multicenter
sites	I-Settings_Multicenter
in	O
the	O
United	B-Settings_Location
States	I-Settings_Location
(	O
ClinicalTrials.gov	O
no	O
.	O

Assuming	O
a	O
total	O
planned	O
enrollment	O
sample	O
size	O
of	O
approximately	O
2190	B-Sample_Size_Target
(	O
1095	O
per	O
group	O
)	O
,	O
an	O
attrition	O
rate	O
of	O
5	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
,	O
a	O
1-sided	B-Sample_Size_Calculation_Alpha_Value
alpha	I-Sample_Size_Calculation_Alpha_Value
of	I-Sample_Size_Calculation_Alpha_Value
2.5	I-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
,	O
an	O
expected	O
14.3	O
%	O
rate	O
of	O
fever	O
,	O
and	O
a	O
noninferiority	O
margin	O
of	O
5	O
%	O
,	O
the	O
study	O
was	O
powered	O
at	O
approximately	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
to	O
demonstrate	O
noninferiority	B-Design_Comparative_Intent_NonInferiority
for	O
fever	O
.	O

The	O
investigators	B-Blinding_Object_Investigators
and	O
sponsor	B-Blinding_Object_Others
were	O
blinded	O
to	O
the	O
lymphocyte	O
count	O
results	O
and	O
first-dose	O
effects	O
of	O
ponesimod	O
,	O
unless	O
alerted	O
for	O
safety	O
reasons	O
.	O

Randomization	O
and	O
Masking	O
Subjects	O
were	O
randomly	O
assigned	O
(	O
1:1	B-Randomization_Ratio
ratio	O
)	O
by	O
Interactive	B-Randomization_Sequence_Generation_Method
Web	I-Randomization_Sequence_Generation_Method
Response	I-Randomization_Sequence_Generation_Method
System	I-Randomization_Sequence_Generation_Method
(	I-Randomization_Sequence_Generation_Method
IWRS	I-Randomization_Sequence_Generation_Method
)	I-Randomization_Sequence_Generation_Method
to	O
receive	O
MB02	O
or	O
EU-bevacizumab	O
according	O
to	O
a	O
pre-specified	O
blocked	B-Randomization_Type_Block
randomization	O
scheme	O
.	O

Randomization	O
was	O
stratified	B-Randomization_Type_Stratified
by	O
“	B-Randomization_Stratified_Criteria
Mainland	I-Randomization_Stratified_Criteria
China	I-Randomization_Stratified_Criteria
”	I-Randomization_Stratified_Criteria
and	I-Randomization_Stratified_Criteria
“	I-Randomization_Stratified_Criteria
Other	I-Randomization_Stratified_Criteria
”	I-Randomization_Stratified_Criteria
.	O

Overall	O
,	O
175	B-Sample_Size_Actual_at_Outcome_Analysis
(	O
90.7	O
%	O
)	O
subjects	O
completed	O
the	O
study	O
.	O

Methods	O
:	O
In	O
this	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
,	O
double-blind	B-Blinding_Double_Blind
study	O
,	O
patients	O
with	O
IBS-C	O
(	O
Rome	O
III	O
criteria	O
)	O
were	O
randomized	O
(	O
1:1:1:1	B-Randomization_Ratio
)	O
to	O
receive	O
tenapanor	B-Design_Parallel_Group
5	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
,	I-Design_Parallel_Group
20	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
50	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
b.i.d.	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
b.i.d	I-Design_Parallel_Group
.	I-Design_Parallel_Group

Randomization	O
and	O
Masking	O
Permuted-block	B-Randomization_Type_Block
randomization	O
was	O
used	O
to	O
randomize	O
eligible	O
subjects	O
1:1	B-Randomization_Ratio
(	O
by	O
Interactive	B-Randomization_Sequence_Generation_Method
Response	I-Randomization_Sequence_Generation_Method
Technology	I-Randomization_Sequence_Generation_Method
)	O
to	O
receive	O
omidenepag	O
isopropyl	O
0.002	O
%	O
either	O
QD	O
(	O
vehicle	O
at	O
8:00	O
am	O
and	O
omidenepag	O
isopropyl	O
at	O
8:00	O
pm	O
±60	O
min	O
)	O
,	O
or	O
BID	O
(	O
8:00	O
am	O
and	O
8:00	O
pm	O
±60	O
min	O
)	O
,	O
1	O
drop/eye	O
for	O
6	O
weeks	O
.	O

If	O
these	O
findings	O
replicate	O
in	O
phase	B-Design_Phase_3
3	I-Design_Phase_3
studies	O
,	O
lebrikizumab	O
may	O
meaningfully	O
advance	O
the	O
standard	O
of	O
care	O
for	O
moderate	O
to	O
severe	O
AD	O
.	O

Methods	O
This	O
was	O
a	O
randomized	O
,	O
double‐blind	B-Blinding_Double_Blind
,	O
first‐in‐human	O
study	O
(	O
trial	O
registration	O
:	O
ClinicalTrials.gov	O
NCT03469336	O
)	O
.	O

To	O
reduce	O
the	O
risk	O
of	O
a	O
perioperative	O
allogeneic	O
transfusion	O
event	O
from	O
30	O
%	O
to	O
15	O
%	O
(	O
a	O
50	O
%	O
risk	O
reduction	O
)	O
with	O
a	O
power	O
of	O
β	O
=	O
0.8	B-Sample_Size_Calculation_Power_Value
and	O
a	O
significance	O
level	O
of	O
α	O
=	O
0.05	B-Sample_Size_Calculation_Alpha_Value
,	O
it	O
was	O
determined	O
that	O
a	O
total	O
of	O
121	B-Sample_Size_Required
patients	I-Sample_Size_Required
in	I-Sample_Size_Required
each	I-Sample_Size_Required
group	I-Sample_Size_Required
would	O
be	O
needed	O
.	O

RESULTS	O
A	O
total	O
of	O
76	B-Sample_Size_Actual_at_Enrollment
participants	O
(	O
55	O
[	O
72	O
%	O
]	O
of	O
whom	O
were	O
≤18	O
years	O
of	O
age	O
)	O
underwent	O
randomization	O
—	O
44	O
to	O
the	O
teplizumab	O
group	O
and	O
32	O
to	O
the	O
placebo	O
group	O
.	O

The	O
underlying	O
assumption	O
for	O
the	O
sample	O
size	O
calculation	O
was	O
a	O
50	O
%	O
decrease	O
in	O
the	O
mean	O
cumulative	O
number	O
of	O
new	O
Gd+	O
lesions	O
from	O
weeks	O
12	O
to	O
24	O
in	O
at	O
least	O
one	O
ponesimod	O
treatment	O
group	O
compared	O
with	O
placebo	O
and	O
assuming	O
a	O
mean	O
of	O
eight	O
lesions	O
under	O
placebo	O
;	O
the	O
anticipated	O
sample	O
size	O
of	O
90	B-Sample_Size_Required
evaluable	I-Sample_Size_Required
patients	I-Sample_Size_Required
per	I-Sample_Size_Required
group	I-Sample_Size_Required
had	O
a	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
significant	O
difference	O
between	O
ponesimod	O
groups	O
and	O
placebo	O
.	O

The	O
Neuroepidemiology	O
Unit	O
at	O
the	O
coordinating	O
centre	O
,	O
independent	O
of	O
the	O
study	O
,	O
generated	O
the	O
computer-based	B-Randomization_Sequence_Generation_Method
randomisation	I-Randomization_Sequence_Generation_Method
sequence	I-Randomization_Sequence_Generation_Method
known	O
only	O
to	O
two	O
staff	O
persons	O
and	O
the	O
drug	O
dispenser	O
.	O

Results	O
Of	O
450	O
patients	O
screened	O
,	O
189	B-Sample_Size_Actual_at_Enrollment
were	O
randomized	O
to	O
receive	O
either	O
placebo	O
(	O
n	O
=	O
94	O
)	O
or	O
canakinumab	O
150	O
mg	O
(	O
n	O
=	O
95	O
)	O
.	O

Sample	O
size	O
was	O
calculated	O
assuming	O
this	O
equivalence	O
margin	O
of	O
±15	O
%	O
,	O
an	O
effect	O
size	O
of	O
57	O
%	O
and	O
a	O
20	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
dropout	O
rate	O
.	O

Background	O
This	O
examiner-blind	B-Blinding_Single_Blind
,	O
stratified	B-Randomization_Stratified_Criteria
,	O
parallel	B-Design_Parallel_Group
study	O
aimed	O
to	O
evaluate	O
the	O
anti-gingivitis	O
efficacy	O
of	O
a	O
non-aqueous	O
(	O
anhydrous	O
)	O
0.454	O
%	O
w/w	O
stannous	O
fluoride	O
toothpaste	O
(	O
‘	O
Test	O
’	O
)	O
versus	O
a	O
sodium	O
monofluorophosphate	O
toothpaste	O
(	O
‘	O
Control	O
’	O
)	O
in	O
people	O
with	O
clinically-confirmed	O
mild-moderate	O
gingivitis	O
.	O

After	O
8	O
weeks	O
of	O
double-blind	B-Blinding_Double_Blind
treatment	O
,	O
all	O
patients	O
entered	O
a	O
2-week	O
single-blind	O
,	O
placebo	O
withdrawal	O
period	O
.	O

either	O
patients	O
who	O
discontinued	O
from	O
the	O
study	O
,	O
discontinued	O
study	O
medication	O
or	O
took	O
rescue	O
medication	O
and	O
were	O
censored	O
)	O
,	O
~396	B-Sample_Size_Required
patients	O
from	O
mainland	O
China	O
(	O
132	O
per	O
group	O
)	O
were	O
to	O
be	O
randomized	O
.	O

Results	O
584	B-Sample_Size_Actual_at_Enrollment
subjects	O
were	O
randomised	O
into	O
SB2	O
(	O
N=291	O
;	O
290	O
analysed	O
)	O
or	O
INF	O
(	O
N=293	O
)	O
.	O

Methods	O
:	O
Healthy	O
infants	O
6–12	O
weeks	O
old	O
were	O
randomized	B-Randomization_Type_Simple
to	O
receive	O
a	O
4-dose	O
regimen	O
of	O
V114	O
Lot	O
1	O
,	O
V114	O
Lot	O
2	O
or	O
PCV13	O
at	O
2	O
,	O
4	O
,	O
6	O
and	O
12–15	O
months	O
old	O
.	O

Randomised	O
,	O
phase	B-Design_Phase_1
I	I-Design_Phase_1
pharmacokinetic	O
study	O
of	O
adalimumab	O
biosimilar	O
CT‐P17	O
(	O
40	O
mg/0.4	O
mL	O
)	O
by	O
autoinjector	O
and	O
prefilled	O
syringe	O
in	O
healthy	O
subjects	O

After	O
randomisation	O
,	O
no	B-Blinding_Open_Label
blinding	I-Blinding_Open_Label
was	O
performed	O
,	O
but	O
outcomes	O
were	O
adjudicated	O
blinded	O
to	O
allocation	O
.	O

METHODS	O
Study	O
Design	O
This	O
randomized	B-Randomization_Type_Simple
,	O
multisite	B-Settings_Multicenter
,	O
double-blind	B-Blinding_Double_Blind
phase	B-Design_Phase_2
2	I-Design_Phase_2
study	O
compared	O
the	O
safety	O
,	O
tolerability	O
and	O
immunogenicity	O
profiles	O
of	O
2	O
different	O
lots	O
of	O
V114	O
compared	O
with	O
PCV13	O
in	O
healthy	O
infants	O
6–12	O
weeks	O
of	O
age	O
.	O

Methods	O
Patients	O
This	O
Food	O
and	O
Drug	O
Administration—approved	O
phase	B-Design_Phase_2
II	I-Design_Phase_2
,	O
multicentre	B-Settings_Multicenter
,	O
randomised	O
,	O
double-blind	B-Blinding_Double_Blind
trial	O
was	O
conducted	O
from	O
September	O
2017	O
through	O
February	O
2020	O
at	O
15	B-Settings_Multicenter
centres	I-Settings_Multicenter
in	O
the	O
USA	B-Settings_Location
.	O

Study	O
design	O
and	O
procedures	O
This	O
was	O
a	O
prospective	O
,	O
multicentre	B-Settings_Multicenter
and	O
multinational	O
(	O
94	B-Settings_Multicenter
centres	I-Settings_Multicenter
in	O
23	B-Settings_Location
countries	I-Settings_Location
,	I-Settings_Location
including	I-Settings_Location
Europe	I-Settings_Location
,	I-Settings_Location
Australia	I-Settings_Location
,	I-Settings_Location
Canada	I-Settings_Location
and	I-Settings_Location
USA	I-Settings_Location
)	O
,	O
randomised	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
,	O
four-arm	O
,	O
parallel-group	B-Design_Parallel_Group
,	O
dose-finding	O
phase	B-Design_Phase_2
IIb	I-Design_Phase_2
study	O
,	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
adhering	O
to	O
the	O
International	O
Conference	O
on	O
Harmonisation	O
Guidelines	O
for	O
Good	O
Clinical	O
Practice	O
.	O

Vitamin	B-Design_Parallel_Group
D	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
was	O
given	O
by	O
fieldworkers	O
once	O
every	O
3	O
months	O
for	O
18	O
months	O
.	O

Statistical	O
analysis	O
Sample	O
size	O
was	O
based	O
on	O
the	O
primary	O
endpoint	O
of	O
trough	O
FEV1	O
at	O
Day	O
85	O
and	O
assumed	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
,	O
a	B-Sample_Size_Calculation_Alpha_Value
two-sided	I-Sample_Size_Calculation_Alpha_Value
1	I-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
significance	I-Sample_Size_Calculation_Alpha_Value
level	I-Sample_Size_Calculation_Alpha_Value
,	O
an	O
estimate	O
of	O
residual	O
standard	O
deviation	O
of	O
240	O
mL	O
(	O
based	O
on	O
mixed	O
model	O
repeated	O
measures	O
[	O
MMRM	O
]	O
analyses	O
of	O
the	O
Phase	O
III	O
IMPACT	O
study	O
)	O
and	O
a	O
treatment	O
difference	O
of	O
70	O
mL	O
.	O

Sample	O
size	O
and	O
analysis	O
To	O
establish	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
,	O
we	O
allowed	O
a	O
difference	O
of	O
up	O
to	O
15	O
%	O
in	O
the	O
primary	O
outcome	O
.	O

Methods	O
STAIRWAY	O
was	O
a	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
,	O
multicenter	B-Settings_Multicenter
,	O
randomized	O
,	O
active	O
comparator–controlled	O
,	O
participant-	O
and	O
outcome-assessor	B-Blinding_Object_Outcome_Assessors
masked	O
,	O
parallel-group	B-Design_Parallel_Group
,	O
52-week	O
clinical	O
trial	O
conducted	O
at	O
25	B-Settings_Multicenter
sites	I-Settings_Multicenter
in	O
the	O
United	B-Settings_Location
States	I-Settings_Location
between	O
January	O
and	O
March	O
2017	O
.	O

Results	O
Twenty-one	B-Sample_Size_Actual_at_Enrollment
patients	I-Sample_Size_Actual_at_Enrollment
received	O
golimumab	O
plus	O
MTX	O
and	O
23	O
MTX	O
monotherapy	O
for	O
24	O
weeks	O
.	O

Randomization	O
was	O
stratified	B-Randomization_Type_Stratified
by	O
baseline	B-Randomization_Stratified_Criteria
migraine	I-Randomization_Stratified_Criteria
frequency	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
CM	I-Randomization_Stratified_Criteria
versus	I-Randomization_Stratified_Criteria
EM	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
and	O
geographical	B-Randomization_Stratified_Criteria
region	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
North	I-Randomization_Stratified_Criteria
America	I-Randomization_Stratified_Criteria
vs.	I-Randomization_Stratified_Criteria
rest	I-Randomization_Stratified_Criteria
of	I-Randomization_Stratified_Criteria
world	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
.	O

We	O
therefore	O
conducted	O
the	O
present	O
phase	O
2	O
study	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
three	O
,	O
twice-daily	O
doses	O
of	O
tenapanor	O
(	O
5	O
,	O
20	O
,	O
and	O
50	O
mg	O
)	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
IBS-C.	O
Methods	O
Study	O
design	O
This	O
was	O
a	O
multicenter	B-Settings_Multicenter
,	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
,	O
randomized	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
study	O
conducted	O
at	O
79	B-Settings_Multicenter
sites	I-Settings_Multicenter
in	O
the	O
USA	B-Settings_Location
(	O
ClinicalTrials.gov	O
identifier	O
:	O
NCT01923428	O
)	O
between	O
August	O
2013	O
and	O
October	O
2014	O
(	O
last	O
patient	O
last	O
visit	O
July	O
2014	O
)	O
.	O

Eligible	O
patients	O
were	O
then	O
randomized	O
1:1	B-Randomization_Ratio
(	O
using	O
an	B-Randomization_Sequence_Generation_Method
Interactive	I-Randomization_Sequence_Generation_Method
Web	I-Randomization_Sequence_Generation_Method
Response	I-Randomization_Sequence_Generation_Method
System	I-Randomization_Sequence_Generation_Method
)	O
to	O
receive	O
either	O
FF/UMEC/VI	O
100/62.5/25	O
mcg	O
via	O
ELLIPTA	O
and	O
placebo	O
via	O
HandiHaler	O
or	O
TIO	O
18	O
mcg	O
via	O
HandiHaler	O
and	O
placebo	O
via	O
ELLIPTA	O
,	O
all	O
taken	O
once	O
daily	O
in	O
the	O
morning	O
(	O
Visit	O
2	O
)	O
.	O

Statistical	O
analysis	O
We	O
estimated	O
that	O
a	O
sample	O
size	O
of	O
305	B-Sample_Size_Required
patients	I-Sample_Size_Required
in	I-Sample_Size_Required
each	I-Sample_Size_Required
group	I-Sample_Size_Required
would	O
detect	O
a	O
5	O
mm	O
Hg	O
difference	O
in	O
systolic	O
blood	O
pressure	O
between	O
groups	O
with	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
at	O
a	O
significance	O
level	O
of	O
5	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
assuming	O
a	O
standard	O
deviation	O
of	O
17.5	O
mm	O
Hg	O
,	O
10	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
loss	I-Sample_Size_Calculation_Dropout_Rate_Value
to	I-Sample_Size_Calculation_Dropout_Rate_Value
follow-up	I-Sample_Size_Calculation_Dropout_Rate_Value
,	I-Sample_Size_Calculation_Dropout_Rate_Value
5	I-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
mortality	I-Sample_Size_Calculation_Dropout_Rate_Value
,	I-Sample_Size_Calculation_Dropout_Rate_Value
and	I-Sample_Size_Calculation_Dropout_Rate_Value
10	I-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
major	I-Sample_Size_Calculation_Dropout_Rate_Value
vascular	I-Sample_Size_Calculation_Dropout_Rate_Value
events	I-Sample_Size_Calculation_Dropout_Rate_Value
.	O

This	O
12-week	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
double-dummy	O
study	O
randomized	O
800	B-Sample_Size_Actual_at_Enrollment
symptomatic	O
moderate-to-very-severe	O
COPD	O
patients	O
receiving	O
tiotropium	B-Design_Parallel_Group
(	I-Design_Parallel_Group
TIO	I-Design_Parallel_Group
)	I-Design_Parallel_Group
for	I-Design_Parallel_Group
≥3	I-Design_Parallel_Group
months	I-Design_Parallel_Group
to	I-Design_Parallel_Group
once-daily	I-Design_Parallel_Group
fluticasone	I-Design_Parallel_Group
furoate/umeclidinium/vilanterol	I-Design_Parallel_Group
(	I-Design_Parallel_Group
FF/UMEC/VI	I-Design_Parallel_Group
)	I-Design_Parallel_Group
100/62.5/25	I-Design_Parallel_Group
mcg	I-Design_Parallel_Group
via	I-Design_Parallel_Group
ELLIPTA	I-Design_Parallel_Group
(	I-Design_Parallel_Group
n	I-Design_Parallel_Group
=	I-Design_Parallel_Group
400	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
TIO	I-Design_Parallel_Group
18	I-Design_Parallel_Group
mcg	I-Design_Parallel_Group
via	I-Design_Parallel_Group
HandiHaler	I-Design_Parallel_Group
(	I-Design_Parallel_Group
n	I-Design_Parallel_Group
=	I-Design_Parallel_Group
400	I-Design_Parallel_Group
)	I-Design_Parallel_Group
plus	I-Design_Parallel_Group
matched	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
.	O

Patients	O
were	O
randomised	O
by	O
assignment	O
of	O
a	O
unique	O
randomisation	O
number	O
using	O
an	B-Randomization_Sequence_Generation_Method
interactive	I-Randomization_Sequence_Generation_Method
voice	I-Randomization_Sequence_Generation_Method
or	I-Randomization_Sequence_Generation_Method
web	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
,	O
supplied	O
by	O
an	O
independent	O
service	O
provider	O
(	O
ICON	O
Clinical	O
,	O
Research	O
,	O
USA	O
)	O
.	O

The	O
statistical	O
criterion	O
for	O
noninferiority	B-Design_Comparative_Intent_NonInferiority
corresponds	O
to	O
the	O
lower	O
bound	O
of	O
the	O
adjusted	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
of	O
the	O
proportion	O
difference	O
(	O
V114	O
−	O
PCV13	O
)	O
being	O
greater	O
than	O
−0.15	O
for	O
each	O
of	O
the	O
13	O
shared	O
serotypes	O
.	O

A	O
Randomized	O
Phase	B-Design_Phase_2
2	I-Design_Phase_2
Trial	O
Comparing	O
Omidenepag	O
Isopropyl	O
0.002	O
%	O
Once	O
and	O
Twice	O
Daily	O
in	O
Subjects	O
With	O
Primary	O
Open-angle	O
Glaucoma	O
or	O
Ocular	O
Hypertension	O
(	O
SPECTRUM-6	O
)	O

The	O
study	O
was	O
conducted	O
in	O
72	B-Settings_Multicenter
centers	I-Settings_Multicenter
in	O
three	B-Settings_Location
countries	I-Settings_Location
(	I-Settings_Location
Poland	I-Settings_Location
,	I-Settings_Location
Russian	I-Settings_Location
Federation	I-Settings_Location
,	I-Settings_Location
and	I-Settings_Location
the	I-Settings_Location
USA	I-Settings_Location
)	I-Settings_Location
from	O
March	O
2018	O
to	O
July	O
2019	O
.	O

Statistical	O
analyses	O
Sample	O
size	O
was	O
calculated	O
from	O
the	O
study	O
of	O
Lee	O
et	O
al..	O
To	O
detect	O
a	O
35	O
%	O
change	O
in	O
aortic	O
distensibility	O
or	O
an	O
11	O
%	O
change	O
in	O
plaque	O
burden	O
at	O
12	O
months	O
to	O
achieve	O
a	O
power	O
of	O
0.8	B-Sample_Size_Calculation_Power_Value
and	O
nominal	O
p	O
<	O
0.05	B-Sample_Size_Calculation_Alpha_Value
(	I-Sample_Size_Calculation_Alpha_Value
2-sided	I-Sample_Size_Calculation_Alpha_Value
)	I-Sample_Size_Calculation_Alpha_Value
,	O
60	B-Sample_Size_Required
patients	I-Sample_Size_Required
per	I-Sample_Size_Required
group	I-Sample_Size_Required
were	I-Sample_Size_Required
required	I-Sample_Size_Required
.	O

Results	O
We	O
evaluated	O
782	O
patients	O
with	O
clinically	O
significant	O
MRSA	O
isolates	O
,	O
of	O
whom	O
252	B-Sample_Size_Actual_at_Enrollment
were	O
included	O
.	O

No	O
formal	O
hypothesis	O
tests	O
were	O
conducted	O
except	O
for	O
the	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
in	O
primary	O
end	O
point	O
.	O

Children	O
were	O
randomized	O
2:1	B-Randomization_Ratio
to	O
receive	O
either	O
a	O
single	B-Design_Parallel_Group
dose	I-Design_Parallel_Group
of	I-Design_Parallel_Group
oral	I-Design_Parallel_Group
baloxavir	I-Design_Parallel_Group
or	I-Design_Parallel_Group
oral	I-Design_Parallel_Group
oseltamivir	I-Design_Parallel_Group
twice	O
daily	O
for	O
5	O
days	O
.	O

Randomization	O
Participants	O
were	O
randomized	O
1:2:2	B-Randomization_Ratio
to	O
receive	O
intravitreal	O
ranibizumab	O
,	O
0.5	O
mg	O
,	O
every	O
4	O
weeks	O
;	O
faricimab	O
,	O
6.0	O
mg	O
,	O
every	O
12	O
weeks	O
after	O
initiation	O
(	O
4	O
total	O
injections	O
every	O
4	O
weeks	O
from	O
baseline	O
to	O
week	O
12	O
)	O
;	O
or	O
faricimab	O
,	O
6.0	O
mg	O
,	O
every	O
16	O
weeks	O
after	O
initiation	O
(	O
4	O
total	O
injections	O
every	O
4	O
weeks	O
from	O
baseline	O
to	O
week	O
12	O
)	O
.	O

With	O
this	O
number	O
per	O
group	O
,	O
it	O
was	O
estimated	O
to	O
detect	O
a	O
0.1	O
difference	O
in	O
BI	O
(	O
standard	O
deviation	O
[	O
SD	O
]	O
=	O
0.17	O
)	O
with	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
and	O
a	B-Sample_Size_Calculation_Alpha_Value
2-sided	I-Sample_Size_Calculation_Alpha_Value
5	I-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
significance	I-Sample_Size_Calculation_Alpha_Value
level	I-Sample_Size_Calculation_Alpha_Value
.	O

Typically	O
,	O
a	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
margin	O
that	O
represents	O
⩾50	O
%	O
of	O
the	O
placebo-adjusted	O
control	O
drug	O
effect	O
is	O
suggested	O
;	O
thus	O
,	O
a	O
particularly	O
stringent	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
margin	O
was	O
used	O
in	O
the	O
present	O
study	O
.	O

Patients	O
were	O
randomized	B-Randomization_Type_Simple
(	O
1:1	B-Randomization_Ratio
)	O
to	O
oral	B-Design_Parallel_Group
abemaciclib	I-Design_Parallel_Group
150	I-Design_Parallel_Group
or	I-Design_Parallel_Group
200	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
every	O
12	O
h	O
on	O
a	O
28-day	O
cycle	O
.	O

After	O
consent	O
,	O
eligible	O
patients	O
were	O
randomized	O
(	O
1:1	B-Randomization_Ratio
)	O
to	O
receive	O
canakinumab	B-Design_Parallel_Group
150	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
,	O
subcutaneously	O
,	O
monthly	O
for	O
12	O
months	O
.	O

For	O
the	O
first	O
two	O
superiority	O
hypotheses	O
and	O
based	O
on	O
the	O
assumptions	O
above	O
,	O
a	O
sample	O
size	O
of	O
267	B-Sample_Size_Required
(	O
89	O
per	O
arm	O
)	O
provided	O
98	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
greater	O
reduction	O
in	O
retinal	O
thickness	O
from	O
25	O
%	O
for	O
periocular	O
injection	O
to	O
40	O
%	O
for	O
intravitreal	O
injection	O
or	O
dexamethasone	O
implant	O
on	O
the	O
log	O
scale	O
,	O
i.e.	O
,	O
difference	O
in	O
log	O
change	O
in	O
retinal	O
thickness	O
of	O
log	O
(	O
0.6	O
)	O
vs.	O
log	O
(	O
0.75	O
)	O
,	O
with	O
a	B-Sample_Size_Calculation_Alpha_Value
two-sided	I-Sample_Size_Calculation_Alpha_Value
type	I-Sample_Size_Calculation_Alpha_Value
I	I-Sample_Size_Calculation_Alpha_Value
error	I-Sample_Size_Calculation_Alpha_Value
rate	I-Sample_Size_Calculation_Alpha_Value
of	I-Sample_Size_Calculation_Alpha_Value
0.01667	I-Sample_Size_Calculation_Alpha_Value
.	O

Two	B-Sample_Size_Actual_at_Outcome_Analysis
hundred	I-Sample_Size_Actual_at_Outcome_Analysis
and	I-Sample_Size_Actual_at_Outcome_Analysis
forty-six	I-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
from	I-Sample_Size_Actual_at_Outcome_Analysis
the	I-Sample_Size_Actual_at_Outcome_Analysis
SB2	I-Sample_Size_Actual_at_Outcome_Analysis
treatment	I-Sample_Size_Actual_at_Outcome_Analysis
group	I-Sample_Size_Actual_at_Outcome_Analysis
and	I-Sample_Size_Actual_at_Outcome_Analysis
259	I-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
from	I-Sample_Size_Actual_at_Outcome_Analysis
the	I-Sample_Size_Actual_at_Outcome_Analysis
INF	I-Sample_Size_Actual_at_Outcome_Analysis
treatment	I-Sample_Size_Actual_at_Outcome_Analysis
group	I-Sample_Size_Actual_at_Outcome_Analysis
completed	O
the	O
week	O
30	O
visit	O
;	O
the	O
most	O
common	O
reason	O
for	O
withdrawal	O
was	O
due	O
to	O
AEs	O
and	O
withdrawal	O
of	O
consent	O
(	O
figure	O
1	O
)	O
.	O

Methods	O
This	O
phase	B-Design_Phase_1
I	I-Design_Phase_1
,	O
open‐label	B-Blinding_Open_Label
study	O
(	O
ClinicalTrials.gov	O
:	O
NCT04295356	O
)	O
randomised	O
subjects	O
(	O
1:1	B-Randomization_Ratio
)	O
to	O
receive	O
a	B-Design_Parallel_Group
single	I-Design_Parallel_Group
40‐mg	I-Design_Parallel_Group
(	I-Design_Parallel_Group
100	I-Design_Parallel_Group
mg/mL	I-Design_Parallel_Group
)	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
of	I-Design_Parallel_Group
CT‐P17	I-Design_Parallel_Group
AI	I-Design_Parallel_Group
or	I-Design_Parallel_Group
CT‐P17	I-Design_Parallel_Group
PFS	I-Design_Parallel_Group
.	O

Participants	B-Blinding_Object_Patients
and	O
study	B-Blinding_Object_Outcome_Assessors
staff	I-Blinding_Object_Outcome_Assessors
performing	O
data	O
collection	O
and	O
analysis	O
were	O
blinded	O
to	O
treatment	O
allocation	O
.	O

Overall	O
,	O
111	B-Sample_Size_Actual_at_Enrollment
women	O
participated	O
in	O
the	O
ursodeoxycholic	O
acid	O
comparison	O
;	O
at	O
randomisation	O
28	O
(	O
25	O
%	O
)	O
had	O
severe	O
disease	O
(	O
bile	O
acid	O
levels	O
>	O
40	O
µmol/L	O
)	O
,	O
71	O
(	O
64	O
%	O
)	O
mild	O
disease	O
(	O
≤40	O
µmol/L	O
)	O
,	O
and	O
12	O
(	O
11	O
%	O
)	O
normal	O
bile	O
acid	O
levels	O
with	O
raised	O
alanine	O
transaminase	O
levels	O
.	O

Before	O
the	O
start	O
of	O
the	O
trial	O
,	O
an	B-Randomization_Sequence_Generation_Method
interactive	I-Randomization_Sequence_Generation_Method
voice	I-Randomization_Sequence_Generation_Method
response/interactive	I-Randomization_Sequence_Generation_Method
web	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
was	O
used	O
to	O
facilitate	O
randomization	O
and	O
stratification	O
,	O
and	O
the	O
randomization	O
treatment	O
assignment	O
was	O
generated	O
by	O
the	O
sponsor	B-Randomization_Personnel
’	I-Randomization_Personnel
s	I-Randomization_Personnel
Global	I-Randomization_Personnel
Randomization	I-Randomization_Personnel
and	I-Randomization_Personnel
Blinding	I-Randomization_Personnel
group	I-Randomization_Personnel
independent	O
of	O
the	O
study	O
.	O

The	O
randomization	O
and	O
treatment	O
allocation	O
were	O
performed	O
centrally	O
by	O
an	B-Randomization_Sequence_Generation_Method
interactive	I-Randomization_Sequence_Generation_Method
voice	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
(	I-Randomization_Sequence_Generation_Method
IVRS	I-Randomization_Sequence_Generation_Method
)	I-Randomization_Sequence_Generation_Method
with	I-Randomization_Sequence_Generation_Method
simple	I-Randomization_Sequence_Generation_Method
sequential	I-Randomization_Sequence_Generation_Method
allocation	I-Randomization_Sequence_Generation_Method
from	O
blocked	B-Randomization_Type_Block
randomization	I-Randomization_Type_Block
schedule	O
without	O
stratifying	O
factors	O
(	O
including	O
site	O
)	O
.	O

This	O
randomized	B-Randomization_Type_Simple
controlled	O
trial	O
aimed	O
to	O
determine	O
whether	O
perioperative	O
IV	O
iron	O
reduced	O
the	O
need	O
for	O
ABT	O
.	O

Methods	O
:	O
In	O
this	O
phase	B-Design_Phase_4
IV	I-Design_Phase_4
,	O
randomized	B-Randomization_Type_Simple
,	O
observer-blinded	B-Blinding_Object_Others
,	O
multi-center	B-Settings_Multicenter
study	O
,	O
healthy	O
children	O
6–35	O
months	O
of	O
age	O
were	O
randomized	O
1:1	B-Randomization_Ratio
to	O
be	O
vaccinated	O
with	O
a	O
half	B-Design_Parallel_Group
or	I-Design_Parallel_Group
full	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
of	I-Design_Parallel_Group
IIV4	I-Design_Parallel_Group
(	O
NCT02915302	O
)	O
.	O

Study	O
design	O
This	O
was	O
a	O
phase	B-Design_Phase_3
III	I-Design_Phase_3
,	O
randomized	B-Randomization_Type_Simple
,	O
double-blind	B-Blinding_Double_Blind
,	O
double-dummy	O
,	O
parallel-group	B-Design_Parallel_Group
,	O
12-week	O
study	O
(	O
ClinicalTrials.gov	O
:	O
NCT02281552	O
)	O
.	O

The	O
randomization	O
list	O
was	O
prepared	O
by	O
the	O
data	O
management	O
vendor	O
using	O
the	O
randomization	B-Randomization_Sequence_Generation_Method
module	I-Randomization_Sequence_Generation_Method
in	I-Randomization_Sequence_Generation_Method
Informatics	I-Randomization_Sequence_Generation_Method
ClinPhone	I-Randomization_Sequence_Generation_Method
RTSM	I-Randomization_Sequence_Generation_Method
service	I-Randomization_Sequence_Generation_Method
.	O

GP	O
MDI	O
18	O
μg	O
was	O
non-inferior	B-Design_Comparative_Intent_NonInferiority
to	O
open-label	B-Blinding_Open_Label
tiotropium	O
for	O
peak	O
change	O
in	O
FEV1	O
on	O
Day	O
1	O
and	O
morning	O
pre-dose	O
trough	O
FEV1	O
on	O
Day	O
14	O
.	O

Patients	O
received	O
danirixin	B-Design_Parallel_Group
5	I-Design_Parallel_Group
,	I-Design_Parallel_Group
10	I-Design_Parallel_Group
,	I-Design_Parallel_Group
25	I-Design_Parallel_Group
,	I-Design_Parallel_Group
35	I-Design_Parallel_Group
or	I-Design_Parallel_Group
50	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
twice	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
in	O
addition	O
to	O
standard	O
of	O
care	O
.	O

Randomization	O
was	O
based	O
on	O
a	B-Randomization_Sequence_Generation_Method
simple	I-Randomization_Sequence_Generation_Method
computer‐generated	I-Randomization_Sequence_Generation_Method
list	I-Randomization_Sequence_Generation_Method
that	O
was	O
placed	O
in	O
sealed	B-Allocation_Concealment_Method
envelopes	I-Allocation_Concealment_Method
.	O

Also	O
accounting	O
for	O
less	O
exclusion	O
from	O
the	O
per-protocol	O
set	O
(	O
17	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
)	O
,	O
the	O
sample	O
size	O
was	O
reduced	O
to	O
480	B-Sample_Size_Target
patients	O
.	O

Methods	O
:	O
Between	O
August	O
2011	O
and	O
November	O
2014	O
,	O
72	B-Sample_Size_Actual_at_Enrollment
patients	O
with	O
IDA	O
were	O
assigned	O
to	O
receive	O
either	O
IV	B-Design_Parallel_Group
iron	I-Design_Parallel_Group
or	I-Design_Parallel_Group
usual	I-Design_Parallel_Group
care	I-Design_Parallel_Group
.	O

Eight	O
participants	O
withdrew	O
,	O
and	O
13	O
additional	O
participants	O
did	O
not	O
meet	O
eligibility	O
criteria	O
,	O
yielding	O
757	B-Sample_Size_Actual_at_Enrollment
randomized	O
participants	O
;	O
378	O
received	O
aIIV3	O
and	O
379	O
received	O
HD-IIV3	O
in	O
full	O
analysis	O
population	O
2	O
(	O
Figure	O
1	O
)	O
.	O

Methods	O
In	O
a	O
double-blind	B-Blinding_Double_Blind
trial	O
,	O
patients	O
were	O
randomized	O
4:3:3	B-Randomization_Ratio
to	O
placebo	B-Design_Parallel_Group
,	I-Design_Parallel_Group
AMG	I-Design_Parallel_Group
301	I-Design_Parallel_Group
210	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
every	I-Design_Parallel_Group
4	I-Design_Parallel_Group
weeks	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
AMG	I-Design_Parallel_Group
301	I-Design_Parallel_Group
420	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
every	O
2	O
weeks	O
for	O
12	O
weeks	O
.	O

Open-label	B-Blinding_Open_Label
tiotropium	O
demonstrated	O
a	O
statistically	O
and	O
clinically	O
significant	O
increase	O
versus	O
placebo	O
MDI	O
in	O
FEV1	O
AUC0–12	O
on	O
Day	O
14	O
(	O
LSM	O
difference	O
,	O
224	O
mL	O
;	O
p	O
<	O
0.0001	O
)	O
.	O

Methods	O
This	O
was	O
a	O
phase	B-Design_Phase_2
II	I-Design_Phase_2
,	O
randomised	O
,	O
double-blind	B-Blinding_Double_Blind
trial	O
conducted	O
at	O
15	B-Settings_Multicenter
centres	I-Settings_Multicenter
in	O
the	O
USA	B-Settings_Location
to	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
filgotinib	O
or	O
lanraplenib	O
for	O
the	O
treatment	O
of	O
LMN	O
.	O

The	O
randomisation	O
was	O
stratified	B-Randomization_Type_Stratified
by	O
centre	B-Randomization_Stratified_Criteria
and	O
age	B-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
35	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
35–37	I-Randomization_Stratified_Criteria
and	I-Randomization_Stratified_Criteria
38–40	I-Randomization_Stratified_Criteria
years	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
using	O
a	O
block	B-Randomization_Type_Block
size	O
of	O
four	B-Randomization_Block_Size
.	O

Allocation	O
concealment	O
was	O
maintained	O
by	O
identically	B-Allocation_Concealment_Method
labeled	I-Allocation_Concealment_Method
,	I-Allocation_Concealment_Method
sealed	I-Allocation_Concealment_Method
,	I-Allocation_Concealment_Method
sequentially	I-Allocation_Concealment_Method
numbered	I-Allocation_Concealment_Method
opaque	I-Allocation_Concealment_Method
pill	I-Allocation_Concealment_Method
containers	I-Allocation_Concealment_Method
.	O

Randomization	O
Patients	O
were	O
randomized	O
in	O
a	O
2:1	O
ratio	O
to	O
receive	O
IIM	B-Design_Parallel_Group
or	I-Design_Parallel_Group
IS	I-Design_Parallel_Group
using	O
stratified	B-Randomization_Type_Stratified
block	B-Randomization_Type_Block
randomization	O
according	O
to	O
eGFR	B-Randomization_Stratified_Criteria
at	I-Randomization_Stratified_Criteria
screening	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
46	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
46–	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
60	I-Randomization_Stratified_Criteria
or	I-Randomization_Stratified_Criteria
60–	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
90	I-Randomization_Stratified_Criteria
mL/min/1.73	I-Randomization_Stratified_Criteria
m2	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
and	O
baseline	B-Randomization_Stratified_Criteria
cardiovascular	I-Randomization_Stratified_Criteria
risk	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
history	I-Randomization_Stratified_Criteria
of	I-Randomization_Stratified_Criteria
myocardial	I-Randomization_Stratified_Criteria
infarction	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
stroke	I-Randomization_Stratified_Criteria
or	I-Randomization_Stratified_Criteria
congestive	I-Randomization_Stratified_Criteria
heart	I-Randomization_Stratified_Criteria
failure	I-Randomization_Stratified_Criteria
;	I-Randomization_Stratified_Criteria
yes/no	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
.	O

Full	O
data	O
to	O
calculate	O
the	O
AUC	O
for	O
cTnI	O
(	O
primary	O
outcome	O
)	O
were	O
obtained	O
in	O
83	B-Sample_Size_Actual_at_Outcome_Analysis
patients	O
(	O
95	O
%	O
)	O
.	O

It	O
was	O
analysed	O
using	O
a	O
generalised	O
linear	O
model	O
,	O
including	O
terms	O
for	O
the	O
treatment	O
allocation	O
and	O
the	O
variables	O
on	O
which	O
the	O
randomisation	O
was	O
minimised	B-Randomization_Type_Minimization
.	O

Results	O
A	O
total	O
of	O
280	B-Sample_Size_Actual_at_Enrollment
patients	O
(	O
mean	O
[	O
SD	O
]	O
age	O
,	O
39.3	O
[	O
17.5	O
]	O
years	O
;	O
166	O
[	O
59.3	O
%	O
]	O
female	O
)	O
were	O
randomized	O
to	O
placebo	O
(	O
n	O
=	O
52	O
)	O
or	O
to	O
lebrikizumab	O
at	O
doses	O
of	O
125	O
mg	O
every	O
4	O
weeks	O
(	O
n	O
=	O
73	O
)	O
,	O
250	O
mg	O
every	O
4	O
weeks	O
(	O
n	O
=	O
80	O
)	O
,	O
or	O
250	O
mg	O
every	O
2	O
weeks	O
(	O
n	O
=	O
75	O
)	O
.	O

Study	O
Design	O
This	O
was	O
a	O
phase	B-Design_Phase_3
3	I-Design_Phase_3
,	O
multicenter	B-Settings_Multicenter
,	O
randomized	B-Randomization_Type_Simple
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
clinical	O
trial	O
,	O
conducted	O
at	O
38	B-Settings_Multicenter
medical	I-Settings_Multicenter
institutions	I-Settings_Multicenter
in	O
Japan	B-Settings_Location
from	O
August	O
2017	O
through	O
January	O
2019	O
.	O

In	O
order	O
to	O
assure	O
blinding	O
,	O
randomization	O
was	O
performed	O
by	O
the	O
study	B-Randomization_Personnel
statistician	I-Randomization_Personnel
who	O
forwarded	O
the	O
randomization	B-Randomization_Sequence_Generation_Method
list	I-Randomization_Sequence_Generation_Method
to	O
the	O
research	O
pharmacist	O
who	O
in-turn	O
dispensed	O
the	O
study	O
drug	O
directly	O
to	O
the	O
subjects	O
.	O

Results	O
From	O
September	O
2013	O
to	O
December	O
2018	O
,	O
a	O
total	O
of	O
408	B-Sample_Size_Actual_at_Enrollment
pregnant	I-Sample_Size_Actual_at_Enrollment
women	I-Sample_Size_Actual_at_Enrollment
(	O
206	O
randomized	O
to	O
raltegravir	O
,	O
202	O
to	O
efavirenz	O
)	O
were	O
enrolled	O
at	O
sites	O
in	O
Argentina	O
(	O
N=20	O
)	O
,	O
Brazil	O
(	O
N=190	O
)	O
,	O
South	O
Africa	O
(	O
N=60	O
)	O
,	O
Tanzania	O
(	O
N=84	O
)	O
,	O
Thailand	O
(	O
N=47	O
)	O
,	O
and	O
the	O
US	O
(	O
N=7	O
)	O
;	O
205	O
(	O
50	O
%	O
)	O
enrolled	O
from	O
20	O
to	O
less	O
than	O
28	O
weeks	O
gestation	O
,	O
and	O
203	O
(	O
50	O
%	O
)	O
from	O
28	O
to	O
less	O
than	O
37	O
weeks	O
gestation	O
.	O

Key	O
Points	O
Question	O
Is	O
lebrikizumab	O
,	O
a	O
novel	O
,	O
high-affinity	O
,	O
monoclonal	O
antibody	O
targeting	O
interleukin	O
13	O
that	O
selectively	O
inhibits	O
interleukin	O
13	O
signaling	O
,	O
efficacious	O
and	O
safe	O
in	O
adults	O
with	O
moderate	O
to	O
severe	O
atopic	O
dermatitis	O
?	O
Findings	O
Among	O
280	B-Sample_Size_Actual_at_Enrollment
patients	O
with	O
moderate	O
to	O
severe	O
atopic	O
dermatitis	O
in	O
this	O
phase	O
2b	O
,	O
placebo-controlled	O
randomized	O
clinical	O
trial	O
,	O
lebrikizumab	O
statistically	O
significantly	O
improved	O
measures	O
of	O
clinical	O
manifestations	O
of	O
atopic	O
dermatitis	O
,	O
pruritus	O
,	O
and	O
quality	O
of	O
life	O
in	O
a	O
dose-dependent	O
manner	O
vs	O
placebo	O
during	O
16	O
weeks	O
of	O
treatment	O
.	O

Results	O
Trial	O
Participants	O
Participants	O
(	O
n	O
=	O
1,091	B-Sample_Size_Actual_at_Enrollment
)	O
were	O
randomized	O
to	O
faster	O
aspart	O
(	O
n	O
=	O
546	O
)	O
or	O
IAsp	O
(	O
n	O
=	O
545	O
)	O
,	O
and	O
99.6	O
%	O
(	O
n	O
=	O
544	O
)	O
and	O
99.8	O
%	O
(	O
n	O
=	O
544	O
)	O
of	O
participants	O
,	O
respectively	O
,	O
were	O
exposed	O
to	O
randomized	O
trial	O
product	O
.	O

We	O
selected	O
a	O
sample	O
size	O
of	O
84	B-Sample_Size_Target
(	O
42	O
per	O
group	O
)	O
to	O
have	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
of	O
IN	O
fentanyl	O
versus	O
IV	O
hydromorphone	O
using	O
a	O
one-sided	O
,	O
two-sample	O
t-test	O
,	O
with	O
a	O
non-inferiority	O
margin	O
of	O
0.9	O
and	O
an	O
alpha	O
of	O
0.05	B-Sample_Size_Calculation_Alpha_Value
.	O

Equivalence	B-Design_Comparative_Intent_Equivalence
was	O
determined	O
if	O
the	O
90	O
%	O
confidence	O
interval	O
for	O
the	O
geometric	O
least‐squares	O
mean	O
ratio	O
was	O
within	O
the	O
80–125	O
%	O
equivalence	O
margin	O
.	O

Randomization	O
was	O
undertaken	O
using	O
permuted	B-Randomization_Type_Block
blocks	I-Randomization_Type_Block
of	O
varying	B-Randomization_Block_Size
lengths	I-Randomization_Block_Size
to	O
yield	O
the	O
expected	O
1:1:1	B-Randomization_Ratio
allocation	O
ratio	O
and	O
stratified	B-Randomization_Type_Stratified
by	O
the	O
presence	B-Randomization_Stratified_Criteria
or	I-Randomization_Stratified_Criteria
absence	I-Randomization_Stratified_Criteria
of	I-Randomization_Stratified_Criteria
concomitant	I-Randomization_Stratified_Criteria
systemic	I-Randomization_Stratified_Criteria
treatment	I-Randomization_Stratified_Criteria
for	I-Randomization_Stratified_Criteria
uveitis	I-Randomization_Stratified_Criteria
(	O
e.g	O
.	O

Key	O
Points	O
Question	O
What	O
are	O
the	O
comparative	O
safety	O
,	O
reactogenicity	O
,	O
and	O
short-term	O
effects	O
of	O
vaccination	O
on	O
health-related	O
quality	O
of	O
life	O
after	O
trivalent	O
adjuvanted	O
inactivated	O
influenza	O
vaccine	O
(	O
aIIV3	O
)	O
or	O
trivalent	O
high-dose	O
inactivated	O
influenza	O
vaccine	O
(	O
HD-IIV3	O
)	O
in	O
adults	O
aged	O
65	O
years	O
and	O
older	O
?	O
Findings	O
In	O
this	O
randomized	O
clinical	O
trial	O
of	O
757	B-Sample_Size_Actual_at_Enrollment
older	I-Sample_Size_Actual_at_Enrollment
adults	I-Sample_Size_Actual_at_Enrollment
(	O
378	O
receiving	O
aIIV3	O
and	O
379	O
receiving	O
HD-IIV3	O
)	O
,	O
the	O
proportion	O
of	O
participants	O
with	O
moderate-to-severe	O
injection-site	O
pain	O
(	O
primary	O
outcome	O
)	O
was	O
not	O
higher	O
after	O
aIIV3	O
than	O
HD-IIV3	O
.	O

METHODS	O
This	O
was	O
a	O
randomized	B-Randomization_Type_Simple
controlled	O
trial	O
.	O

Following	O
screening	O
,	O
patients	O
were	O
randomized	O
using	O
an	B-Randomization_Sequence_Generation_Method
interactive	I-Randomization_Sequence_Generation_Method
web	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
to	O
one	O
of	O
120	O
pre-defined	O
treatment	O
sequences	O
,	O
comprising	O
four	O
out	O
of	O
the	O
eight	O
possible	O
treatments	O
.	O

Methods	O
We	O
undertook	O
a	O
semifactorial	B-Design_Factorial
randomised	O
controlled	O
trial	O
of	O
two	O
interventions	O
in	O
women	O
with	O
intrahepatic	O
cholestasis	O
of	O
pregnancy	O
at	O
nine	B-Settings_Multicenter
maternity	I-Settings_Multicenter
units	I-Settings_Multicenter
in	O
the	O
United	B-Settings_Location
Kingdom	I-Settings_Location
.	O

All	O
25	B-Sample_Size_Actual_at_Outcome_Analysis
patients	O
(	O
100	O
%	O
)	O
reported	O
at	O
least	O
one	O
treatment-emergent	O
AE	O
(	O
TEAE	O
)	O
of	O
any	O
grade	O
and	O
the	O
safety	O
profiles	O
were	O
comparable	O
in	O
both	O
cohorts	O
(	O
Table	O
2	O
)	O
.	O

Randomisation	O
was	O
done	O
by	O
a	B-Randomization_Sequence_Generation_Method
central	I-Randomization_Sequence_Generation_Method
telephone	I-Randomization_Sequence_Generation_Method
or	I-Randomization_Sequence_Generation_Method
web-based	I-Randomization_Sequence_Generation_Method
randomisation	I-Randomization_Sequence_Generation_Method
service	I-Randomization_Sequence_Generation_Method
with	O
minmisation	B-Randomization_Type_Minimization
by	O
centre	B-Randomization_Minimization_Criteria
,	O
pressure	B-Randomization_Minimization_Criteria
of	I-Randomization_Minimization_Criteria
arterial	I-Randomization_Minimization_Criteria
oxygen	I-Randomization_Minimization_Criteria
to	I-Randomization_Minimization_Criteria
fractional	I-Randomization_Minimization_Criteria
inspired	I-Randomization_Minimization_Criteria
oxygen	I-Randomization_Minimization_Criteria
concentration	I-Randomization_Minimization_Criteria
(	I-Randomization_Minimization_Criteria
PaO2/FIO2	I-Randomization_Minimization_Criteria
)	I-Randomization_Minimization_Criteria
ratio	I-Randomization_Minimization_Criteria
,	O
and	O
age	B-Randomization_Minimization_Criteria
.	O

GP	O
MDI	O
18	O
and	O
9	O
μg	O
were	O
non-inferior	B-Design_Comparative_Intent_NonInferiority
to	O
open-label	B-Blinding_Open_Label
tiotropium	O
for	O
change	O
from	O
baseline	O
in	O
morning	O
pre-dose	O
trough	O
FEV1	O
,	O
using	O
the	O
pre-specified	O
margin	O
of	O
100	O
mL	O
,	O
on	O
Days	O
7	O
and	O
14	O
.	O

Design	O
Parallel	B-Design_Parallel_Group
,	O
open	B-Blinding_Open_Label
label	I-Blinding_Open_Label
,	O
randomised	O
controlled	O
trial	O
.	O

Thus	O
,	O
the	O
final	O
analysis	O
was	O
based	O
on	O
data	O
from	O
37	B-Sample_Size_Actual_at_Outcome_Analysis
patients	O
.	O

Results	O
Patient	O
Disposition	O
and	O
Baseline	O
Characteristics	O
A	O
total	O
of	O
475	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomized	O
–	O
136	O
to	O
placebo	O
,	O
67	O
to	O
erenumab	O
28	O
mg	O
,	O
135	O
to	O
erenumab	O
70	O
mg	O
,	O
and	O
137	O
to	O
erenumab	O
140	O
mg	O
(	O
Fig	O
.	O

On	O
day	O
1	O
(	O
randomization	O
)	O
,	O
each	O
participant	O
was	O
assigned	O
(	O
1:1:1	B-Randomization_Ratio
)	O
to	O
oral	O
,	O
once‐daily	O
ertugliflozin	O
5	O
mg	O
,	O
15	O
mg	O
or	O
placebo	O
using	O
a	O
computer‐generated	B-Randomization_Sequence_Generation_Method
randomization	I-Randomization_Sequence_Generation_Method
code	I-Randomization_Sequence_Generation_Method
based	O
on	O
the	O
method	O
of	O
random	O
permuted	O
blocks	B-Randomization_Type_Block
.	O

Infusion	O
syringes	O
were	O
prepared	O
immediately	O
before	O
use	O
by	O
the	O
nurse	O
and	O
contained	O
two	O
ampoules	O
of	O
the	O
blinded	O
solutions	O
(	O
salbutamol	B-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
)	O
diluted	O
with	O
40	O
mL	O
of	O
saline	O
in	O
a	O
50	O
mL	O
syringe	O
.	O

Methods	O
464	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomised	O
to	O
receive	O
once-daily	B-Design_Parallel_Group
oral	I-Design_Parallel_Group
ponesimod	I-Design_Parallel_Group
10	I-Design_Parallel_Group
,	I-Design_Parallel_Group
20	I-Design_Parallel_Group
or	I-Design_Parallel_Group
40	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
for	O
24	O
weeks	O
.	O

Procedures	O
After	O
a	O
2-week	O
screening	O
period	O
,	O
participants	O
were	O
randomized	O
in	O
a	O
1:1	B-Randomization_Ratio
manner	O
to	O
either	O
open	O
label	O
IAsp	O
or	O
FA	O
.	O

Patients	O
Eligible	O
patients	O
were	O
men	O
and	O
women	O
,	O
aged	O
20–80	O
years	O
and	O
Japanese	B-Settings_Location
by	O
self-identification	O
,	O
for	O
whom	O
at	O
least	O
two	O
statins	O
failed	O
because	O
of	O
myalgia	O
(	O
muscle	O
pain	O
,	O
ache	O
,	O
or	O
weakness	O
without	O
creatinine	O
kinase	O
[	O
CK	O
]	O
elevation	O
)	O
,	O
myositis	O
(	O
muscle	O
symptoms	O
with	O
increased	O
CK	O
levels	O
)	O
,	O
or	O
rhabdomyolysis	O
(	O
defined	O
as	O
CK	O
>	O
10	O
×	O
upper	O
limit	O
normal	O
[	O
ULN	O
]	O
)	O
.	O

In	O
eight	O
participants	O
(	O
five	O
in	O
the	O
teplizumab	O
group	O
and	O
three	O
in	O
the	O
placebo	O
group	O
)	O
,	O
the	O
second	O
pretreatment	O
oral	O
glucose-tolerance	O
test	O
was	O
performed	O
on	O
the	O
first	O
day	O
of	O
administration	O
of	O
teplizumab	B-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
.	O

Statistical	O
analysis	O
We	O
estimated	O
that	O
a	O
sample	O
size	O
of	O
90	B-Sample_Size_Required
patients	O
was	O
required	O
to	O
detect	O
a	O
difference	O
in	O
DSS	O
of	O
2.52	O
between	O
groups	O
(	O
absolute	O
change	O
from	O
GO-REVEAL	O
trial	O
)	O
,	O
assuming	O
a	O
SD	O
of	O
4.01	O
,	O
with	O
a	O
0.05	B-Sample_Size_Calculation_Alpha_Value
significance	O
level	O
,	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
and	O
accounting	O
for	O
a	O
dropout	O
rate	O
of	O
10	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
.	O

Methods	O
We	O
randomized	B-Randomization_Type_Simple
82	B-Sample_Size_Actual_at_Enrollment
patients	O
from	O
a	B-Settings_Single_Center
comprehensive	I-Settings_Single_Center
cancer	I-Settings_Single_Center
center	I-Settings_Single_Center
ED	I-Settings_Single_Center
to	O
receive	O
INF	B-Design_Parallel_Group
(	I-Design_Parallel_Group
n	I-Design_Parallel_Group
=	I-Design_Parallel_Group
42	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
IVH	I-Design_Parallel_Group
(	I-Design_Parallel_Group
n	I-Design_Parallel_Group
=	I-Design_Parallel_Group
40	I-Design_Parallel_Group
)	I-Design_Parallel_Group
.	O

Trimethoprim-sulfamethoxazole	B-Design_Parallel_Group
versus	I-Design_Parallel_Group
vancomycin	I-Design_Parallel_Group
for	O
severe	O
infections	O
caused	O
by	O
meticillin	O
resistant	O
Staphylococcus	O
aureus	O
:	O
randomised	O
controlled	O
trial	O

The	O
study	O
was	O
completed	O
by	O
890	B-Sample_Size_Actual_at_Outcome_Analysis
(	I-Sample_Size_Actual_at_Outcome_Analysis
93.2	I-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
)	I-Sample_Size_Actual_at_Outcome_Analysis
participants	I-Sample_Size_Actual_at_Outcome_Analysis
in	I-Sample_Size_Actual_at_Outcome_Analysis
the	I-Sample_Size_Actual_at_Outcome_Analysis
half-dose	I-Sample_Size_Actual_at_Outcome_Analysis
group	I-Sample_Size_Actual_at_Outcome_Analysis
and	O
917	B-Sample_Size_Actual_at_Outcome_Analysis
(	I-Sample_Size_Actual_at_Outcome_Analysis
92.2	I-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
)	I-Sample_Size_Actual_at_Outcome_Analysis
in	I-Sample_Size_Actual_at_Outcome_Analysis
the	I-Sample_Size_Actual_at_Outcome_Analysis
full-dose	I-Sample_Size_Actual_at_Outcome_Analysis
group	I-Sample_Size_Actual_at_Outcome_Analysis
.	O

The	O
investigator	O
(	O
or	O
designee	O
)	O
obtained	O
the	O
unique	O
study	O
treatment	O
number	O
via	O
an	O
interactive	B-Randomization_Sequence_Generation_Method
voice/internet	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
.	O

Of	O
the	O
88	O
participants	O
in	O
the	O
safety	O
set	O
(	O
placebo	O
,	O
n	O
=	O
43	O
;	O
SHP465	O
MAS	O
,	O
n	O
=	O
45	O
)	O
,	O
87	O
were	O
included	O
in	O
the	O
full	O
analysis	O
set	O
(	O
placebo	O
,	O
n	O
=	O
42	O
;	O
SHP465	O
MAS	O
,	O
n	O
=	O
45	O
)	O
and	O
83	B-Sample_Size_Actual_at_Outcome_Analysis
completed	O
the	O
study	O
(	O
placebo	O
,	O
n	O
=	O
41	O
;	O
SHP465	O
MAS	O
,	O
n	O
=	O
42	O
)	O
.	O

Following	O
a	O
screening	O
visit	O
and	O
completion	O
of	O
the	O
run-in	O
period	O
assessments	O
,	O
participants	O
were	O
randomised	O
(	B-Randomization_Ratio
1:1:1:1:1:1	I-Randomization_Ratio
)	I-Randomization_Ratio
using	O
an	O
interactive	B-Randomization_Sequence_Generation_Method
voice	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
to	O
receive	O
oral	O
danirixin	O
hydrobromide	O
salt	O
tablets	O
(	O
5	O
,	O
10	O
,	O
25	O
,	O
35	O
or	O
50	O
mg	O
)	O
or	O
placebo	O
tablets	O
for	O
24	O
weeks	O
(	O
in	O
addition	O
to	O
COPD	O
standard-of-care	O
)	O
.	O

Methods	O
This	O
randomized	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
chronic-dosing	O
,	O
balanced	B-Randomization_Type_Block
incomplete-block	I-Randomization_Type_Block
,	O
placebo-controlled	O
,	O
crossover	B-Design_Crossover
study	O
compared	O
six	O
doses	O
of	O
GP	O
MDI	O
(	O
18	O
,	O
9	O
,	O
4.6	O
,	O
2.4	O
,	O
1.2	O
,	O
and	O
0.6	O
μg	O
,	O
twice	O
daily	O
[	O
BID	O
]	O
)	O
with	O
placebo	O
MDI	O
BID	O
and	O
open-label	B-Blinding_Open_Label
tiotropium	O
dry	O
powder	O
inhaler	O
(	O
18	O
μg	O
,	O
once	O
daily	O
[	O
QD	O
]	O
)	O
in	O
patients	O
with	O
moderate-to-severe	O
COPD	O
.	O

Central	B-Blinding_Object_Outcome_Assessors
reading	I-Blinding_Object_Outcome_Assessors
center	I-Blinding_Object_Outcome_Assessors
personnel	I-Blinding_Object_Outcome_Assessors
,	O
study	B-Blinding_Object_Others
vendors	I-Blinding_Object_Others
,	O
and	O
the	O
sponsor	B-Blinding_Object_Others
and	I-Blinding_Object_Others
its	I-Blinding_Object_Others
agents	I-Blinding_Object_Others
were	O
masked	O
to	O
study	O
eye	O
drug	O
assignment	O
.	O

The	O
dosing	O
data	O
in	O
the	O
open-label	B-Blinding_Open_Label
phase	O
will	O
inform	O
optimal	O
use	O
of	O
onabotulinumtoxinA	O
in	O
clinical	O
practice	O
(	O
ClinicalTrials.gov	O
:	O
NCT03261167	O
)	O
.	O

Assuming	O
an	O
8	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
withdrawal	I-Sample_Size_Calculation_Dropout_Rate_Value
rate	I-Sample_Size_Calculation_Dropout_Rate_Value
during	I-Sample_Size_Calculation_Dropout_Rate_Value
the	I-Sample_Size_Calculation_Dropout_Rate_Value
run-in	I-Sample_Size_Calculation_Dropout_Rate_Value
period	I-Sample_Size_Calculation_Dropout_Rate_Value
and	O
10	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
withdrawal	I-Sample_Size_Calculation_Dropout_Rate_Value
rate	I-Sample_Size_Calculation_Dropout_Rate_Value
during	I-Sample_Size_Calculation_Dropout_Rate_Value
the	I-Sample_Size_Calculation_Dropout_Rate_Value
study	I-Sample_Size_Calculation_Dropout_Rate_Value
period	I-Sample_Size_Calculation_Dropout_Rate_Value
,	O
it	O
was	O
aimed	O
to	O
enroll	O
~848	O
patients	O
into	O
the	O
4-week	O
run-in	O
period	O
in	O
order	O
to	O
randomize	O
780	O
patients	O
.	O

Non-inferiority	B-Design_Comparative_Intent_NonInferiority
was	O
to	O
be	O
declared	O
if	O
the	O
upper	O
bound	O
of	O
the	O
two-sided	O
95	O
%	O
CI	O
for	O
the	O
difference	O
in	O
DAS28-4	O
(	O
CRP	O
)	O
between	O
treatment	O
groups	O
was	O
<	O
0.6	O
.	O

Patients	B-Blinding_Object_Patients
and	O
investigators	B-Blinding_Object_Investigators
were	O
blind	O
to	O
treatment	O
by	O
providing	O
identical	O
prefilled	O
syringes	O
(	O
MSD	O
Pharmaceutics	O
)	O
.	O

A	O
Randomized	B-Randomization_Type_Simple
Trial	O
Evaluating	O
the	O
Efficacy	O
and	O
Safety	O
of	O
Fast-Acting	O
Insulin	O
Aspart	O
Compared	O
With	O
Insulin	O
Aspart	O
,	O
Both	O
in	O
Combination	O
With	O
Insulin	O
Degludec	O
With	O
or	O
Without	O
Metformin	O
,	O
in	O
Adults	O
With	O
Type	O
2	O
Diabetes	O
(	O
ONSET	O
9	O
)	O

A	O
randomised	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
phase	B-Design_Phase_3
III	I-Design_Phase_3
study	O
comparing	O
SB2	O
,	O
an	O
infliximab	O
biosimilar	O
,	O
to	O
the	O
infliximab	O
reference	O
product	O
Remicade	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
rheumatoid	O
arthritis	O
despite	O
methotrexate	O
therapy	O

Results	O
:	O
Of	O
89	B-Sample_Size_Actual_at_Enrollment
randomized	O
participants	O
,	O
83	B-Sample_Size_Actual_at_Outcome_Analysis
completed	O
the	O
study	O
(	O
placebo	O
,	O
n	O
=	O
41	O
;	O
SHP465	O
MAS	O
,	O
n	O
=	O
42	O
)	O
.	O

Methods	O
This	O
was	O
an	O
open	B-Blinding_Open_Label
label	I-Blinding_Open_Label
,	O
parallel	B-Design_Parallel_Group
,	O
one	B-Randomization_Ratio
to	I-Randomization_Ratio
one	I-Randomization_Ratio
randomised	O
controlled	O
trial	O
,	O
conducted	O
in	O
four	B-Settings_Multicenter
acute	I-Settings_Multicenter
care	I-Settings_Multicenter
hospitals	I-Settings_Multicenter
(	O
Rabin	O
Medical	O
Center	O
,	O
Petah-Tikva	O
(	O
192	O
patients	O
)	O
;	O
Rambam	O
Health	O
Care	O
Campus	O
(	O
38	O
patients	O
)	O
;	O
Holy	O
Family	O
Hospital	O
Nazareth	O
(	O
7	O
patients	O
)	O
;	O
Wolfson	O
Medical	O
Center	O
(	O
6	O
patients	O
)	O
)	O
in	O
Israel	B-Settings_Location
,	O
between	O
July	O
2007	O
and	O
April	O
2014	O
.	O

Assuming	O
5	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
of	I-Sample_Size_Calculation_Dropout_Rate_Value
women	I-Sample_Size_Calculation_Dropout_Rate_Value
were	I-Sample_Size_Calculation_Dropout_Rate_Value
non-evaluable	I-Sample_Size_Calculation_Dropout_Rate_Value
,	O
and	O
10	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
were	I-Sample_Size_Calculation_Dropout_Rate_Value
excluded	I-Sample_Size_Calculation_Dropout_Rate_Value
due	I-Sample_Size_Calculation_Dropout_Rate_Value
to	I-Sample_Size_Calculation_Dropout_Rate_Value
genotypic	I-Sample_Size_Calculation_Dropout_Rate_Value
resistance	I-Sample_Size_Calculation_Dropout_Rate_Value
,	O
target	O
enrollment	O
was	O
394	B-Sample_Size_Target
women	O
(	O
approximately	O
197	O
per	O
arm	O
)	O
.	O

The	O
trial	O
was	O
conducted	O
at	O
26	B-Settings_Multicenter
investigational	I-Settings_Multicenter
sites	I-Settings_Multicenter
(	O
Supplementary	O
Table	O
SI	O
)	O
in	O
the	O
following	O
countries/regions	O
:	O
mainland	B-Settings_Location
China	I-Settings_Location
,	I-Settings_Location
South	I-Settings_Location
Korea	I-Settings_Location
,	I-Settings_Location
Taiwan	I-Settings_Location
and	I-Settings_Location
Vietnam	I-Settings_Location
.	O

Interventions	O
Participants	O
were	O
randomized	O
1:2:2	B-Randomization_Ratio
to	O
receive	O
intravitreal	O
ranibizumab	O
,	O
0.5	O
mg	O
,	O
every	O
4	O
weeks	O
or	O
faricimab	O
,	O
6.0	O
mg	O
,	O
every	O
12	O
or	O
16	O
weeks	O
.	O

Methods	O
Study	O
design	O
This	O
was	O
a	O
randomized	B-Randomization_Type_Simple
,	O
double-blinded	B-Blinding_Double_Blind
,	O
dose-ranging	O
,	O
placebo-controlled	O
,	O
parallel	B-Design_Parallel_Group
group	I-Design_Parallel_Group
study	O
.	O

In	O
total	O
,	O
209	B-Sample_Size_Actual_at_Enrollment
patients	O
participated	O
in	O
this	O
study	O
:	O
104	O
received	O
tofacitinib	O
MR	O
11	O
mg	O
QD	O
,	O
and	O
105	O
received	O
tofacitinib	O
IR	O
5	O
mg	O
BID	O
.	O

A	O
Randomized	B-Randomization_Type_Simple
Phase	O
I	O
Study	O
of	O
Abemaciclib	O
in	O
Chinese	O
Patients	O
with	O
Advanced	O
and/or	O
Metastatic	O
Cancers	O

Aim	O
Phase	B-Design_Phase_3
III	I-Design_Phase_3
,	O
randomized	O
,	O
double‐blind	B-Blinding_Double_Blind
study	O
evaluating	O
the	O
efficacy	O
and	O
safety	O
of	O
ertugliflozin	O
in	O
Asian	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
inadequately	O
controlled	O
on	O
metformin	O
,	O
including	O
evaluation	O
in	O
the	O
China	O
subpopulation	O
.	O

Randomization	O
was	O
stratified	B-Randomization_Type_Stratified
by	O
sex	B-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
male/female	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
smoking	B-Randomization_Stratified_Criteria
status	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
smoker/non-smoker	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
disease	B-Randomization_Stratified_Criteria
diagnosis	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
newly	I-Randomization_Stratified_Criteria
diagnosed/recurrent	I-Randomization_Stratified_Criteria
disease	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
and	O
disease	B-Randomization_Stratified_Criteria
stage	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
Stage	I-Randomization_Stratified_Criteria
IIIB/Stage	I-Randomization_Stratified_Criteria
IV	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
.	O

The	O
active	O
and	O
placebo	O
drug	O
components	O
of	O
the	O
infusions	O
were	O
packaged	O
identically	O
into	O
numbered	O
treatment	O
packs	O
,	O
each	O
containing	O
5	O
mL	O
of	O
either	O
salbutamol	B-Design_Parallel_Group
sulphate	I-Design_Parallel_Group
BP	I-Design_Parallel_Group
(	I-Design_Parallel_Group
1	I-Design_Parallel_Group
mg/mL	I-Design_Parallel_Group
in	I-Design_Parallel_Group
a	I-Design_Parallel_Group
sterile	I-Design_Parallel_Group
isotonic	I-Design_Parallel_Group
solution	I-Design_Parallel_Group
,	I-Design_Parallel_Group
GlaxoSmithKline	I-Design_Parallel_Group
,	I-Design_Parallel_Group
Middlesex	I-Design_Parallel_Group
,	I-Design_Parallel_Group
UK	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
(	O
0·9	O
%	O
sterile	O
sodium	O
chloride	O
)	O
.	O

Randomization	O
was	O
performed	O
using	O
an	B-Randomization_Sequence_Generation_Method
electronic	I-Randomization_Sequence_Generation_Method
random	I-Randomization_Sequence_Generation_Method
numbers	I-Randomization_Sequence_Generation_Method
assignment	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
by	O
a	O
Nutritionist	O
who	O
was	O
not	O
involved	O
in	O
the	O
study	O
.	O

This	O
study	O
was	O
performed	O
at	O
the	O
Duke	B-Settings_Single_Center
Family	I-Settings_Single_Center
Planning	I-Settings_Single_Center
Clinic	I-Settings_Single_Center
at	O
the	O
Duke	O
Gynecology	O
Outpatient	O
Clinic	O
.	O

The	O
treatment-group	O
assignments	O
were	O
double-masked	B-Blinding_Double_Blind
.	O

After	O
randomisation	O
to	O
the	O
ursodeoxycholic	B-Design_Parallel_Group
acid	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
comparison	O
,	O
an	O
online	O
prescription	O
form	O
was	O
generated	O
for	O
printing	O
.	O

Among	O
805	O
patients	O
screened	O
,	O
584	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomised	O
(	O
SB2	O
,	O
N=291	O
and	O
INF	O
,	O
N=293	O
,	O
figure	O
1	O
)	O
.	O

This	O
study	O
was	O
conducted	O
in	O
a	O
12-week	O
,	O
double-blind	B-Blinding_Double_Blind
period	O
followed	O
by	O
an	O
open-label	B-Blinding_Open_Label
extension	O
period	O
designed	O
to	O
characterize	O
the	O
safety	O
and	O
efficacy	O
of	O
52	O
weeks	O
of	O
evolocumab	O
treatment	O
.	O

Concomitant	O
use	O
of	O
centrally	O
acting	O
muscle	O
relaxants	O
was	O
allowed	O
if	O
the	O
patient	O
had	O
been	O
using	O
them	O
before	O
participating	O
in	O
the	O
trial	O
,	O
but	O
the	O
dose	O
was	O
not	O
to	O
be	O
changed	O
from	O
the	O
screening	O
phase	O
until	O
the	O
completion	O
of	O
the	O
double-blind	B-Blinding_Double_Blind
phase	O
.	O

Methods	O
Study	O
design	O
and	O
participants	O
We	O
undertook	O
a	O
multicentre	B-Settings_Multicenter
,	O
pragmatic	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
,	O
parallel-group	B-Design_Parallel_Group
,	O
randomised	O
trial	O
at	O
46	B-Settings_Multicenter
UK	B-Settings_Location
intensive-care	I-Settings_Multicenter
units	I-Settings_Multicenter
between	O
December	O
,	O
2006	O
,	O
and	O
March	O
,	O
2010	O
.	O

Randomisation	O
was	O
stratified	B-Randomization_Type_Stratified
by	O
the	B-Randomization_Stratified_Criteria
gestation	I-Randomization_Stratified_Criteria
at	I-Randomization_Stratified_Criteria
recruitment	I-Randomization_Stratified_Criteria
for	I-Randomization_Stratified_Criteria
the	I-Randomization_Stratified_Criteria
ursodeoxycholic	I-Randomization_Stratified_Criteria
acid	I-Randomization_Stratified_Criteria
comparison	I-Randomization_Stratified_Criteria
and	O
by	O
trial	B-Randomization_Stratified_Criteria
centre	I-Randomization_Stratified_Criteria
for	O
both	O
comparisons	O
.	O

In	O
all	O
analyses	O
,	O
regression	O
methods	O
were	O
used	O
and	O
adjustment	O
made	O
for	O
stratification	B-Randomization_Type_Stratified
variables	O
(	O
gestation	B-Randomization_Stratified_Criteria
at	I-Randomization_Stratified_Criteria
recruitment	I-Randomization_Stratified_Criteria
for	I-Randomization_Stratified_Criteria
ursodeoxycholic	I-Randomization_Stratified_Criteria
acid	I-Randomization_Stratified_Criteria
trial	I-Randomization_Stratified_Criteria
only	O
,	O
and	O
study	B-Randomization_Stratified_Criteria
centre	I-Randomization_Stratified_Criteria
for	O
both	O
trials	O
)	O
and	O
for	O
potential	O
confounders	O
(	O
baseline	O
bile	O
acid	O
levels	O
,	O
and	O
others	O
where	O
the	O
imbalance	O
was	O
substantial	O
)	O
.	O

Results	O
529	B-Sample_Size_Actual_at_Enrollment
patients	O
(	O
mean	O
age	O
72	O
)	O
were	O
enrolled	O
,	O
266	O
to	O
the	O
intensive	O
target	O
arm	O
and	O
263	O
to	O
the	O
standard	O
target	O
arm	O
,	O
of	O
whom	O
379	B-Sample_Size_Actual_at_Outcome_Analysis
were	O
included	O
in	O
the	O
primary	O
analysis	O
(	O
182	O
(	O
68	O
%	O
)	O
intensive	O
arm	O
;	O
197	O
(	O
75	O
%	O
)	O
standard	O
arm	O
)	O
.	O

At	O
completion	O
of	O
the	O
24-week	O
randomised	O
treatment	O
period	O
,	O
all	O
patients	O
were	O
offered	O
open-label	B-Blinding_Open_Label
treatment	O
with	O
TCZ	O
8	O
mg/kg	O
plus	O
MTX	O
.	O

Methods	O
This	O
randomized	O
clinical	O
trial	O
was	O
conducted	O
at	O
57	B-Settings_Multicenter
US	B-Settings_Location
centers	I-Settings_Multicenter
.	O

Due	O
to	O
lower	O
than	O
expected	O
recruitment	O
,	O
1950	B-Sample_Size_Actual_at_Enrollment
participants	O
were	O
enrolled	O
in	O
the	O
study	O
instead	O
of	O
the	O
planned	O
2190	O
(	O
Fig	O
.	O

Twenty-six	B-Settings_Multicenter
clinical	I-Settings_Multicenter
centers	I-Settings_Multicenter
(	O
23	B-Settings_Location
in	I-Settings_Location
the	I-Settings_Location
United	I-Settings_Location
States	I-Settings_Location
and	I-Settings_Location
one	I-Settings_Location
center	I-Settings_Location
each	I-Settings_Location
in	I-Settings_Location
Australia	I-Settings_Location
,	I-Settings_Location
Canada	I-Settings_Location
,	I-Settings_Location
and	I-Settings_Location
the	I-Settings_Location
United	I-Settings_Location
Kingdom	I-Settings_Location
)	O
participated	O
in	O
the	O
trial	O
(	O
see	O
Appendix	O
1	O
,	O
available	O
at	O
http	O
:	O
//aaojournal.org	O
)	O
.	O

Patients	O
using	O
oral	O
β-agonists	O
,	O
inhaled	O
LABAs	O
,	O
LABA/ICS	O
combination	O
inhalers	O
,	O
phosphodiesterase	O
inhibitors	O
,	O
mast	O
cell	O
stabilizers	O
,	O
leukotriene	O
antagonists	O
,	O
or	O
tiotropium	O
,	O
discontinued	O
these	O
for	O
the	O
duration	O
of	O
the	O
trial	O
and	O
instead	O
received	O
open-label	B-Blinding_Open_Label
ipratropium	O
four	O
times	O
daily	O
during	O
the	O
run-in	O
period	O
.	O

Study	O
design	O
This	O
study	O
(	O
trial	O
registration	O
:	O
ClinicalTrials.gov	O
NCT03469336	O
)	O
was	O
conducted	O
between	O
24	O
April	O
2018	O
and	O
20	O
March	O
2019	O
at	O
two	B-Settings_Multicenter
sites	I-Settings_Multicenter
in	O
Germany	B-Settings_Location
.	O

SUBJECTS	O
AND	O
METHODS	O
Study	O
design	O
and	O
procedures	O
This	O
phase	B-Design_Phase_1
I	I-Design_Phase_1
,	O
randomised	O
,	O
open‐label	B-Blinding_Open_Label
,	O
2‐arm	O
,	O
parallel‐group	B-Design_Parallel_Group
study	O
was	O
conducted	O
at	O
2	B-Settings_Multicenter
US	I-Settings_Multicenter
PPD	I-Settings_Multicenter
Development	I-Settings_Multicenter
sites	I-Settings_Multicenter
(	O
Austin	B-Settings_Location
,	I-Settings_Location
TX	I-Settings_Location
;	I-Settings_Location
Las	I-Settings_Location
Vegas	I-Settings_Location
,	I-Settings_Location
NV	I-Settings_Location
)	O
.	O

Objectives	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
IL-1β	O
inhibition	O
with	O
canakinumab	B-Design_Parallel_Group
versus	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
on	O
arterial	O
structure	O
and	O
function	O
,	O
determined	O
by	O
magnetic	O
resonance	O
imaging	O
.	O

GP	O
MDI	O
18	O
and	O
9	O
μg	O
were	O
non-inferior	B-Design_Comparative_Intent_NonInferiority
to	O
open-label	B-Blinding_Open_Label
tiotropium	O
for	O
peak	O
change	O
from	O
baseline	O
in	O
FEV1	O
on	O
Day	O
1	O
,	O
but	O
this	O
was	O
not	O
replicated	O
on	O
Days	O
7	O
and	O
14	O
.	O

Forty-two	B-Sample_Size_Actual_at_Outcome_Analysis
completed	O
the	O
study	O
,	O
with	O
one	O
patient	O
on	O
golimumab/MTX	O
discontinuing	O
due	O
to	O
an	O
adverse	O
event	O
(	O
asthma	O
exacerbation	O
)	O
,	O
and	O
another	O
patient	O
on	O
placebo/MTX	O
discontinuing	O
due	O
to	O
an	O
insufficient	O
therapeutic	O
effect	O
(	O
figure	O
1	O
)	O
.	O

For	O
the	O
third	O
hypothesis	O
,	O
a	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
margin	O
of	O
10	O
%	O
was	O
selected	O
based	O
on	O
previous	O
research	O
indicating	O
that	O
the	O
threshold	O
for	O
reproducibility	O
of	O
OCT	O
evaluation	O
of	O
retinal	O
thickness	O
is	O
10	O
%	O
and	O
that	O
a	O
20	O
%	O
change	O
is	O
associated	O
with	O
meaningful	O
changes	O
in	O
visual	O
acuity	O
.	O

The	O
study	O
was	O
undertaken	O
at	O
9	B-Settings_Multicenter
centers	I-Settings_Multicenter
in	O
Canada	B-Settings_Location
,	I-Settings_Location
the	I-Settings_Location
United	I-Settings_Location
Kingdom	I-Settings_Location
,	I-Settings_Location
the	I-Settings_Location
United	I-Settings_Location
States	I-Settings_Location
,	I-Settings_Location
Germany	I-Settings_Location
,	I-Settings_Location
and	I-Settings_Location
Israel	I-Settings_Location
,	O
in	O
compliance	O
with	O
the	O
principles	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
according	O
to	O
Good	O
Clinical	O
Practice	O
guidelines	O
.	O

The	O
study	O
was	O
conducted	O
at	O
two	B-Settings_Multicenter
clinical	I-Settings_Multicenter
sites	I-Settings_Multicenter
in	O
China	B-Settings_Location
from	O
14	O
August	O
2017	O
(	O
first	O
patient	O
enrolled	O
)	O
to	O
data	O
cut-off	O
on	O
23	O
November	O
2018	O
;	O
3	O
patients	O
were	O
still	O
on	O
treatment	O
at	O
the	O
time	O
of	O
data	O
cut-off	O
.	O

Methods	O
This	O
is	O
a	O
phase	B-Design_Phase_3
III	I-Design_Phase_3
,	O
randomised	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
multinational	O
,	O
multicentre	B-Settings_Multicenter
parallel	B-Design_Parallel_Group
group	I-Design_Parallel_Group
study	O
.	O

Treatment	O
randomisation	O
and	O
blinding	O
Women	O
were	O
randomised	O
in	O
a	O
1:1	B-Randomization_Ratio
ratio	O
to	O
treatment	O
with	O
either	O
follitropin	O
delta	O
(	O
Rekovelle	O
;	O
Ferring	O
Pharmaceuticals	O
,	O
Saint-Prex	O
,	O
Switzerland	O
)	O
or	O
follitropin	O
alfa	O
(	O
Gonal-f	O
;	O
Merck	O
Serono	O
,	O
Geneva	O
,	O
Switzerland	O
)	O
via	O
a	B-Randomization_Sequence_Generation_Method
central	I-Randomization_Sequence_Generation_Method
computer-generated	I-Randomization_Sequence_Generation_Method
randomisation	I-Randomization_Sequence_Generation_Method
list	I-Randomization_Sequence_Generation_Method
,	O
prepared	O
by	O
an	B-Randomization_Personnel
independent	I-Randomization_Personnel
statistician	I-Randomization_Personnel
.	O

Children	O
presenting	O
at	O
the	B-Settings_Single_Center
study	I-Settings_Single_Center
hospital	I-Settings_Single_Center
with	O
signs	O
of	O
pneumonia	O
had	O
their	O
diagnosis	O
confirmed	O
radiographically	O
.	O

Design	O
Open	B-Blinding_Open_Label
label	I-Blinding_Open_Label
randomised	O
controlled	O
trial	O
.	O

Conclusion	O
:	O
Evolocumab	O
was	O
superior	O
to	O
ezetimibe	O
in	O
reducing	O
LDL-C	O
during	O
the	O
12-week	O
double-blind	B-Blinding_Double_Blind
period	O
in	O
this	O
population	O
of	O
Japanese	O
patients	O
with	O
statin	O
intolerance	O
,	O
with	O
efficacy	O
and	O
safety	O
results	O
maintained	O
for	O
1	O
year	O
.	O

Non-inferiority	B-Design_Comparative_Intent_NonInferiority
testing	O
was	O
not	O
performed	O
for	O
time	O
to	O
onset	O
of	O
action	O
on	O
Day	O
1	O
,	O
for	O
which	O
cumulative	O
incidence	O
Kaplan–Meier	O
curves	O
were	O
plotted	O
.	O

In	O
total	O
,	O
93	B-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
of	I-Sample_Size_Actual_at_Outcome_Analysis
participants	I-Sample_Size_Actual_at_Outcome_Analysis
in	I-Sample_Size_Actual_at_Outcome_Analysis
the	I-Sample_Size_Actual_at_Outcome_Analysis
teplizumab	I-Sample_Size_Actual_at_Outcome_Analysis
group	I-Sample_Size_Actual_at_Outcome_Analysis
(	I-Sample_Size_Actual_at_Outcome_Analysis
41	I-Sample_Size_Actual_at_Outcome_Analysis
of	I-Sample_Size_Actual_at_Outcome_Analysis
44	I-Sample_Size_Actual_at_Outcome_Analysis
)	I-Sample_Size_Actual_at_Outcome_Analysis
and	O
88	B-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
of	I-Sample_Size_Actual_at_Outcome_Analysis
participants	I-Sample_Size_Actual_at_Outcome_Analysis
in	I-Sample_Size_Actual_at_Outcome_Analysis
the	I-Sample_Size_Actual_at_Outcome_Analysis
placebo	I-Sample_Size_Actual_at_Outcome_Analysis
group	I-Sample_Size_Actual_at_Outcome_Analysis
(	I-Sample_Size_Actual_at_Outcome_Analysis
28	I-Sample_Size_Actual_at_Outcome_Analysis
of	I-Sample_Size_Actual_at_Outcome_Analysis
32	I-Sample_Size_Actual_at_Outcome_Analysis
)	I-Sample_Size_Actual_at_Outcome_Analysis
completed	O
the	O
14-day	O
course	O
of	O
the	O
assigned	O
trial	O
agent	O
.	O

Results	O
Overall	O
,	O
726	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomized	O
(	O
tedizolid	O
,	O
n	O
=	O
366	O
;	O
linezolid	O
,	O
n	O
=	O
360	O
)	O
.	O

The	O
study	O
planned	O
to	O
enroll	O
approximately	O
440	B-Sample_Size_Target
subjects	O
(	O
220	O
per	O
group	O
)	O
to	O
provide	O
a	O
sample	O
size	O
sufficient	O
to	O
detect	O
infrequent	O
local	O
reactions	O
,	O
systemic	O
events	O
,	O
and	O
AEs	O
(	O
probability	O
of	O
0.89	O
and	O
>	O
0.999	O
of	O
detecting	O
≥1	O
event	O
with	O
a	O
true	O
rate	O
of	O
1	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
and	O
≥	B-Sample_Size_Calculation_Alpha_Value
5	I-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
,	O
respectively	O
,	O
in	O
a	O
group	O
of	O
200	O
subjects	O
)	O
.	O

Findings	O
We	O
randomly	O
assigned	O
162	B-Sample_Size_Actual_at_Enrollment
patients	I-Sample_Size_Actual_at_Enrollment
to	I-Sample_Size_Actual_at_Enrollment
the	I-Sample_Size_Actual_at_Enrollment
salbutamol	I-Sample_Size_Actual_at_Enrollment
group	I-Sample_Size_Actual_at_Enrollment
and	I-Sample_Size_Actual_at_Enrollment
164	I-Sample_Size_Actual_at_Enrollment
to	I-Sample_Size_Actual_at_Enrollment
the	I-Sample_Size_Actual_at_Enrollment
placebo	I-Sample_Size_Actual_at_Enrollment
group	I-Sample_Size_Actual_at_Enrollment
.	O

STUDY	O
DESIGN	O
,	O
SIZE	O
,	O
DURATION	O
Randomised	O
,	O
controlled	O
,	O
multi-centre	B-Settings_Multicenter
,	O
assessor-blind	B-Blinding_Single_Blind
trial	O
conducted	O
in	O
1009	B-Sample_Size_Actual_at_Enrollment
Asian	I-Sample_Size_Actual_at_Enrollment
patients	I-Sample_Size_Actual_at_Enrollment
from	O
mainland	B-Settings_Location
China	I-Settings_Location
,	I-Settings_Location
South	I-Settings_Location
Korea	I-Settings_Location
,	I-Settings_Location
Vietnam	I-Settings_Location
and	I-Settings_Location
Taiwan	I-Settings_Location
,	O
undergoing	O
their	O
first	O
IVF/ICSI	O
cycle	O
.	O

Participants	O
were	O
randomized	O
in	O
equal	O
proportions	O
to	O
a	O
daprodustat	B-Design_Parallel_Group
dose	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
within	O
each	O
stratum	O
without	O
using	O
prior	O
rhEPO	O
dose	O
to	O
determine	O
the	O
daprodustat	O
dose	O
.	O

Methods	O
Multicentre	B-Settings_Multicenter
,	O
investigator-initiated	O
,	O
randomised	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
,	O
parallel-design	B-Design_Parallel_Group
phase	B-Design_Phase_3
3b	I-Design_Phase_3
trial	O
in	O
11	B-Settings_Multicenter
Portuguese	B-Settings_Location
rheumatology	I-Settings_Multicenter
centres	I-Settings_Multicenter
.	O

The	O
web-based	B-Randomization_Sequence_Generation_Method
,	I-Randomization_Sequence_Generation_Method
central	I-Randomization_Sequence_Generation_Method
computer	I-Randomization_Sequence_Generation_Method
randomization	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
used	O
permuted	B-Randomization_Type_Block
block	I-Randomization_Type_Block
allocation	O
(	O
block	B-Randomization_Block_Size
size	I-Randomization_Block_Size
4	I-Randomization_Block_Size
)	O
with	O
stratification	B-Randomization_Type_Stratified
by	O
gestational	B-Randomization_Stratified_Criteria
age	I-Randomization_Stratified_Criteria
at	I-Randomization_Stratified_Criteria
enrollment	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
20	I-Randomization_Stratified_Criteria
to	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
28	I-Randomization_Stratified_Criteria
weeks	I-Randomization_Stratified_Criteria
;	I-Randomization_Stratified_Criteria
28	I-Randomization_Stratified_Criteria
to	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
31	I-Randomization_Stratified_Criteria
weeks	I-Randomization_Stratified_Criteria
;	I-Randomization_Stratified_Criteria
31	I-Randomization_Stratified_Criteria
to	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
34	I-Randomization_Stratified_Criteria
weeks	I-Randomization_Stratified_Criteria
;	I-Randomization_Stratified_Criteria
34	I-Randomization_Stratified_Criteria
to	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
37	I-Randomization_Stratified_Criteria
weeks	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
and	O
NRTI	B-Randomization_Stratified_Criteria
backbone	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
lamivudine/zidovudine	I-Randomization_Stratified_Criteria
or	I-Randomization_Stratified_Criteria
alternative	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
locally-supplied	I-Randomization_Stratified_Criteria
NRTI	I-Randomization_Stratified_Criteria
regimen	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
and	O
dynamic	B-Randomization_Stratified_Criteria
balancing	I-Randomization_Stratified_Criteria
by	I-Randomization_Stratified_Criteria
study	I-Randomization_Stratified_Criteria
site	I-Randomization_Stratified_Criteria
.	O

Long‐term	O
(	O
up	O
to	O
64	O
weeks	O
)	O
efficacy	O
and	O
safety	O
of	O
erenumab	O
in	O
patients	O
with	O
episodic	O
migraine	O
has	O
been	O
demonstrated	O
in	O
a	O
global	O
open‐label	O
extension	O
study.22	O
A	O
randomized	B-Randomization_Type_Simple
,	O
29-day	O
,	O
dose-ranging	O
,	O
efficacy	O
and	O
safety	O
study	O
of	O
daprodustat	O
,	O
administered	O
three	O
times	O
weekly	O
in	O
patients	O
with	O
anemia	O
on	O
hemodialysis	O

Randomisation	O
was	O
stratified	B-Randomization_Type_Stratified
by	O
age	B-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
35	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
35–37	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
38–40	I-Randomization_Stratified_Criteria
years	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
.	O

The	O
study	O
comprised	O
a	O
≤3‐week	O
screening	O
phase	O
,	O
4‐week	O
baseline	O
phase	O
,	O
24‐week	O
double‐blind	B-Blinding_Double_Blind
treatment	O
phase	O
(	O
DBTP	O
)	O
,	O
76‐week	O
open‐label	O
treatment	O
phase	O
(	O
increased	O
from	O
52	O
weeks	O
after	O
a	O
protocol	O
amendment	O
)	O
,	O
and	O
12‐week	O
safety	O
follow‐up	O
phase	O
(	O
16	O
weeks	O
after	O
the	O
last	O
dose	O
of	O
investigational	O
product	O
)	O
(	O
Supporting	O
Fig	O
.	O

Findings	O
1524	B-Sample_Size_Actual_at_Enrollment
children	I-Sample_Size_Actual_at_Enrollment
were	I-Sample_Size_Actual_at_Enrollment
assigned	I-Sample_Size_Actual_at_Enrollment
to	I-Sample_Size_Actual_at_Enrollment
receive	I-Sample_Size_Actual_at_Enrollment
vitamin	I-Sample_Size_Actual_at_Enrollment
D3	I-Sample_Size_Actual_at_Enrollment
and	I-Sample_Size_Actual_at_Enrollment
1522	I-Sample_Size_Actual_at_Enrollment
placebo	I-Sample_Size_Actual_at_Enrollment
.	O

This	O
original	O
sample	O
size	O
was	O
chosen	O
based	O
on	O
the	O
assumption	O
that	O
16	O
subjects	O
per	O
treatment	O
group	O
(	O
32	B-Sample_Size_Required
subjects	O
total	O
)	O
,	O
would	O
provide	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
35	O
%	O
reduction	O
from	O
baseline	O
in	O
proteinuria	O
at	O
week	O
16	O
with	O
an	O
SD	O
of	O
50	O
%	O
and	O
a	B-Sample_Size_Calculation_Alpha_Value
two-sided	I-Sample_Size_Calculation_Alpha_Value
0.05	I-Sample_Size_Calculation_Alpha_Value
significance	I-Sample_Size_Calculation_Alpha_Value
level	I-Sample_Size_Calculation_Alpha_Value
.	O

Results	O
STAIRWAY	O
Enrollment	O
and	O
Patient	O
Disposition	O
STAIRWAY	O
enrolled	O
76	B-Sample_Size_Actual_at_Enrollment
anti-VEGF	O
treatment-naive	O
patients	O
with	O
nAMD	O
(	O
Figure	O
1	O
and	O
eFigure	O
1	O
in	O
Supplement	O
2	O
)	O
.	O

Randomization	O
Patients	O
were	O
randomized	B-Randomization_Type_Simple
1:1	B-Randomization_Ratio
to	O
receive	O
oral	B-Design_Parallel_Group
abemaciclib	I-Design_Parallel_Group
at	I-Design_Parallel_Group
150	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
or	I-Design_Parallel_Group
200	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
.	O

The	O
research	O
nurse	O
ascertained	O
treatment	O
allocation	O
either	O
by	O
telephone	B-Allocation_Concealment_Method
or	I-Allocation_Concealment_Method
online	I-Allocation_Concealment_Method
.	O

Randomisation	O
Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
intravenous	B-Design_Parallel_Group
rhEPO	I-Design_Parallel_Group
40	I-Design_Parallel_Group
000	I-Design_Parallel_Group
IU	I-Design_Parallel_Group
or	I-Design_Parallel_Group
matching	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
(	O
1:1	B-Randomization_Ratio
ratio	O
)	O
fortnightly	O
for	O
12	O
months	O
.	O

The	O
trial	O
included	O
165	B-Settings_Multicenter
sites	I-Settings_Multicenter
across	O
17	B-Settings_Location
countries	I-Settings_Location
(	O
Supplementary	O
Data	O
)	O
.	O

Results	O
46	B-Settings_Multicenter
study	I-Settings_Multicenter
sites	I-Settings_Multicenter
participated	O
in	O
recruitment	O
;	O
a	O
further	O
25	O
sites	O
obtained	O
approval	O
to	O
start	O
the	O
trial	O
,	O
but	O
were	O
unable	O
to	O
do	O
so	O
before	O
recruitment	O
was	O
stopped	O
.	O

Each	O
participant	O
received	O
the	O
following	O
six	O
treatments	O
on	O
up	O
to	O
three	O
comparable	O
plaques	O
(	O
six	O
treatment	O
areas	O
)	O
once	O
daily	O
for	O
18	O
days	O
:	O
three	B-Design_Parallel_Group
topical	I-Design_Parallel_Group
doses	I-Design_Parallel_Group
(	I-Design_Parallel_Group
2.3	I-Design_Parallel_Group
%	I-Design_Parallel_Group
,	I-Design_Parallel_Group
0.8	I-Design_Parallel_Group
%	I-Design_Parallel_Group
and	I-Design_Parallel_Group
0.23	I-Design_Parallel_Group
%	I-Design_Parallel_Group
)	I-Design_Parallel_Group
of	I-Design_Parallel_Group
PF‐06763809	I-Design_Parallel_Group
,	I-Design_Parallel_Group
the	I-Design_Parallel_Group
PF‐06763809	I-Design_Parallel_Group
vehicle	I-Design_Parallel_Group
and	I-Design_Parallel_Group
two	I-Design_Parallel_Group
active	I-Design_Parallel_Group
comparators	I-Design_Parallel_Group
[	I-Design_Parallel_Group
0.1	I-Design_Parallel_Group
%	I-Design_Parallel_Group
betamethasone	I-Design_Parallel_Group
1	I-Design_Parallel_Group
mg/g	I-Design_Parallel_Group
and	I-Design_Parallel_Group
calcipotriol	I-Design_Parallel_Group
0.005	I-Design_Parallel_Group
%	I-Design_Parallel_Group
(	I-Design_Parallel_Group
50	I-Design_Parallel_Group
µg/mL	I-Design_Parallel_Group
)	I-Design_Parallel_Group
]	I-Design_Parallel_Group
.	O

Methods	O
:	O
MiniSTONE-2	O
(	O
Clinicaltrials.gov	O
:	O
NCT03629184	O
)	O
was	O
a	O
double-blind	B-Blinding_Double_Blind
,	O
randomized	O
,	O
active	O
controlled	O
trial	O
enrolling	O
children	O
1–	O
<	O
12	O
years	O
old	O
with	O
a	O
clinical	O
diagnosis	O
of	O
influenza	O
.	O

Patients	O
Patients	O
were	O
recruited	O
from	O
99	B-Settings_Multicenter
sites	I-Settings_Multicenter
in	O
Canada	B-Settings_Location
,	I-Settings_Location
Israel	I-Settings_Location
,	I-Settings_Location
and	I-Settings_Location
the	I-Settings_Location
United	I-Settings_Location
States	I-Settings_Location
between	O
December	O
2015	O
and	O
December	O
2016	O
.	O

Results	O
One-hundred	O
ninety-five	O
subjects	O
were	O
screened	O
,	O
and	O
23	B-Sample_Size_Actual_at_Enrollment
participants	O
were	O
included	O
in	O
the	O
study	O
.	O

We	O
used	O
a	B-Randomization_Sequence_Generation_Method
central	I-Randomization_Sequence_Generation_Method
computer	I-Randomization_Sequence_Generation_Method
generated	I-Randomization_Sequence_Generation_Method
random	I-Randomization_Sequence_Generation_Method
number	I-Randomization_Sequence_Generation_Method
list	I-Randomization_Sequence_Generation_Method
to	O
randomise	O
patients	O
to	O
treatment	O
with	O
trimethoprim-sulfamethoxazole	B-Design_Parallel_Group
or	I-Design_Parallel_Group
vancomycin	I-Design_Parallel_Group
.	O

The	O
study	O
was	O
a	O
randomised	B-Randomization_Type_Simple
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
,	O
parallel-group	B-Design_Parallel_Group
study	O
.	O

This	O
phase	B-Design_Phase_3
3	I-Design_Phase_3
,	O
randomized	O
,	O
double-blind	B-Blinding_Double_Blind
trial	O
in	O
Japanese	B-Settings_Location
patients	O
with	O
statin	O
intolerance	O
aimed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
evolocumab	B-Design_Parallel_Group
vs.	I-Design_Parallel_Group
ezetimibe	I-Design_Parallel_Group
in	O
lowering	O
low-density	O
lipoprotein-cholesterol	O
(	O
LDL-C	O
)	O
.	O

Statistical	O
Analysis	O
Sample	O
Size	O
The	O
planned	O
sample	O
size	O
for	O
the	O
double-blind	O
comparison	O
was	O
60	B-Sample_Size_Target
patients	O
,	O
of	O
whom	O
40	O
were	O
for	O
evolocumab	O
(	O
n	O
=	O
20	O
at	O
Q2W	O
and	O
n	O
=	O
20	O
at	O
Q4W	O
)	O
and	O
20	O
were	O
for	O
ezetimibe	O
(	O
n	O
=	O
10	O
at	O
Q2W	O
and	O
n	O
=	O
10	O
at	O
Q4W	O
)	O
.	O

The	O
upper	O
bound	O
of	O
the	O
95	O
%	O
CI	O
was	O
greater	O
than	O
the	O
prespecified	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
margin	O
of	O
0.6	O
;	O
hence	O
,	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
of	O
tofacitinib	O
MR	O
11	O
mg	O
QD	O
relative	O
to	O
IR	O
5	O
mg	O
BID	O
was	O
not	O
met	O
(	O
Fig	O
.	O

Methods	O
Study	O
design	O
and	O
treatment	O
This	O
phase	B-Design_Phase_3
3	I-Design_Phase_3
,	O
randomized	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
fixed-dose	O
study	O
in	O
children	O
aged	O
6–12	O
years	O
with	O
ADHD	O
was	O
conducted	O
at	O
27	B-Settings_Multicenter
sites	I-Settings_Multicenter
in	O
the	O
United	B-Settings_Location
States	I-Settings_Location
between	O
December	O
9	O
,	O
2017	O
,	O
and	O
June	O
7	O
,	O
2018	O
.	O

No	O
dose	O
of	O
GP	O
MDI	O
demonstrated	O
non-inferiority	O
to	O
open-label	B-Blinding_Open_Label
tiotropium	O
with	O
the	O
lower	O
bound	O
of	O
the	O
95	O
%	O
CI	O
exceeding	O
the	O
clinically	O
relevant	O
difference	O
of	O
−100	O
mL	O
in	O
FEV1	O
AUC0–12	O
on	O
Day	O
14	O
(	O
see	O
Additional	O
file	O
1	O
:	O
Figure	O
S2	O
)	O
.	O

Randomization	O
and	O
masking	O
Patients	O
were	O
randomly	B-Randomization_Type_Simple
assigned	I-Randomization_Type_Simple
in	O
a	O
1:1	B-Randomization_Ratio
ratio	O
to	O
receive	O
linagliptin/metformin	B-Design_Parallel_Group
2.5/850	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
every	I-Design_Parallel_Group
12	I-Design_Parallel_Group
h	I-Design_Parallel_Group
+	I-Design_Parallel_Group
lifestyle	I-Design_Parallel_Group
modification	I-Design_Parallel_Group
program	I-Design_Parallel_Group
(	I-Design_Parallel_Group
LM	I-Design_Parallel_Group
group	I-Design_Parallel_Group
)	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
to	I-Design_Parallel_Group
continue	I-Design_Parallel_Group
with	I-Design_Parallel_Group
metformin	I-Design_Parallel_Group
850	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
every	I-Design_Parallel_Group
12	I-Design_Parallel_Group
h	I-Design_Parallel_Group
+	I-Design_Parallel_Group
lifestyle	I-Design_Parallel_Group
modification	I-Design_Parallel_Group
program	I-Design_Parallel_Group
(	I-Design_Parallel_Group
M	I-Design_Parallel_Group
group	I-Design_Parallel_Group
)	I-Design_Parallel_Group
.	O

The	O
study	O
was	O
conducted	O
at	O
13	B-Settings_Multicenter
investigational	I-Settings_Multicenter
sites	I-Settings_Multicenter
in	O
the	O
United	B-Settings_Location
States	I-Settings_Location
from	O
January	O
2019	O
through	O
June	O
2019	O
.	O

Setting	O
Nine	B-Settings_Multicenter
consultant	I-Settings_Multicenter
led	I-Settings_Multicenter
maternity	I-Settings_Multicenter
units	I-Settings_Multicenter
,	O
United	B-Settings_Location
Kingdom	I-Settings_Location
.	O

Results	O
:	O
Out	O
of	O
113	O
women	O
screened	O
for	O
this	O
study	O
;	O
96	B-Sample_Size_Actual_at_Enrollment
women	I-Sample_Size_Actual_at_Enrollment
were	O
recruited	O
,	O
enrolled	O
and	O
randomized	O
to	O
study	O
treatment	O
arm	O
from	O
August	O
2016	O
to	O
June	O
2018	O
.	O

Results	O
Subjects	O
and	O
Exposure	O
Between	O
January	O
23	O
,	O
2018	O
and	O
March	O
5	O
,	O
2019	O
,	O
804	O
subjects	O
were	O
screened	O
and	O
627	B-Sample_Size_Actual_at_Enrollment
were	O
randomized	O
in	O
a	O
1:1	O
ratio	O
(	O
ITT	O
population	O
;	O
MB02	O
:	O
315	O
subjects	O
;	O
EU-bevacizumab	O
:	O
312	O
subjects	O
)	O
.	O

Ursodeoxycholic	O
acid	O
versus	O
placebo	O
,	O
and	O
early	O
term	O
delivery	O
versus	O
expectant	O
management	O
,	O
in	O
women	O
with	O
intrahepatic	O
cholestasis	O
of	O
pregnancy	O
:	O
semifactorial	B-Design_Factorial
randomised	O
clinical	O
trial	O

Intubated	O
and	O
mechanically	O
ventilated	O
patients	O
(	O
aged	O
≥16	O
years	O
)	O
within	O
72	O
h	O
of	O
ARDS	O
onset	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
salbutamol	B-Design_Parallel_Group
(	I-Design_Parallel_Group
15	I-Design_Parallel_Group
μg/kg	I-Design_Parallel_Group
ideal	I-Design_Parallel_Group
bodyweight	I-Design_Parallel_Group
per	I-Design_Parallel_Group
h	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
for	O
up	O
to	O
7	O
days	O
.	O

Results	O
Four	B-Sample_Size_Actual_at_Enrollment
hundred	I-Sample_Size_Actual_at_Enrollment
and	I-Sample_Size_Actual_at_Enrollment
seventy	I-Sample_Size_Actual_at_Enrollment
five	I-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomized	O
2:1:2:2	B-Randomization_Ratio
to	O
placebo	B-Design_Parallel_Group
and	I-Design_Parallel_Group
erenumab	I-Design_Parallel_Group
28	I-Design_Parallel_Group
,	I-Design_Parallel_Group
70	I-Design_Parallel_Group
,	I-Design_Parallel_Group
and	I-Design_Parallel_Group
140	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
,	O
respectively	O
.	O

Methods	O
:	O
Twenty-three	B-Sample_Size_Actual_at_Enrollment
obese	I-Sample_Size_Actual_at_Enrollment
men	I-Sample_Size_Actual_at_Enrollment
(	O
BMI≥35	O
kg/m2	O
)	O
,	O
35–65	O
years	O
old	O
,	O
were	O
randomized	O
to	O
weight	B-Design_Parallel_Group
loss	I-Design_Parallel_Group
(	I-Design_Parallel_Group
diet	I-Design_Parallel_Group
and	I-Design_Parallel_Group
exercise	I-Design_Parallel_Group
)	I-Design_Parallel_Group
plus	I-Design_Parallel_Group
either	I-Design_Parallel_Group
anastrozole	I-Design_Parallel_Group
(	I-Design_Parallel_Group
AI+WL	I-Design_Parallel_Group
,	I-Design_Parallel_Group
n	I-Design_Parallel_Group
=	I-Design_Parallel_Group
12	I-Design_Parallel_Group
)	I-Design_Parallel_Group
at	I-Design_Parallel_Group
1	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
(	I-Design_Parallel_Group
PBO+WL	I-Design_Parallel_Group
,	I-Design_Parallel_Group
n	I-Design_Parallel_Group
=	I-Design_Parallel_Group
11	I-Design_Parallel_Group
)	I-Design_Parallel_Group
for	O
6	O
months	O
.	O

The	O
examiner	B-Blinding_Object_Outcome_Assessors
,	O
study	B-Blinding_Object_Others
statistician	I-Blinding_Object_Others
,	O
and	O
sponsor	B-Blinding_Object_Others
employees	I-Blinding_Object_Others
were	O
blinded	O
to	O
treatment	O
allocation	O
.	O

Results	O
Patients	O
A	O
total	O
of	O
26	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
enrolled	O
in	O
the	O
study	O
:	O
12	O
in	O
the	O
150	O
mg	O
cohort	O
and	O
14	O
in	O
the	O
200	O
mg	O
cohort	O
.	O

A	O
total	O
of	O
113	B-Sample_Size_Actual_at_Outcome_Analysis
patients	O
completed	O
the	O
48-week	O
study	O
,	O
while	O
11	O
patients	O
(	O
5	O
in	O
the	O
400	O
U	O
group	O
;	O
6	O
in	O
the	O
240	O
U	O
group	O
)	O
withdrew	O
from	O
the	O
trial	O
.	O

MATERIALS	O
AND	O
METHODS	O
Study	O
Design	O
This	O
was	O
a	O
phase	B-Design_Phase_4
IV	I-Design_Phase_4
,	O
randomized	B-Randomization_Type_Simple
,	O
observer-blinded	B-Blinding_Object_Others
,	O
2-arm	B-Design_Parallel_Group
,	O
multi-center	B-Settings_Multicenter
study	O
to	O
evaluate	O
the	O
safety	O
and	O
immunogenicity	O
of	O
2	O
different	O
doses	O
of	O
IIV4	O
in	O
healthy	O
children	O
6–35	O
months	O
of	O
age	O
.	O

Results	O
of	O
participants	O
receiving	O
exactly	O
1	O
dose	O
of	O
IIV4	O
and	O
those	O
receiving	O
2	O
doses	O
were	O
combined	O
in	O
all	O
noninferiority	B-Design_Comparative_Intent_NonInferiority
assessments	O
(	O
ie	O
,	O
for	O
fever	O
rate	O
,	O
postvaccination	O
HAI	O
GMTs	O
and	O
seroconversion	O
rates	O
)	O
.	O

Under	O
these	O
assumptions	O
,	O
a	O
total	O
of	O
702	B-Sample_Size_Required
evaluable	O
patients	O
(	O
351	O
per	O
treatment	O
group	O
)	O
were	O
required	O
.	O

Methods	O
Trial	O
population	O
Between	O
June	O
2011	O
and	O
September	O
2013	O
,	O
consecutive	O
patients	O
referred	O
for	O
elective	O
CABG	O
surgery	O
were	O
recruited	O
from	O
two	B-Settings_Multicenter
clinics	I-Settings_Multicenter
at	O
Edinburgh	B-Settings_Location
Heart	O
Centre	O
.	O

A	O
Phase	B-Design_Phase_3
3	I-Design_Phase_3
,	O
Randomized	O
Double-Blind	B-Blinding_Double_Blind
Study	O
of	O
the	O
Efficacy	O
and	O
Safety	O
of	O
Low-Dose	O
SHP465	O
Mixed	O
Amphetamine	O
Salts	O
Extended-Release	O
in	O
Children	O
with	O
Attention-Deficit/Hyperactivity	O
Disorder	O

Efficacy	O
,	O
Safety	O
and	O
Immunogenicity	O
of	O
MB02	O
(	O
Bevacizumab	O
Biosimilar	O
)	O
versus	O
Reference	O
Bevacizumab	O
in	O
Advanced	O
Non-Small	O
Cell	O
Lung	O
Cancer	O
:	O
A	O
Randomized	O
,	O
Double-Blind	B-Blinding_Double_Blind
,	O
Phase	B-Design_Phase_3
III	I-Design_Phase_3
Study	O
(	O
STELLA	O
)	O

Entry	O
criteria	O
for	O
the	O
open-label	O
phase	O
included	O
a	O
MAS	O
score	O
of	O
at	O
least	O
2	O
in	O
the	O
elbow	O
,	O
and	O
at	O
least	O
2	O
in	O
the	O
wrist	O
or	O
fingers	O
,	O
and	O
no	O
drug-related	O
SAE	O
during	O
the	O
double-blind	B-Blinding_Double_Blind
phase	O
.	O

Of	O
124	O
patients	O
who	O
completed	O
blinded	O
treatment	O
,	O
117	O
elected	O
to	O
continue	O
to	O
the	O
open-label	O
phase	O
;	O
92	B-Sample_Size_Actual_at_Outcome_Analysis
completed	O
treatment	O
for	O
96	O
weeks	O
.	O

Results	O
There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
canakinumab	B-Design_Parallel_Group
compared	I-Design_Parallel_Group
with	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
in	O
the	O
primary	O
efficacy	O
and	O
safety	O
endpoints	O
.	O

Noninferiority	B-Design_Comparative_Intent_NonInferiority
for	O
seroconversion	O
rates	O
was	O
considered	O
demonstrated	O
if	O
the	O
lower	O
limit	O
of	O
the	O
2-sided	O
95	O
%	O
CI	O
for	O
the	O
rate	O
difference	O
for	O
the	O
full	O
dose	O
minus	O
the	O
half	O
dose	O
was	O
>	O
−10	O
%	O
.	O

Overall	O
,	O
193	B-Sample_Size_Actual_at_Enrollment
subjects	O
were	O
randomised	O
(	O
CT‐P17	O
AI	O
:	O
98	O
;	O
CT‐P17	O
PFS	O
:	O
95	O
;	O
Figure	O
1	O
)	O
.	O

The	O
trial	O
was	O
open-label	B-Blinding_Open_Label
with	O
no	O
masking	O
of	O
treatment	O
assignment	O
for	O
participants	O
or	O
clinicians	O
.	O

Purpose	O
:	O
This	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
,	O
randomized	O
,	O
double-masked	B-Blinding_Double_Blind
,	O
parallel-arm	B-Design_Parallel_Group
,	O
multicenter	B-Settings_Multicenter
study	O
(	O
NCT03858894	O
)	O
was	O
conducted	O
in	O
the	O
United	B-Settings_Location
States	I-Settings_Location
to	O
examine	O
whether	O
the	O
efficacy	O
and	O
safety	O
of	O
omidenepag	O
isopropyl	O
0.002	O
%	O
BID	O
dosing	O
was	O
superior	O
to	O
QD	O
dosing	O
in	O
subjects	O
with	O
primary	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension	O
.	O

Funding	O
UK	B-Settings_Location
Medical	O
Research	O
Council	O
,	O
UK	B-Settings_Location
Department	O
of	O
Health	O
,	O
UK	B-Settings_Location
Intensive	O
Care	O
Foundation	O
.	O

This	O
phase	B-Design_Phase_2
2b	I-Design_Phase_2
,	O
placebo-controlled	O
,	O
randomized	O
clinical	O
trial	O
evaluates	O
the	O
efficacy	O
and	O
safety	O
of	O
lebrikizumab	O
,	O
a	O
novel	O
,	O
high-affinity	O
,	O
monoclonal	O
antibody	O
targeting	O
interleukin	O
(	O
IL	O
)	O
–13	O
that	O
selectively	O
prevents	O
formation	O
of	O
the	O
IL-13Rα1/IL-4Rα	O
heterodimer	O
receptor	O
signaling	O
complex	O
,	O
in	O
adults	O
with	O
moderate	O
to	O
severe	O
atopic	O
dermatitis	O
.	O

In	O
the	O
eptifibatide	O
bolus	O
plus	O
clopidogrel	O
group	O
,	O
PCI	O
was	O
successfully	O
performed	O
in	O
all	O
patients	O
;	O
blood	O
samples	O
were	O
hemolyzed	O
in	O
2	O
patients	O
,	O
and	O
pharmacodynamic	B-Sample_Size_Actual_at_Outcome_Analysis
study	I-Sample_Size_Actual_at_Outcome_Analysis
was	I-Sample_Size_Actual_at_Outcome_Analysis
performed	I-Sample_Size_Actual_at_Outcome_Analysis
in	I-Sample_Size_Actual_at_Outcome_Analysis
48	I-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
(	O
Figure	O
2	O
)	O
.	O

Results	O
Patients	O
Of	O
the	O
621	O
patients	O
screened	O
,	O
464	B-Sample_Size_Actual_at_Enrollment
were	O
randomised	O
between	O
October	O
2009	O
and	O
November	O
2010	O
to	O
receive	O
ponesimod	B-Design_Parallel_Group
10	I-Design_Parallel_Group
,	I-Design_Parallel_Group
20	I-Design_Parallel_Group
or	I-Design_Parallel_Group
40	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	O
.	O

Subjects	O
were	O
randomly	O
assigned	O
in	O
a	O
1:1	B-Randomization_Ratio
ratio	O
to	O
receive	O
a	O
single	B-Design_Parallel_Group
0.5-mL	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
of	I-Design_Parallel_Group
either	I-Design_Parallel_Group
PCV20	I-Design_Parallel_Group
or	I-Design_Parallel_Group
PCV13	I-Design_Parallel_Group
(	O
vaccination	O
1	O
;	O
Figure	O
1	O
)	O
.	O

Objective	O
To	O
show	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
of	O
trimethoprim-sulfamethoxazole	O
compared	O
with	O
vancomycin	O
for	O
the	O
treatment	O
of	O
severe	O
infections	O
due	O
to	O
meticillin	O
resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
.	O

In	O
a	O
randomized	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
parallel	B-Design_Parallel_Group
study	O
design	O
,	O
eligible	O
patients	O
with	O
a	O
sitting	O
diastolic	O
blood	O
pressure	O
(	O
BP	O
)	O
of	O
90–109	O
mm	O
Hg	O
received	O
aprocitentan	O
5	O
,	O
10	O
,	O
25	O
,	O
or	O
50	O
mg	O
,	O
placebo	O
,	O
or	O
lisinopril	O
20	O
mg	O
as	O
a	O
positive	O
control	O
once	O
daily	O
for	O
8	O
weeks	O
.	O

This	O
randomized	B-Randomization_Type_Simple
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
study	O
characterized	O
the	O
initial	O
dose-hemoglobin	O
response	O
as	O
well	O
as	O
the	O
efficacy	O
and	O
safety	O
of	O
three	O
times	O
weekly	O
(	O
TIW	O
)	O
daprodustat	O
in	O
hemodialysis	O
patients	O
switched	O
from	O
stable	O
recombinant	O
human	O
erythropoietin	O
(	O
rhEPO	O
)	O
,	O
in	O
accordance	O
with	O
a	O
TIW	O
hemodialysis	O
schedule	O
.	O

RESULTS	O
Patients	O
and	O
Pathogens	O
A	O
total	O
of	O
726	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
enrolled	O
and	O
randomized	O
(	O
tedizolid	O
,	O
n	O
=	O
366	O
;	O
linezolid	O
,	O
n	O
=	O
360	O
)	O
at	O
122	O
study	O
sites	O
in	O
32	O
countries	O
.	O

Methods	O
Study	O
design	O
and	O
objectives	O
Between	O
April	O
2017	O
and	O
October	O
2018	O
,	O
we	O
conducted	O
a	O
phase	B-Design_Phase_2
II	I-Design_Phase_2
study	O
in	O
64	B-Settings_Multicenter
centers	I-Settings_Multicenter
in	O
9	B-Settings_Location
countries	I-Settings_Location
(	O
GSK	O
protocol	O
205,724	O
;	O
ClinicalTrials.gov	O
identifier	O
NCT03034967	O
)	O
.	O

Design	O
,	O
Setting	O
,	O
and	O
Participants	O
This	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
randomized	O
clinical	O
trial	O
was	O
a	O
52-week	O
multicenter	B-Settings_Multicenter
,	O
active	O
comparator–controlled	O
,	O
parallel-group	B-Design_Parallel_Group
study	O
.	O

Participants	O
received	O
each	O
of	O
the	O
following	O
six	O
treatments	O
once	O
daily	O
for	O
18	O
days	O
:	O
three	B-Design_Parallel_Group
topical	I-Design_Parallel_Group
doses	I-Design_Parallel_Group
(	I-Design_Parallel_Group
2.3	I-Design_Parallel_Group
%	I-Design_Parallel_Group
,	I-Design_Parallel_Group
0.8	I-Design_Parallel_Group
%	I-Design_Parallel_Group
,	I-Design_Parallel_Group
0.23	I-Design_Parallel_Group
%	I-Design_Parallel_Group
)	I-Design_Parallel_Group
of	I-Design_Parallel_Group
PF‐06763809	I-Design_Parallel_Group
,	I-Design_Parallel_Group
a	I-Design_Parallel_Group
vehicle	I-Design_Parallel_Group
and	I-Design_Parallel_Group
two	I-Design_Parallel_Group
active	I-Design_Parallel_Group
comparators	I-Design_Parallel_Group
(	I-Design_Parallel_Group
betamethasone	I-Design_Parallel_Group
and	I-Design_Parallel_Group
calcipotriol	I-Design_Parallel_Group
)	I-Design_Parallel_Group
.	O

The	O
investigator	B-Blinding_Object_Investigators
,	O
pharmacist	B-Blinding_Object_Others
,	O
and	O
trial	B-Blinding_Object_Patients
participant	I-Blinding_Object_Patients
were	O
blind	O
to	O
group	O
allocation	O
.	O

The	O
sample	O
size	O
calculations	O
were	O
based	O
on	O
the	O
primary	O
efficacy	O
variable	O
of	O
WOMAC	O
A1	O
over	O
26	O
weeks	O
,	O
with	O
the	O
following	O
assumptions	O
:	O
0.75	O
mean	O
difference	O
in	O
treatment	O
effect	O
of	O
single	O
6	O
ml	O
Hylan	O
G-F	O
20	O
injection	O
on	O
the	O
change	O
from	O
baseline	O
in	O
WOMAC	O
A1	O
over	O
26	O
weeks	O
,	O
compared	O
to	O
placebo	O
and	O
a	O
t-test	O
at	O
a	O
2-sided	B-Sample_Size_Calculation_Alpha_Value
5	I-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
significance	O
level	O
with	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
.	O

Results	O
A	O
total	O
of	O
757	B-Sample_Size_Actual_at_Enrollment
adults	O
were	O
randomized	O
,	O
378	O
to	O
receive	O
aIIV3	O
and	O
379	O
to	O
receive	O
HD-IIV3	O
.	O

Study	O
Design	O
This	O
phase	B-Design_Phase_2
2b	I-Design_Phase_2
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
,	O
parallel-group	B-Design_Parallel_Group
,	O
dose-ranging	O
randomized	O
clinical	O
trial	O
of	O
lebrikizumab	O
injections	O
every	O
4	O
weeks	O
or	O
every	O
2	O
weeks	O
consisted	O
of	O
a	O
16-week	O
treatment	O
period	O
with	O
a	O
16-week	O
safety	O
follow-up	O
(	O
eFigure	O
1	O
in	O
Supplement	O
2	O
)	O
.	O

The	O
trial	O
was	O
conducted	O
from	O
July	O
2011	O
through	O
November	O
2018	O
at	O
sites	B-Settings_Multicenter
in	O
the	O
United	B-Settings_Location
States	I-Settings_Location
,	I-Settings_Location
Canada	I-Settings_Location
,	I-Settings_Location
Australia	I-Settings_Location
,	I-Settings_Location
and	I-Settings_Location
Germany	I-Settings_Location
(	O
Fig	O
.	O

Randomization	O
of	O
participants	O
in	O
variable	O
blocks	B-Randomization_Type_Block
of	O
eight	B-Randomization_Block_Size
and	I-Randomization_Block_Size
ten	I-Randomization_Block_Size
was	O
accomplished	O
using	O
computer-generated	B-Randomization_Sequence_Generation_Method
random	I-Randomization_Sequence_Generation_Method
numbers	I-Randomization_Sequence_Generation_Method
(	O
http	O
:	O
//www.randomization.com	O
)	O
.	O

The	O
study	O
was	O
designed	O
to	O
enroll	O
approximately	O
1050	B-Sample_Size_Target
participants	O
randomized	O
in	O
a	O
1:1:1	B-Randomization_Ratio
ratio	O
to	O
either	O
V114	B-Design_Parallel_Group
Lot	I-Design_Parallel_Group
1	I-Design_Parallel_Group
,	I-Design_Parallel_Group
V114	I-Design_Parallel_Group
Lot	I-Design_Parallel_Group
2	I-Design_Parallel_Group
or	I-Design_Parallel_Group
PCV13	I-Design_Parallel_Group
vaccination	I-Design_Parallel_Group
groups	I-Design_Parallel_Group
.	O

They	O
received	O
a	O
randomization	O
number	O
at	O
registration	O
based	O
on	O
a	O
computer-generated	B-Randomization_Sequence_Generation_Method
randomization	I-Randomization_Sequence_Generation_Method
allocation	I-Randomization_Sequence_Generation_Method
table	I-Randomization_Sequence_Generation_Method
.	O

Patient	O
Demographics	O
and	O
Clinical	O
Characteristics	O
Of	O
131	O
patients	O
who	O
were	O
screened	O
,	O
124	B-Sample_Size_Actual_at_Enrollment
were	O
randomized	O
(	O
61	O
in	O
the	O
400	O
U	O
group	O
;	O
63	O
in	O
the	O
240	O
U	O
group	O
)	O
and	O
received	O
the	O
first	O
administration	O
of	O
the	O
study	O
drug	O
.	O

This	O
was	O
a	O
randomized	O
,	O
double‐blind	B-Blinding_Double_Blind
,	O
vehicle‐	O
and	O
active	O
comparator‐controlled	O
,	O
multiple‐dose	O
study	O
in	O
participants	O
with	O
psoriasis	O
.	O

The	O
IWRS	O
was	O
managed	O
by	O
an	O
unblinded	B-Randomization_Personnel
third-party	I-Randomization_Personnel
provider	I-Randomization_Personnel
,	O
and	O
the	O
randomization	O
schedule	O
was	O
provided	O
by	O
a	O
separate	B-Randomization_Personnel
unblinded	I-Randomization_Personnel
statistical	I-Randomization_Personnel
team	I-Randomization_Personnel
.	O

Methods	O
Novartis	O
Pharmaceuticals	O
(	O
Cambridge	O
,	O
Massachusetts	O
)	O
initiated	O
this	O
Phase	B-Design_Phase_2
II	I-Design_Phase_2
,	O
double-blind	B-Blinding_Double_Blind
,	O
randomized	O
,	O
placebo-controlled	O
trial	O
,	O
with	O
the	O
final	O
study	O
protocol	O
designed	O
in	O
collaboration	O
with	O
the	O
investigators	O
(	O
R.P.C.	O
,	O
J.-C.T.	O
,	O
and	O
Z.A.F	O
.	O

Statistical	O
Analysis	O
A	O
sample	O
size	O
of	O
80	O
children	O
in	O
the	O
baloxavir	O
arm	O
(	O
120	O
in	O
total	O
)	O
provided	O
a	O
probability	O
of	O
≥90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
that	O
≥1	O
child	O
would	O
experience	O
an	O
AE	O
with	O
a	O
background	O
incidence	O
rate	O
of	O
3	O
%	O
.	O

Methods	O
103	B-Sample_Size_Actual_at_Enrollment
patients	O
on	O
hemodialysis	O
with	O
baseline	O
hemoglobin	O
of	O
9.0	O
to	O
11.5	O
g/dL	O
and	O
previously	O
receiving	O
a	O
stable	O
dose	O
of	O
rhEPO	O
or	O
its	O
analogs	O
were	O
randomized	O
1:1:1:1:1	B-Randomization_Ratio
to	O
receive	O
daprodustat	B-Design_Parallel_Group
10	I-Design_Parallel_Group
,	I-Design_Parallel_Group
15	I-Design_Parallel_Group
,	I-Design_Parallel_Group
25	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
30	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
TIW	O
over	O
29	O
days	O
.	O

Randomization	O
was	O
stratified	B-Randomization_Type_Stratified
by	O
migraine	B-Randomization_Stratified_Criteria
preventive	I-Randomization_Stratified_Criteria
treatment	I-Randomization_Stratified_Criteria
status	I-Randomization_Stratified_Criteria
:	I-Randomization_Stratified_Criteria
current	I-Randomization_Stratified_Criteria
use	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
previous	I-Randomization_Stratified_Criteria
use	I-Randomization_Stratified_Criteria
only	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
and	I-Randomization_Stratified_Criteria
no	I-Randomization_Stratified_Criteria
current	I-Randomization_Stratified_Criteria
or	I-Randomization_Stratified_Criteria
previous	I-Randomization_Stratified_Criteria
use	I-Randomization_Stratified_Criteria
.	O

This	O
study	O
had	O
a	O
double-masked	O
design	O
;	O
the	O
treatment	O
was	O
masked	O
to	O
the	O
subjects	B-Blinding_Object_Patients
,	O
examiners	O
,	O
Santen	B-Blinding_Object_Others
personnel	I-Blinding_Object_Others
,	O
and	O
clinical	B-Blinding_Object_Investigators
investigators	I-Blinding_Object_Investigators
.	O

The	O
82	B-Sample_Size_Actual_at_Outcome_Analysis
evaluable	O
participants	O
ranged	O
from	O
22–84	O
years	O
of	O
age	O
(	O
Mean	O
52.9	O
years	O
,	O
standard	O
deviation	O
(	O
SD	O
)	O
13.3	O
)	O
.	O

Results	O
Patient	O
Disposition	O
,	O
Baseline	O
Demographics	O
,	O
and	O
Disease	O
Characteristics	O
A	O
total	O
of	O
280	B-Sample_Size_Actual_at_Enrollment
patients	O
(	O
mean	O
[	O
SD	O
]	O
age	O
,	O
39.3	O
[	O
17.5	O
]	O
years	O
;	O
166	O
[	O
59.3	O
%	O
]	O
female	O
)	O
were	O
randomized	O
to	O
placebo	O
(	O
n	O
=	O
52	O
)	O
or	O
to	O
lebrikizumab	O
at	O
the	O
following	O
doses	O
:	O
125	O
mg	O
every	O
4	O
weeks	O
(	O
n	O
=	O
73	O
)	O
,	O
250	O
mg	O
every	O
4	O
weeks	O
(	O
n	O
=	O
80	O
)	O
,	O
or	O
250	O
mg	O
every	O
2	O
weeks	O
(	O
n	O
=	O
75	O
)	O
(	O
Figure	O
1	O
)	O
.	O

Noninferiority	B-Design_Comparative_Intent_NonInferiority
(	O
primary	O
end	O
point	O
)	O
was	O
confirmed	O
if	O
the	O
upper	O
boundary	O
of	O
the	O
two-sided	O
95	O
%	O
CI	O
was	O
≤0.4	O
%	O
.	O

Results	O
Of	O
the	O
26	B-Sample_Size_Actual_at_Enrollment
patients	O
randomized	O
,	O
25	B-Sample_Size_Actual_at_Outcome_Analysis
received	O
abemaciclib	O
150	O
mg	O
(	O
n	O
=	O
12	O
)	O
or	O
200	O
mg	O
(	O
n	O
=	O
13	O
)	O
.	O

METHODS	O
Study	O
Design	O
and	O
Subjects	O
This	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
,	O
randomized	B-Randomization_Type_Simple
,	O
active-controlled	O
,	O
double-blind	B-Blinding_Double_Blind
study	O
conducted	O
at	O
14	B-Settings_Multicenter
US	I-Settings_Multicenter
sites	I-Settings_Multicenter
evaluated	O
PCV20	O
safety	O
and	O
immunogenicity	O
in	O
healthy	O
pneumococcal	O
vaccine-naive	O
adults	O
60–64	O
years	O
of	O
age	O
.	O

Screening	O
,	O
randomization	O
and	O
enrolment	O
of	O
the	O
patients	O
were	O
performed	O
by	O
the	O
investigator	B-Randomization_Personnel
or	I-Randomization_Personnel
delegated	I-Randomization_Personnel
staff	I-Randomization_Personnel
at	I-Randomization_Personnel
each	I-Randomization_Personnel
trial	I-Randomization_Personnel
site	I-Randomization_Personnel
.	O

Participants	O
discontinued	O
their	O
current	O
rhEPO	O
therapy	O
prior	O
to	O
day	O
1	O
and	O
were	O
randomized	O
by	O
a	B-Randomization_Sequence_Generation_Method
computer-generated	I-Randomization_Sequence_Generation_Method
randomization	I-Randomization_Sequence_Generation_Method
schedule	I-Randomization_Sequence_Generation_Method
using	I-Randomization_Sequence_Generation_Method
the	I-Randomization_Sequence_Generation_Method
Prism	I-Randomization_Sequence_Generation_Method
randomization	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
in	O
a	O
1:1:1:1:1	B-Randomization_Ratio
ratio	O
to	O
receive	O
oral	B-Design_Parallel_Group
daprodustat	I-Design_Parallel_Group
10	I-Design_Parallel_Group
,	I-Design_Parallel_Group
15	I-Design_Parallel_Group
,	I-Design_Parallel_Group
25	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
30	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
TIW	O
on	O
a	O
dialysis	O
day	O
.	O

Noninferiority	B-Design_Comparative_Intent_NonInferiority
in	O
the	O
rate	O
of	O
fever	O
was	O
demonstrated	O
for	O
the	O
full	O
dose	O
versus	O
the	O
half	O
dose	O
of	O
IIV4	O
(	O
difference	O
in	O
rate	O
=	O
0.84	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
−2.13	O
%	O
to	O
3.80	O
%	O
)	O
.	O

Results	O
252	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
included	O
in	O
the	O
trial	O
,	O
of	O
whom	O
91	O
(	O
36	O
%	O
)	O
had	O
bacteraemia	O
.	O

Summary	O
Background	O
In	O
a	O
previous	O
randomised	O
controlled	O
phase	B-Design_Phase_2
2	I-Design_Phase_2
trial	O
,	O
intravenous	O
infusion	O
of	O
salbutamol	O
for	O
up	O
to	O
7	O
days	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
reduced	O
extravascular	O
lung	O
water	O
and	O
plateau	O
airway	O
pressure	O
.	O

Conclusion	O
Non-inferiority	B-Design_Comparative_Intent_NonInferiority
of	O
MR	O
11	O
mg	O
QD	O
to	O
IR	O
5	O
mg	O
BID	O
was	O
not	O
met	O
in	O
this	O
study	O
.	O

Participants	O
were	O
randomized	O
(	O
1:1	B-Randomization_Ratio
)	O
to	O
receive	O
aIIV3	B-Design_Parallel_Group
or	I-Design_Parallel_Group
HD-IIV3	I-Design_Parallel_Group
using	O
a	O
permuted	B-Randomization_Type_Block
block	I-Randomization_Type_Block
randomization	O
scheme	O
stratified	B-Randomization_Type_Stratified
by	O
study	B-Randomization_Stratified_Criteria
site	I-Randomization_Stratified_Criteria
.	O

RESULTS	O
Ninety-six	B-Sample_Size_Actual_at_Enrollment
women	I-Sample_Size_Actual_at_Enrollment
were	O
recruited	O
,	O
enrolled	O
,	O
and	O
randomized	O
in	O
the	O
study	O
;	O
48	O
in	O
each	O
of	O
the	O
placebo	O
and	O
gabapentin	O
groups	O
from	O
August	O
2016	O
to	O
June	O
2018	O
(	O
Figure	O
1	O
)	O
.	O

Of	O
those	O
randomized	O
,	O
621	B-Sample_Size_Actual_at_Outcome_Analysis
subjects	O
were	O
treated	O
with	O
investigational	O
product	O
(	O
IP	O
)	O
.	O

In	O
order	O
to	O
be	O
able	O
to	O
detect	O
these	O
differences	O
between	O
groups	O
and	O
assuming	O
an	O
alpha	O
error	O
of	O
5	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
and	O
a	B-Sample_Size_Calculation_Power_Value
beta	I-Sample_Size_Calculation_Power_Value
error	I-Sample_Size_Calculation_Power_Value
of	I-Sample_Size_Calculation_Power_Value
20	I-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
,	O
we	O
required	O
a	O
minimum	O
of	O
12	B-Sample_Size_Required
patients	I-Sample_Size_Required
per	I-Sample_Size_Required
group	I-Sample_Size_Required
.	O

Interventions	O
Patients	O
were	O
randomized	B-Randomization_Type_Simple
2:3:3:3	B-Randomization_Ratio
to	O
placebo	B-Design_Parallel_Group
every	I-Design_Parallel_Group
2	I-Design_Parallel_Group
weeks	I-Design_Parallel_Group
or	I-Design_Parallel_Group
to	I-Design_Parallel_Group
subcutaneous	I-Design_Parallel_Group
injections	I-Design_Parallel_Group
of	I-Design_Parallel_Group
lebrikizumab	I-Design_Parallel_Group
at	I-Design_Parallel_Group
the	I-Design_Parallel_Group
following	I-Design_Parallel_Group
doses	I-Design_Parallel_Group
:	I-Design_Parallel_Group
125	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
every	I-Design_Parallel_Group
4	I-Design_Parallel_Group
weeks	I-Design_Parallel_Group
(	I-Design_Parallel_Group
250-mg	I-Design_Parallel_Group
loading	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
[	I-Design_Parallel_Group
LD	I-Design_Parallel_Group
]	I-Design_Parallel_Group
)	I-Design_Parallel_Group
,	I-Design_Parallel_Group
250	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
every	I-Design_Parallel_Group
4	I-Design_Parallel_Group
weeks	I-Design_Parallel_Group
(	I-Design_Parallel_Group
500-mg	I-Design_Parallel_Group
LD	I-Design_Parallel_Group
)	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
250	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
every	I-Design_Parallel_Group
2	I-Design_Parallel_Group
weeks	I-Design_Parallel_Group
(	I-Design_Parallel_Group
500-mg	I-Design_Parallel_Group
LD	I-Design_Parallel_Group
at	I-Design_Parallel_Group
baseline	I-Design_Parallel_Group
and	I-Design_Parallel_Group
week	I-Design_Parallel_Group
2	I-Design_Parallel_Group
)	I-Design_Parallel_Group
.	O

If	O
the	O
lower	O
limit	O
of	O
the	O
two-sided	B-Sample_Size_Calculation_Alpha_Value
95	I-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
CI	I-Sample_Size_Calculation_Alpha_Value
was	O
greater	O
than	O
the	O
non-inferiority	O
limit	O
(	O
−10.0	O
%	O
)	O
for	O
both	O
the	O
full	O
analysis	O
set	O
(	O
FAS	O
)	O
,	O
i.e	O
.	O

The	O
sites	O
conducting	O
the	O
study	O
were	O
gastroenterology	B-Settings_Multicenter
practices	I-Settings_Multicenter
(	O
n=26	O
)	O
or	O
primary	O
care	O
and	O
research	B-Settings_Multicenter
practices	I-Settings_Multicenter
(	O
n=53	O
)	O
specializing	O
in	O
internal	O
medicine	O
and/or	O
gastroenterology	O
.	O

A	O
sample	O
size	O
of	O
120	O
children	O
provided	O
a	O
probability	O
of	O
80.1	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
that	O
≥1	O
child	O
would	O
experience	O
an	O
AE	O
with	O
an	O
incidence	O
rate	O
of	O
2	O
%	O
.	O

Methods	O
Study	O
Design	O
NICHD	O
P1081	O
was	O
a	O
Phase	B-Design_Phase_4
IV	I-Design_Phase_4
multicenter	B-Settings_Multicenter
,	O
randomized	O
,	O
open-label	B-Blinding_Open_Label
trial	O
comparing	O
the	O
virologic	O
response	O
,	O
safety	O
,	O
and	O
tolerability	O
of	O
raltegravir	O
,	O
the	O
first	O
licensed	O
integrase	O
inhibitor	O
,	O
with	O
efavirenz	O
,	O
a	O
non-nucleoside	O
reverse	O
transcriptase	O
inhibitor	O
(	O
NNRTI	O
)	O
,	O
in	O
combination	O
with	O
two	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
(	O
NRTI	O
)	O
in	O
ART-naïve	O
pregnant	O
women	O
initiating	O
ART	O
from	O
20	O
to	O
36	O
weeks	O
gestation	O
.	O

The	O
block	B-Randomization_Block_Size
size	I-Randomization_Block_Size
was	I-Randomization_Block_Size
4	I-Randomization_Block_Size
and	O
the	O
allocation	O
ratio	O
was	O
1:1	B-Randomization_Ratio
.	O

